Wednesday, 18 November, 2020

8:00 am - 11:00 am  TARPSWG Meeting (email: tarpswg@gmail.com) – Chair: Alessandro Gronchi
11:00 am - 1:00 pm  Ultra Rare Sarcoma Meeting – Chair: Silvia Stacchiotti
1:00 pm - 3:00 pm  SARC Meeting
3:00 pm - 5:00 pm  SELNET Meeting: State of Art of Management for Localized STS in Limbs and Retroperitoneum – Chair: Javier Martin-Broto

Thursday, 19 November, 2020

8:00 am - 9:00 am  – Session 1 –  
OPENING CEREMONY INTRODUCTION TO CTOS 2020
President: Kirsten Sundby Hall
Program Chairs: Silvia Stacchiotti, Margaret von Mehren, Inga-Marie Schaefer

25 YEAR RETROSPECTIVE
Presenter: Shreyas Patel

9:00 am - 10:00 am  – Session 2 –  
IMMUNOTHERAPY IN SARCOMA: ALVEOLAR SOFT PART SARCOMA, CLEAR CELL SARCOMA, SYNOVIAL SARCOMA
Chair: Seth Pollack
Discussant: Breelyn Wilky
Panelists: Armelle Dufresne, Bob Maki, Enrico Grignani
Presenters: Akira Kawai, Nadia Hindi, Sandra d’Angelo, Brian van Tine

Paper #01 3421748
EFFICACY AND SAFETY OF NIVOLUMAB MONOTHERAPY IN PATIENTS WITH UNRESECTABLE CLEAR CELL SARCOMA AND ALVEOLAR SOFT PART SARCOMA (OSCAR TRIAL, NCCH1510): A MULTICENTER, PHASE 2 CLINICAL TRIAL
Akira Kawai1, Tadaaki Nishikawa2, Mamiko Kawasaki3, Sawako Tomatsuri4, Nobuko Okamura5, Gakuto Ogawa5, Akihiro Hirakawa5, Taro Shibata5, Kenichi Nakamura5, Shigeki Kakunaga5, Kenji Tamura1, Masashi Ando1, Toshifumi Ozaki7, Takafumi Ueda5, Kan Yonemori1
1Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, JAPAN; 2Oncology and Rehabilitation Medicine, National Cancer Center Hospital, Tokyo, JAPAN; 3National Cancer Center, Tokyo, JAPAN; 4Tokyo Medical and Dental University, Tokyo, JAPAN; 5Orthopaedic Surgery, National Hospital Organization Osaka National Hospital, Osaka, JAPAN; 6Aichi Cancer Center, Aichi, JAPAN; 7Orthopaedic Surgery, Okayama University, Okayama, JAPAN

ALL TIMES ARE EASTERN STANDARD TIME (EST)
Thursday, 19 November, 2020

Paper #02 3464044

EFFICACY OF IMMUNE CHECKPOINT INHIBITORS IN ALVEOLAR SOFT PART SARCOMA: RESULTS FROM A RETROSPECTIVE WORLD-WIDE REGISTRY

Nadia Hindi,1 Evan Rosenbaum2, Piotr Rutkowski3, Hans Gelderblom4, Kjetil Boye5, Clemence Henon6, Bruno Vincenzi7, Andres Redondo8, Javier Martinez-Trufero9, Claudia Valverde10, Jose Antonio Lopez-Martin11, Paulina Jagodzinska3, Elizabeth Connolly12, William D. Tap2, Javier Martin-Broto1

1Medical Oncology, Hospital Universitario Virgen del Rocio, Instituto de Biomedicina de Sevilla (IBIS), Seville, SPAIN; 2Memorial Sloan Kettering Cancer Center, New York, New York, UNITED STATES; 3Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, POLAND; 4Leiden University Medical Center, Leiden, NETHERLANDS; 5Institute for Cancer Research, Oslo University Hospital, Department of Oncology, Oslo University Hospital, Oslo, NORWAY; 6C. Henon, Medical Oncology, Institut de Cancérologie Gustave Roussy, Villejuif, FRANCE; 7Medical Oncology, University Campus Bio-Medico, Rome, ITALY; 8Medical Oncology, Hospital Universitario La Paz - IdiPAZ, Madrid, SPAIN; 9Medical Oncology, Hospital Universitario Miguel Servet, Zaragoza, SPAIN; 10Medical Oncology, Hospital Universitario Vall d’Hebron, Barcelona, SPAIN; 11Medical Oncology, Hospital Universitario 12 de Octubre, Translational Oncology Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, SPAIN; 12Chris O Brien Lifehouse, Sydney, New South Wales, AUSTRALIA

Paper #03 3462142

FINAL ANALYSIS OF THE PHASE 1 TRIAL OF NY-ESO-1-SPECIFIC T-CELL RECEPTOR (TCR) T-CELL THERAPY (LETETREGENE AUTOLEUCEL; GSK3377794) IN PATIENTS (PTS) WITH ADVANCED SYNOVIAL SARCOMA (SS)

Sandra D’Angelo,1 George Demetri2, Brian A. Van Tine3, Mihaela Druta4, John Glod5, Warren Chow6, Naimish Pandya7, Aisha Hasan7, Victoria L. Chiu7, Jenna Tress8, Julie Edwards9, Tim Young10, Mary Woessner10, Alexandra Gyurdieva10, Stefan Zajic10, Sophia Goodison10, Dejka Araujo9

1Memorial Sloan Kettering Cancer Center, New York, New York, UNITED STATES; 2Dana Farber Cancer Institute and Ludwig Center at Harvard, Boston, Massachusetts, UNITED STATES; 3Washington University, St. Louis, Missouri, UNITED STATES; 4H. Lee Moffitt Cancer Center, Tampa, Florida, UNITED STATES; 5National Cancer Institute, Bethesda, Maryland, UNITED STATES; 6City of Hope Comprehensive Cancer Center, Duarte, California, UNITED STATES; 7GlaxoSmithKline, Collegeville, Pennsylvania, UNITED STATES; 8GlaxoSmithKline, Stockley Park, Middlesex, UNITED KINGDOM; 9University of Texas/MD Anderson Cancer Center, Houston, Texas, UNITED STATES

Paper #04 3463188

DURABLE RESPONSES IN PATIENTS WITH SYNOVIAL SARCOMA IN THE PHASE I TRIAL OF ADP-A2M4 (MAGE-A4)

Brian A. Van Tine,1 David S. Hong2, Melissa L. Johnson3, David A. Liebner3, Kunle Odunsi3, Trupti Trivedi3, Quan Lin3, Swethajit Biswas3, Erica Elefant3, Jean-Marc Navenot4, Joana Senra5, Zohar Wolchinsky6, Robyn Broad7, Gareth Betts8, Natalie Bath9, Will Spinner9, Alex Tipping9, Svetlana Fayngerts9, Karen Miller9, Amy Sun10, Dennis Williams9, Paula M. Fracasso9, Elliott Norry9, Marcus O. Butler9

1Washington University, St. Louis, St. Louis, Missouri, UNITED STATES; 2The University of Texas, MD Anderson Cancer Center, Houston, Texas, UNITED STATES; 3Ohio State University Medical Center, Columbus, Ohio, UNITED STATES; 4Roswell Park Comprehensive Cancer Center, Buffalo, New York, UNITED STATES; 5Princess Margaret Cancer Centre, Toronto, Ontario, CANADA; 6Sarah Cannon Research Institute, Nashville, Tennessee, UNITED STATES; 7Adaptimmune Ltd, Abingdon, Oxfordshire, UNITED KINGDOM; 8Adaptimmune LLC, Philadelphia, Pennsylvania, UNITED STATES

10:00 am - 10:30 am Morning Break
10:30 am - 11:30 am

– Special Awards Session –

**YOUNG INVESTIGATOR AWARD WINNERS**

Brittany Glassberg, BS  
Shiv Verma, MD  
Introduction by Program Chairs: Stacchiotti, von Mehren, Schaefer

**Young Investigator Award**  
3464426

**INCIDENCE OF MALIGNANT PERIPHERAL NERVE SHEATH TUMOR (MPNST) DEVELOPMENT IN PATIENTS WITH NF1 RECEIVING AND NOT RECEIVING MEDICAL THERAPIES DIRECTED AT PLEXIFORM NEUROFIBROMAS (PN)**

Brittany Glassberg¹, Andrea Gross¹, Eva Dombi¹, Andrea Baldwin¹, Trish Whitcomb¹, Ana Best¹, Amanda Carbonell⁴, Kara Heisey¹, Janet Therrien¹, Oxana Kapustina¹, Brigitte C. Widemann¹, Hari Sankaran¹  
¹Pediatric Oncology Branch, National Institutes of Health, Woodbury, New York, UNITED STATES

**Young Investigator Award**  
3465542

**THE ASPSCR1-TFE3 TRANSCRIPTIONAL COMPLEX IN ALVEOLAR SOFT PART SARCOMAGENESIS**

Shiv Verma¹; Amir Pozner¹; Li Li¹; Shuxin Wang²; Jared J. Barrott¹; Sarmishta Kannan¹; Jamie Yu¹; Sydney L. Lambert¹; Alexander Lazar³; Martin Hirst⁵; Torsten O. Nielsen³; Peter S. Shen²; Kevin B. Jones¹  
¹Orthopaedics and Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, UNITED STATES; ²Department of Biochemistry, University of Utah, Salt Lake City, Utah, UNITED STATES; ³Department of Pathology, University of British Columbia, Vancouver, British Columbia, CANADA; ⁵Department of Pathology, MD Anderson Cancer Center, Houston, Texas, UNITED STATES; ⁶Genome Sciences Center, University of British Columbia, Vancouver, British Columbia, CANADA

**LIDDY SHRIVER EARLY RESEARCH AWARD WINNER**

Professor Nicolo Riggi  
Introduction by Chair: David Thomas

**BASIC SCIENCE SARCOMA RESEARCH AWARD WINNERS**

David Kirsch  
Benjamin Nacev  
Isidro Cortes-Ciriano  
Introduction by Chair: Lee Helman

**NATIONAL LEIOMYOSARCOMA FOUNDATION RESEARCH GRANT**

Chair: Seth Pollack
11:30 am - 12:30 pm

– Session 3 –

LEIOMYSARCOMA AND UNDIFFERENTIATED PLEOMORPHIC SARCOMA

Chair: Suzanne George
Discussant: Dirk Strauss
Panelists: Matt van de Rijn, Paolo A. Dei Tos, Robin Jones
Presenters: Sant P. Chawla, Nathaniel Anderson, Nicolas A. Devaud, Nathan D. Seligson

Paper #05 3465673
UPDAted phase I study to evaluate the safety and efficacy of rivoceranib (APatinib) and nivolumab in patients with unresectable or metastatic cancer

Sant P. Chawla¹, Victoria Chua-Alcala¹, Steven M. Wong¹, Doris Quon¹, Ania M. Moradkhani¹, Kelly Wang¹, Ish Bhuiyan¹, Olivia Pelenghian¹, Sandon Scott¹, Natalie Krkyan¹, Kitty Zheng¹, Steven Norton², Kehua Wu², Ted M. Kim¹, Erlinda M. Gordon¹
¹Sarcoma Oncology Center, Santa Monica, California, UNITED STATES; ²Elevartherapeutics,Inc., Salt Lake City, Utah, UNITED STATES

Paper #06 3463196
Lineage-defined leiomyosarcoma subtypes emerge years before diagnosis, determining patient survival

Nathaniel Anderson¹, Yael Babichev², Fabio Fuligni¹, Federico Comitani¹, Mehdi Layeghifard¹, Rosemarie Venier², Anant Maheshwari¹, Sheena Guram², Claire Wunker², J. Drew Thompson¹, Marcus Bernadini², Jay Wunder², Irene Andruulis³, Peter Ferguson⁴, Albiruni Abdul Razak⁴, Carol J. Swallow², Rima Al-Awar³, Richard Marcellus³, Marjan Rouzbahman¹, Daniel Durocher², Ludmil Alexandrov⁴, Brendan Dickson², Rebecca Gladdy², Adam Shlien¹
¹Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Ontario, CANADA; ²Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, CANADA; ³University Health Network, Toronto, Ontario, CANADA; ⁴University Musculoskeletal Oncology Unit, Mount Sinai Hospital, Toronto, Ontario, CANADA

Paper #07 3464097
Is site of origin (IVC vs. non-IVC) prognostic following resection of primary retroperitoneal leiomyosarcoma (RP LMS)? Combined experience of two sarcoma referral centres

Nicolas A. Devaud¹, Deanna Ng¹, Harini Suraweera¹, Abha A. Gupta², Albiruni Razak³, Peter Chung³, Savtaj Brar¹, Thomas Lindsay¹, Rebecca Gladdy¹, Ian McGilvary¹, Claudia Sangalli³, Roberta Sanfilippo³, Silvia Statchiotti³, Dario Callegaro⁶, Marco Fiore⁶, Alessandro Gronchi⁶, Carol J. Swallow¹
¹Surgery, University of Toronto, Toronto, Ontario, CANADA; ²Medical Oncology, University of Toronto, Toronto, Ontario, CANADA; ³Radiation Oncology, University of Toronto, Toronto, Ontario, CANADA; ⁴Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, ITALY; ⁵Radiation Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, ITALY; ⁶Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, ITALY

Paper #08 3457194
Homologous recombination DNA repair and loss of heterozygosity in leiomyosarcoma

Nathan D. Seligson¹, Sherri Z. Millis³, Dexter Jin³, Nicholas Grosenbacher², Monica P. Bennett¹, Alexander M. Litvintchouk¹, Colin M. Stets², Julia A. Elvin³, John L. Hays², James Chen³
¹University of Florida, Jacksonville, Florida, UNITED STATES; ²Ohio State University, Columbus, Ohio, UNITED STATES; ³Foundation Medicine Inc, Cambridge, Massachusetts, UNITED STATES
Thursday, 19 November, 2020

12:30 pm - 1:30 pm  
– Session 4 – 

OSTEOSARCOMA AND PEDIATRIC BONE SARCOMAS

Chair: Maureen O’Sullivan  
Discussant: Lor Randall  
Panelists: Emanuela Palmerini, Petur Nielsen, Kurt Weiss  
Presenters: Jong Min Lee, Kelly Bailey, Reid Davison, Jovana Pavisic

<table>
<thead>
<tr>
<th>Paper #09</th>
<th>3437417</th>
<th>A COMPARISON OF ONCOLOGICAL AND SURGICAL OUTCOMES IN ENDOPROSTHETIC RECONSTRUCTION VERSUS ROTATIONPLASTY FOR PAEDIATRIC LOWER EXTREMITY BONE SARCOMA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jong Min Lee², Jonathan R. Perera¹, Eliane R. Trottier², Sevan Hopyan², Kim Tsoi¹</td>
<td></td>
<td></td>
</tr>
<tr>
<td>¹Orthopaedic Oncology, Mount Sinai Hospital, Amersham, Buckinghamshire, UNITED KINGDOM; ²Paediatric Orthopaedics, SickKids, Toronto, Ontario, CANADA</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Paper #10</th>
<th>3464085</th>
<th>EXPRESSION PROFILING AND SPATIAL LOCALIZATION OF CD45+ LEUKOCYTES INFILTRATING PRIMARY AND RELAPSED BONE SARCOMAS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anthony Cillo², Elina Mukherjee³, Sayali Onkar², Kurt R. Weiss⁴, Melissa A. Burgess⁵, Tanya Heim⁴, Dario Vignali², Tullia Bruno², Kelly Bailey¹</td>
<td></td>
<td></td>
</tr>
<tr>
<td>¹Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, UNITED STATES; ²Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, UNITED STATES; ³Pediatrics, University of Pittsburgh, Pittsburgh, Pennsylvania, UNITED STATES; ⁴Orthopaedic Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, UNITED STATES; ⁵Medicine, University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, Pennsylvania, UNITED STATES</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Thursday, 19 November, 2020

Paper #11 3446540
PULMONARY MICRONODULES LESS THAN 5 MM DETECTED ON CT AT PRESENTATION IN PATIENTS WITH OSTEOSARCOMA DO NOT EFFECT 5 YEAR OVERALL SURVIVAL
Reid Davison¹, Fadi Hamati¹, Paul Kent¹
¹Rush Medical Hospital, Chicago, Illinois, UNITED STATES

Paper #12 3461610
TARGETING MASTER REGULATOR DEPENDENCIES IN PEDIATRIC OSTEOSARCOMA
Jovana Pavisic¹, Katherine Janeway², Andrew Kung³, Filemon Dela Cruz¹, Alejandro Sweet-Cordero⁵, Inge Behroozfard⁶, Stanley Leung⁵, Alex Lee⁵, Darrell Yamashiro¹, Julia Glade Bender¹, Andrea Califano⁴
¹Pediatrics, Columbia University Irving Medical Center, New York, New York, UNITED STATES; ²Pediatrics, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Boston, Massachusetts, UNITED STATES; ³Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, UNITED STATES; ⁴Systems Biology, Columbia University Irving Medical Center, New York, New York, UNITED STATES; ⁵Pediatrics, University of California San Francisco, San Francisco, California, UNITED STATES

1:30 pm - 2:30 pm
MEET THE EXPERTS
Multidisciplinary Discussion of Clinical Cases

Room 1:
GIST
Moderator: William Tap
Presenter: Maria Abbondanza Pantaleo
Panelists: Sara Rothschild, George Demetri, Tom Wei-Wu Chen, Paolo Casali, Piotr Rutkowski, Aisha Miah, Eva Wardelmann

Room 2:
Bone Sarcomas
Moderator & Presenter: Anna Maria Fresza
Panelists: Josh Sommer, Abha Gupta, Hans Gelderblom, Sandra Strauss, Jay Wunder, Thomas DeLaney, Paolo A. Dei Tos, Kannan Rajesparan

Room 3:
Soft Tissue Sarcomas
Moderator: Rick Haas
Presenter: Armelle Dufresne
Panelists: Roger Wilson, Jean Yves Blay, Andrew Wagner, Claudia Valverde Morales, Alessandro Gronchi, Elizabeth Baldini, Christopher Fletcher

2:30 pm - 3:30 pm
CTOS Executive Committee Meeting

3:00 pm - 4:30 pm
– Symposium –
THE CASE FOR CHALLENGING CONVENTIONAL CARE IN TENDOSYNVIOLD GIANT CELL TUMOR: INSIGHTS ON INTEGRATING TARGETED THERAPY INTO MULTIMODAL MANAGEMENT
### Session 5

**“WHAT IS NEW IN SARCOMA PATHOLOGY AND MOLECULAR DIAGNOSTICS”**

Cristina Antonescu

### Session 6

**CHONDROSARCOMA, CHORDOMA, AND OTHER BONE TUMORS**

Chair: Judith Bovée  
Discussant: David Kirsch  
Panelists: Elizabeth Baldini, Javier Martin-Broto, Rick Haas  
Presenters: Sanne Venneker, Ivar Hompland, Thomas F. DeLaney, Sant P. Chawla

**Paper #13 3465391**

**BEYOND THE INFLUENCE OF IDH MUTATIONS: EXPLORING EPIGENETIC VULNERABILITIES IN CHONDROSARCOMA**

Sanne Venneker¹, Alwine B. Kruisselbrink¹, Zuzanna Baranski², leva Palubbeckaite¹, Inge H. Briaire-de Bruijn¹, Jan Oosting¹, Pim J. French³, Erik Danen¹, Judith V. Bovee¹  
¹Department of Pathology, Leiden University Medical Center, Leiden, NETHERLANDS; ²Division of Drug Discovery and Safety, Leiden Academic Centre for Drug Research, Leiden, NETHERLANDS; ³Department of Neurology, Erasmus University Medical Center, Rotterdam, NETHERLANDS

**Paper #14 3442269**

**OUTCOME IN DEDIFFERENTIATED CHONDROSAROMA FOR PATIENTS TREATED WITH MULTIMODAL THERAPY: RESULTS FROM THE EURO-B.O.S.S STUDY**

Ivar Hompland¹, Stefano Ferrari², Stefan Bielack³, Emanuela Palmerini², Kirsten S. Hall¹, Davide M. Donati², Elisabetta Setola², Virginia Ferraresi², Rossella Bertulli², Alessandro Comandone², Piero Picci², Stefanie Hecker-Nolting³, Claudia Blattmann³, Leo Kager¹, Thomas Kühne⁴, Peter Reichardt⁵, Sigbjørn Smeland⁶  
¹Department of Oncology, Oslo University Hospital, Norwegian Radium Hospital, Oslo, NORWAY; ²Oncology Department, Istituto Ortopedico Rizzoli, Bologna, ITALY; ³Stuttgart Cancer Center, Pediatrics 5 (Oncology, Hematology, Immunology), Klinikum Stuttgart Olghospital, Stuttgart, GERMANY; ⁴Oncology Department, Istituto Regina Elena, Rome, ITALY; ⁵Oncology Department, Ospedale Humanitas-Gradenigo, Turin, ITALY; ⁶Division of Oncology and Hematology, University Children’s Hospital, Basel, SWITZERLAND; ⁷Department of Pediatrics, St Anna Children’s Hospital, Medical University Vienna, Vienna, AUSTRIA; ⁸Department of Oncology, Helios Klinikum Berlin-Buch, Berlin, GERMANY; ⁹Oncology Department, Istituto Nazionale Tumori, Milan, ITALY

**Paper #15 3461741**

**DEFINITIVE HIGH-DOSE, PROTON-BASED RADIATION FOR UNRESECTED MOBILE SPINE AND SACRAL CHORDOMAS**

Thomas F. DeLaney¹, Norbert J. Liebsch¹, Saveli Goldberg¹, Walter H. Banfield³, Myrsini Ioakeim-Ioannidou¹, Soha Ahmed¹, Joseph H. Schwab¹, Francis J. Hornicek⁷, Gregory M. Cote⁵, John H. Shin⁶, Edwin Choy⁵, Yen-Lin E. Chen¹  
¹Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, UNITED STATES; ²University of Virginia School of Medicine, Charlottesville, Virginia, UNITED STATES; ³Clinical Oncology, Aswan University Medical Center, New Aswan City, Aswan, EGYPT; ⁴Orthopaedic Oncology, Massachusetts General Hospital, Boston, Massachusetts, UNITED STATES; ⁵Hematology/Oncology Section, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, UNITED STATES; ⁶Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts, UNITED STATES; ⁷Orthopaedic Surgery, UCLA Medical Center, Los Angeles, California, UNITED STATES
RESULTS FROM THE CHONDROSARCOMA PHASE 1 STUDY EXPANSION COHORT OF THE TETRAVALENT DEATH RECEPTOR 5 AGONIST INBRX-109

Sant P. Chawla, Nehal Lakhani, Anthony Tolcher, Christopher Lieu, Breelyn A. Wilky, Klaus W. Wagner, Analeah Heidt, Brendan Eckelman, Quinn Deveraux, James Kalabus, Anthony P. Conley, Vivek Subbiah

1 Sarcoma Oncology Center, Santa Monica, California, UNITED STATES; 2 Inhibrx, Inc, La Jolla, California, UNITED STATES; 3 University of Colorado, Aurora, Colorado, UNITED STATES; 4 START Midwest, Grand Rapids, Michigan, UNITED STATES; 5 NEXT Oncology, San Antonio, Texas, UNITED STATES; 6 MD Anderson Cancer Center, Houston, Texas, UNITED STATES

PREOPERATIVE RADIOTHERAPY IN PATIENTS WITH PRIMARY RETROPERITONEAL SARCOMA (RPS): TRIAL (STRASS) VS OFF-TRIAL (STREXIT) RESULTS

Dario Callegaro, Chandrajit Raut, Ajayi Taiwo, Dirk Strauss, Sylvie Bonvalot, Deanna Ng, Eberhard Stoeckle, Mark Fairweather, Piotr Rutkowski, Winan J. van Houdt, Hans Gelderblom, Claudia Sangalli, Andrew Hayes, Charles Honoré, Rebecca Gladdy, Magali Fau, Rick L. Haas, Dmitri Tzanis, Aisha B. Miah, Peter Chung, Elizabeth H. Baldini, Sandrine Marreaud, Saskia Litière, Carol J. Swallow, Alessandro Gronchi

1 Surgery, Fondazione IRCCS Istituto Nazionale Tumori, Milan, ITALY; 2 EORTC Headquarters, Brussels, BELGIUM; 3 General Surgery, Sarcoma Unit, Royal Marsden NHS Foundation Trust, London, UNITED KINGDOM; 4 Surgery, Institut Curie, Paris, FRANCE; 5 Surgical Oncology, Princess Margaret Cancer Centre/Mount Sinai Hospital, University of Toronto, Toronto, Ontario, CANADA; 6 Surgery, Institut Bergonié, Bordeaux, FRANCE; 7 Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, POLAND; 8 Surgery, The Netherlands Cancer Institute, Amsterdam, NETHERLANDS; 9 Medical Oncology, Leiden University Medical Center, Leiden, NETHERLANDS; 10 Surgery, Institute Gustave Roussy, Villejuif, FRANCE; 11 Radiation Oncology, The Netherland Cancer Institute, Amsterdam, NETHERLANDS; 12 Surgery, Brigham and Women’s Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, UNITED STATES; 13 Radiation Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, ITALY; 14 Radiation Oncology, Royal Marsden NHS Foundation Trust, London, UK, London, UNITED KINGDOM; 15 Radiation Oncology, Princess Margaret Cancer Centre/Mount Sinai Hospital, Toronto, Ontario, CANADA; 16 Radiation Oncology, Brigham and Women’s Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, UNITED STATES

INTERMUSCULAR MYXOID LIPOSARCOMA CAN BE MANAGED BY MARGINAL SURGICAL RESECTION FOLLOWING NEOADJUVANT RADIOTHERAPY

Jonathan R. Perera, Ahmed Aoude, Izuchuwu Ibe, Anthony Griffin, Peter Ferguson, Jay Wunder, Kim Tsoi

1 Orthopaedic Oncology, Mount Sinai Hospital, Amersham, Buckinghamshire, UNITED KINGDOM
NEUTROPHIL-TO-LYMPHOCYTE RATIO IS A PROGNOSTIC FACTOR REGARDLESS PREOPERATIVE TREATMENTS IN PRIMARY RETROPERITONEAL SARCOMA

Marco Fiore1, Sandro Pasquali2, Daniele Morelli3, Giuseppe Cuomo2, Marta Barisella1, Claudia Sangalli4, Alessandro Gronchi7

1Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY; 2Department of Laboratory and Transfusion Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY; 3Department of Pathology and Experimental Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY; 4Department of Radiation Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY

Friday, 20 November, 2020

Paper #19 3437081
DOSE REDUCTION OF PREOPERATIVE RADIOThERAPY FOR MYXOID LIPOSARCOMA (DOREMY): A PROSPECTIVE, MULTICENTER, SINGLE-ARM, PHASE 2 TRIAL

Jules Lansu1, Judith V. Bovee2, Pietra Braam2, Hester van Boven3, Uta Flucke3, Han Bonenkamp3, Aisha B. Miah5, Shane H. Zaidi3, Khin Thway2, Øyvind S. Bruland4, Elizabeth H. Baldini5, Nina L. Jebsen6, Astrid N. Scholten1, Piet L. van den Ende6, Augustinus D. Kro6, Fred Ubbels10, Jos A. van der Hage9, Erik van Werkhoven9, Houke M. Klomp4, Winette T. van der Graaf4, Frits van Coevorden4, Yvonne Schrage4, Winan J. van Houdt4, Rick L. Haas1

1Radiotherapy, Netherlands Cancer Institute, Amsterdam, NETHERLANDS; 2Leiden University Medical Center, Leiden, NETHERLANDS; 3Nijmegen University Medical Center, Nijmegen, NETHERLANDS; 4Netherlands Cancer Institute, Amsterdam, NETHERLANDS; 5The Royal Marsden Hospital and The Institute of Cancer Research, London, UNITED KINGDOM; 6The Norwegian Radium Hospital, Oslo University Hospital, and Institute of Clinical Medicine, Oslo, NORWAY; 7Dana-Farber/Brigham and Women’s Cancer Center, Boston, Massachusetts, UNITED STATES; 8Center for Bone- and Soft Tissue Tumors, Dep. of Oncology/Dep. of Orthopedic Surgery, Haukeland University Hospital, Bergen, NORWAY; 9MAASTRO, Maastricht, NETHERLANDS; 10Groningen University Medical Center, Groningen, NETHERLANDS

Paper #20 3461475
A PHASE 2/3, RANDOMIZED, DOUBLE BLIND, CROSS-OVER, STUDY OF SELINEXOR VERSUS PLACEBO IN ADVANCED UNRESECTABLE DEDIFFERENTIATED LIPOSARCOMA (DDLS)

Mrinal Gounder1, Albiruni Abdul Razak2, Neeta Somaiah, Javier Martin-Broto4, Scott Schuetze6, Giovanni Grignani6, Sant P. Chawla5, Bartosz Chmielowski3, Bruno Vencinetti3, Silvia Stacchiotti10, Andrew J. Wagner11, Axel Le Cesne12, Richard F. Riedel13, Robin L. Jones14, Kristen Ganjoo15, Xavier Garcia del Muro16, Melissa A. Burgess17, Dayana Michel18, Hongwei Wang18, Jatin J. Shah18, Steven Attia19

1Memorial Sloan Kettering Cancer Center, New York, New York, UNITED STATES; 2Princess Margaret Cancer Centre, Toronto, Ontario, CANADA; 3Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, UNITED STATES; 4Virgen del Rocio University Hospital, Institute of Biomedicine Research (IBIS)/ CSIC/Universidad de Sevilla, Seville, SPAIN; 5University of Michigan, Ann Arbor, Michigan, UNITED STATES; 6Division of Medical Oncology, Candiolo Cancer Institute, FPO-IRCCS, Candiolo (TO), Candiolo (TO), ITALY; 7Sarcoma Oncology Center, Santa Monica, California, UNITED STATES; 8Division of Hematology-Oncology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, UNITED STATES; 9Policlinico Universitario Campus Bio-Medico, Rome, ITALY; 10Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY; 11Dana-Farber Cancer Institute, Boston, Massachusetts, UNITED STATES; 12Institut Gustave Roussy, Villejuif, FRANCE; 13Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina, UNITED STATES; 14The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, UNITED KINGDOM; 15Stanford Cancer Institute, Stanford, California, UNITED STATES; 16Catalan Institute of Oncology, IDIBELL, University of Barcelona, Barcelona, SPAIN; 17University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, Pennsylvania, UNITED STATES; 18Karyopharm Therapeutics Inc., Newton, Massachusetts, UNITED STATES; 19Mayo Clinic, Jacksonville, Florida, UNITED STATES
11:30 am - 12:30 pm – Session 8 –

GIST

Chair: Cesar Serrano
Discussant: Ron deMatteo
Panelists: Chandrajit Raut, Piotr Rutkowski
Presenters: Jason Sicklick, Lorenzo D’Ambrosio, Jonathan Trent, Suzanne George, Sebastian Bauer

HUMAN SUCCINATE DEHYDROGENASE-DEFICIENT GASTROINTESTINAL STROMAL TUMORS ARE SENSITIVE TO TEMOZOLOMIDE VIA INDUCTION OF ER STRESS AND DNA DAMAGE

Mayra Yebra1, Avi Kumar2, Adam Burgoyne3, Chih-Min Tang1, Hyunho Yoon1, Sudeep Banerjee4, Joseph Aguilera1, Thekla Cordes1, Vipul Sheth5, Sangkyu Noh1, Rowan Ustoy1, Sunil Advani6, Christopher Corless7, Michael Heinrich6, Razelle Kurzrock1, Scott M. Lippman1, Paul T. Fanta1, Olivier Harismendy1, Christian Metallo1, Jason K. Sicklick1

1University of California, San Diego, La Jolla, California, UNITED STATES; 2University of California San Diego, La Jolla, California, UNITED STATES; 3University of California Los Angeles, Los Angeles, California, UNITED STATES; 4Stanford University, Palo Alto, California, UNITED STATES; 5Portland VA Health Care System, Portland, Oregon, UNITED STATES; 6OHSU Knight Cancer Institute, Portland, Oregon, UNITED STATES
Paper #23  3465722

ASSESSMENT OF A GUIDELINE-BASED FOLLOW-UP STRATEGY AFTER COMPLETE SURGERY IN PATIENTS AFFECTED BY GASTROINTESTINAL STROMAL TUMOR (GIST) WITH LOW-RISK OF RECURRENCE

Lorenzo D'Ambrosio¹, Elena Fumagalli², Margherita Nannini³, Tommaso Martino De Pas⁴, Bruno Vincenzi⁵, Francesca Ligorio², Elisabetta Pennacchioli⁶, Andrea Mogavero¹, Antonella Brunello², Fabio Conforti⁶, Danila Comandini⁸, Giulia Manessi⁷, Silvia Gasparroni⁷, Virginia Ferraresi¹⁰, Giuseppe Badalamenti¹¹, Sandra Aliberti¹, Marco Fiore¹², Maria Pantaleo⁴, Giovanni Grignani¹²

¹Medical Oncology, Candiolo Cancer Institute, Candiolo, ITALY; ²Medical Oncology, IRCCS Istituto Nazionale dei Tumori di Milano, Milan, ITALY; ³Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, ITALY; ⁴Unit of Sarcomas and Thymomas, European Institute of Oncology, Milan, ITALY; ⁵Medical Oncology, Università Campus Bio-Medico, Rome, ITALY; ⁶Surgical Department Melanoma, European Institute of Oncology, Milan, ITALY; ⁷Medical Oncology, Istituto Oncologico Veneto - IRCCS, Padua, ITALY; ⁸Medical Oncology, Ospedale Policlinico San Martino, Genoa, ITALY; ⁹Medical Oncology, AOU Careggi, Florence, ITALY; ¹⁰Medical Oncology, Regina Elena National Cancer Institute, Rome, ITALY; ¹¹Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, ITALY; ¹²Department of Surgery, IRCCS Istituto Nazionale dei Tumori di Milano, Milan, ITALY

Paper #24  3458521

THE POTENT AND SELECTIVE KIT INHIBITOR PLX9486 DOSED IN COMBINATION WITH SUNITINIB DEMONSTRATES PROMISING PROGRESSION FREE SURVIVAL (PFS) IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR (GIST): FINAL RESULTS OF A PHASE 1/2 STUDY

Jonathan Trent¹, William D. Tap², Rashmi Chugh³, Gabriel Tinoco⁴, Athanasios Tsiatis⁵, Paul Severson⁵, Kerry Inokuchi⁵, Chao Zhang⁵, Glenn Michelson⁷, Andrew J. Wagner⁶

¹University of Miami, Miami, Florida, UNITED STATES; ²Memorial Sloan Kettering Cancer Center, New York, New York, UNITED STATES; ³University of Michigan, Ann Arbor, Michigan, UNITED STATES; ⁴The Ohio State University, Columbus, Ohio, UNITED STATES; ⁵Plexxikon, Inc., Berkeley, California, UNITED STATES; ⁶Dana-Farber Cancer Institute, Boston, Massachusetts, UNITED STATES; ⁷KIQ Bio, San Francisco, California, UNITED STATES

Paper #25  3463167

RIPRETINIB INTRA-PATIENT DOSE ESCALATION FOLLOWING DISEASE PROGRESSION PROVIDES CLINICALLY MEANINGFUL PROGRESSION-FREE SURVIVAL IN GASTROINTESTINAL STROMAL TUMOR IN PHASE 1 STUDY

Suzanne George¹, Ping Chi², Michael Heinrich³, Margaret von Mehren⁴, Robin L. Jones⁵, Kristen Ganjoo⁶, Jonathan Trent⁷, Hans Gelderblom⁸, Albiruni Abdul Razak⁹, Michael Gordon¹⁰, Neeta Somaiah¹¹, Julia Jennings¹², Kelvin Shi¹², Rodrigo Ruiz-Soto¹², Filip Janku¹³

¹Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, UNITED STATES; ²Human Oncology and Pathogenesis Program & Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, UNITED STATES; ³Hematology/Medical Oncology, OHSU Knight Cancer Institute, Portland, Oregon, UNITED STATES; ⁴Hematology Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, UNITED STATES; ⁵Royal Marsden and Institute of Cancer Research, London, UNITED KINGDOM; ⁶Medical Oncology, Stanford University, Stanford, California, UNITED STATES; ⁷Medical Oncology, Sylvester Comprehensive Cancer Center/University of Miami, Miami, Florida, UNITED STATES; ⁸Medical Oncology, Leiden University Medical Center, Leiden, NETHERLANDS; ⁹Toronto Sarcoma Program, Princess Margaret Cancer Centre, Toronto, Ontario, CANADA; ¹⁰HonorHealth Research Institute, Scottsdale, Arizona, UNITED STATES; ¹¹Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, UNITED STATES; ¹²Deciphera Pharmaceuticals, LLC, Waltham, Massachusetts, UNITED STATES; ¹³Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, UNITED STATES
CHARACTERIZATION OF THE EXTENSIVE HETEROGENEITY OF KIT/PDGFRA MUTATIONS IN PATIENTS WITH FOURTH-LINE ADVANCED GASTROINTESTINAL STROMAL TUMOR: GENOMIC ANALYSIS OF THE PHASE 3 INVICTUS STUDY

Sebastian Bauer¹, Patrick Schöffski², Michael Heinrich³, Suzanne George⁴, John Zalcberg⁵, Hans Gelderblom⁶, César Serrano⁷, Robin L. Jones⁸, Steven Attia⁹, Gina D’amato¹⁰, Ping Chi¹¹, Peter Reichardt¹², Julie Meade¹³, Vienna L. Reichert¹⁴, Ying Su¹³, Rodrigo Ruiz-Soto¹³, Jean-Yves Blay¹⁴, Margaret von Mehren¹⁵

¹Sarcoma Center, West German Cancer Center, Essen, GERMANY; ²General Medical Oncology, University Hospitals Leuven, Leuven, BELGIUM; ³Hematology/Medical Oncology, OHSU Knight Cancer Institute, Portland, Oregon, UNITED STATES; ⁴Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, UNITED STATES; ⁵School of Public Health, Faculty of Medicine, Monash University, Melbourne, Victoria, AUSTRALIA; ⁶Medical Oncology, Leiden University Medical Center, Leiden, NETHERLANDS; ⁷Medical Oncology, Vall d’Hebron Institute of Oncology, Barcelona, SPAIN; ⁸Sarcoma Unit, Royal Marsden and Institute of Cancer Research, London, UNITED KINGDOM; ⁹Oncology, Mayo Clinic, Jacksonville, Florida, UNITED STATES; ¹⁰Medical Oncology, Sylvester Comprehensive Cancer Center/University of Miami, Miami, Florida, UNITED STATES; ¹¹Human Oncology and Pathogenesis Program & Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, UNITED STATES; ¹²Oncology and Palliative Care, Sarcoma Center, Helios Klinikum Berlin-Buch, Berlin, GERMANY; ¹³Deciphera Pharmaceuticals, LLC, Waltham, Massachusetts, UNITED STATES; ¹⁴Medicine, Centre Leon Berard, Lyon, FRANCE; ¹⁵Hematology Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, UNITED STATES

12:30 pm - 1:30 pm

HERMAN SUIT LECTURE – GENETICS, GENOMICS AND SARCOMAS

David Thomas

1:30 pm - 2:30 pm

VIRTUAL GET-TOGETHER

2:30 pm - 3:30 pm

CTOS Board of Directors Meeting

3:00 pm - 4:00 pm

– Symposium –

PERSONALIZING AND PROLONGING CARE IN GIST: EXPERT GUIDANCE ON INTEGRATING NEW TKI STRATEGIES
8:00 am - 9:00 am  
**Session 9**

**EPIGENETICALLY DRIVEN SARCOMAS**

Presenter: Cigall Kadoch

9:00 am - 10:00 am  
**Session 10**

**ADVANCES IN ANGIOSARCOMA, PECOMA, AND CLEAR CELL SARCOMA**

Chair: Vinod Ravi  
Discussant: William Tap  
Panelists: Winette van der Graaf, Cristina Antonescu, Jayesh Desai  
Presenters: Andrea Espejo-Freire, Jessica Burns, Andrew J. Wagner, Ben Ozenberger

---

**Paper #27 3460221**

**GENOMIC LANDSCAPE OF ANGIOSARCOMA: A TARGETED AND IMMUNOTHERAPY BIOMARKER ANALYSIS OF 143 PATIENTS**

Andrea Espejo-Freire, Andrew Elliott, Yamac Akgun, Philippos A. Costa, Maryam Alasfour, Andrew Rosenberg, Julio Diaz-Perez, Gina D’amato, Ty K. Subhawong, Junaid Arshad, W. Michael Korn, Don Dizon, Margaret von Mehren, Moh’d Khushman, Atif Hussein, Kirsten Leu, Jonathan Trent  
1. University of Miami Sylvester Comprehensive Cancer Center, Jackson Memorial Hospital, Miami, Florida, UNITED STATES; 2. Caris Life Sciences, Irving, Texas, UNITED STATES; 3. Brown University Lifespan Cancer Institute, Providence, Rhode Island, UNITED STATES; 4. Fox Chase Cancer Center, Philadelphia, Pennsylvania, UNITED STATES; 5. University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, UNITED STATES; 6. Memorial Cancer Institute, Hollywood, Florida, UNITED STATES; 7. Nebraska Cancer Specialists, Omaha, Nebraska, UNITED STATES

**Paper #28 3464567**

**THE PROTEOME LANDSCAPE OF SOFT TISSUE SARCOMAS DEFINES TWO FUNCTIONAL SUBGROUPS OF ANGIOSARCOMAS WITH DISTINCT SURVIVAL OUTCOMES**

Jessica Burns, Lukas Krasny, Christopher Wilding, Maggie Cheang, Robin L. Jones, Paul Huang  

**Paper #29 3463014**

**LONG-TERM FOLLOW-UP FROM AMPECT, AN OPEN-LABEL PHASE 2 REGISTRATION TRIAL OF NAB-SIROLIMUS FOR PATIENTS WITH ADVANCED MALIGNANT PERIVASCULAR EPITHELIOLID CELL TUMORS (PECOMA)**

1. Dana-Farber Cancer Institute, Boston, Massachusetts, UNITED STATES; 2. Anderson Cancer Center, Houston, Texas, UNITED STATES; 3. Duke Cancer Institute, Durham, North Carolina, UNITED STATES; 4. Aadi Bioscience, Pacific Palisades, California, UNITED STATES; 5. Stanford University, Stanford, California, UNITED STATES; 6. Washington University in Saint Louis, St. Louis, Missouri, UNITED STATES; 7. University of Michigan, Ann Arbor, Michigan, UNITED STATES; 8. Univ Washington/Fred Hutchinson Cancer Res Ctr, Seattle, Washington, UNITED STATES; 9. Sarcoma Oncology Center, Santa Monica, California, UNITED STATES; 10. Brigham and Women’s Hospital, Boston, Massachusetts, UNITED STATES; 11. Memorial Sloan Kettering Cancer Center, New York, New York, UNITED STATES
BEYOND THE FUSION: THE CLEAR CELL SARCOMA FUNCTIONAL GENOME
Emanuele Panza, Ben Ozenberger, Krystal Straessler, Jared J. Barrott, Anne M. Boulet, Clint Mason, Alexander Lazar, Mario R. Capecchi, Kevin B. Jones

1Orthopaedics and Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, UNITED STATES; 2Department of Medical and Surgical Sciences - DIMEC, University of Bologna, Bologna, ITALY; 3School of Medicine, University of Utah, Salt Lake City, Utah, UNITED STATES; 4College of Pharmacy, Idaho State University, Pocatello, Idaho, UNITED STATES; 5Department of Human Genetics, University of Utah, Salt Lake City, Utah, UNITED STATES; 6Department of Pediatrics, University of Utah, Salt Lake City, Utah, UNITED STATES; 7Department of Pathology, MD Anderson Cancer Center, Houston, Texas, UNITED STATES

10:00 am - 10:30 am  Morning Break

10:30 am - 11:30 am  NINA AXELRAD LECTURE – EVOLUTION OF DOGMAS IN SARCOMA SURGERY

Sylvie Bonvalot
## Session 11 – RHABDOMYOSARCOMA AND EWING SARCOMA

**Chair:** Abha Gupta  
**Discussant:** Katherine Janeway  
**Panelists:** Richard Womer, Kevin Jones  
**Presenters:** Christine M. Heske, Wendy Allen-Rhoades, Margaret B. Nagel, Megann Boone, Joseph A. Ludwig

### Paper #31 3443006
**SURVIVAL OUTCOMES OF PATIENTS WITH LOCALIZED FOXO1 FUSION POSITIVE RHABDOMYOSARCOMA TREATED ON RECENT CHILDREN’S ONCOLOGY GROUP CLINICAL TRIALS**

*Christine M. Heske¹, Yueh-Yun Chi², Rajkumar Venkatramani³, Minjie Li², Michael Arnold⁴, Roshni Dasgupta⁵, Susan M. Hiniker⁶, Douglas S. Hawkins⁷, Leo Mascarenhas⁸*

¹Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland, UNITED STATES; ²Department of Biostatistics, University of Florida, Gainesville, Florida, UNITED STATES; ³Division of Hematology/Oncology, Texas Children’s Hospital, Houston, Texas, UNITED STATES; ⁴Department of Pathology and Laboratory Medicine, Children’s Hospital Colorado, Aurora, Colorado, UNITED STATES; ⁵Division of Pediatric General and Thoracic Surgery, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, UNITED STATES; ⁶Stanford University School of Medicine, Department of Radiation Oncology, Stanford, California, UNITED STATES; ⁷Department of Pediatrics, Seattle Children’s Hospital, Seattle, Washington, UNITED STATES; ⁸Division of Hematology/Oncology, Children’s Hospital Los Angeles, Los Angeles, California, UNITED STATES

### Paper #32 3461602
**ALVEOLAR RHABDOMYOSARCOMA HAS SUPERIOR CLINICAL RESPONSE RATES TO VINORELBINE COMPARED TO EMBRYONAL RHABDOMYOSARCOMA IN PATIENTS WITH REFRACTORY OR RELAPSED DISEASE**

*Wendy Allen-Rhoades¹, Philip Lupo¹, Michael Scheurer¹, Yueh-Yun Chi², John Kuttesch², William H. Meyer³, Rajkumar Venkatramani¹, Leo Mascarenhas²*

¹Pediatrics, Baylor College of Medicine, Houston, Texas, UNITED STATES; ²Pediatrics, Children’s Hospital of Los Angeles, University of Southern California, Los Angeles, California, UNITED STATES; ³Pediatrics, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, UNITED STATES

### Paper #33 3457806
**THE ROLE OF DLK1 IN FUSION-NEGATIVE RHABDOMYOSARCOMA**

*Margaret B. Nagel¹, Matthew R. García¹, Mark E. Hatley¹*

¹St Jude Children’s Research Hospital, Memphis, Tennessee, UNITED STATES

### Paper #34 3435189
**STRUCTURE-FUNCTION MAPPING REVEALS NOVEL REGION OF FLI CRITICAL FOR EWS/FLI ACTIVITY IN EWING SARCOMA**

*Megann Boone¹, Cenny Taslim¹, Julia Selich-Anderson¹, Jesse Crow¹, Emily R. Theisen¹, Iftekhar Showpnil¹, Stephen Lessnick¹*

¹Center for Childhood Cancer, Nationwide Children’s Hospital, Columbus, Ohio, UNITED STATES
TK216 PHASE 1 STUDY IN METASTATIC, RELAPSED/REFRACTORY EWING SARCOMA

Joseph A. Ludwig², Noah Federman³, Peter Anderson⁴, Margaret Macy⁵, Lara E. Davis⁶, Richard F. Riedel⁷, Najat C. Daw², Jodi Muscal⁸, Ravin Ratan², Jeffrey Toretsky⁹, Xen Ianopoulos¹, Frank Hsu¹, James Breitmeyer¹, Paul Meyers⁹
¹Oncternal Therapeutics, San Diego, California, UNITED STATES; ²MD Anderson Cancer Center, Houston, Texas, UNITED STATES; ³Children’s Hospital Colorado, Aurora, Colorado, UNITED STATES; ⁴UCLA David Geffen School of Medicine, Los Angeles, California, UNITED STATES; ⁵Duke University School of Medicine, Durham, North Carolina, UNITED STATES; ⁶Georgetown University, Washington, District of Columbia, UNITED STATES; ⁷Oregon Health & Science University, Portland, Oregon, UNITED STATES; ⁸Baylor College of Medicine, Houston, Texas, UNITED STATES; ⁹Memorial Sloan Kettering Cancer Center, New York, New York, UNITED STATES; ¹⁰Cleveland Clinic Foundation, Cleveland, Ohio, UNITED STATES

12:30 pm - 1:30 pm

LOCALLY AGGRESSIVE MESENCHYMAL TUMORS: DESMOID TUMOR, DIFFUSE-TYPE GIANT CELL TUMOR

Chair: Palma Dileo
Discussant: Winan Van Houdt
Panelists: Alexander Lazar, Bernd Kasper, Jay Wunder
Presenters: Javier Martin-Broto, Michael J. Nathenson, Albiruni Abdul Razak

Lecture: RECENT UPDATES IN LOCALLY AGGRESSIVE MESENCHYMAL TUMORS: DESMOID TUMOR, DIFFUSE-TYPE GIANT CELL TUMOR

Mrinal Gounder
ASSOCIATION OF CTNNB1 MUTATION SUBTYPES WITH RESPONSE TO SYSTEMIC THERAPY IN PATIENTS WITH DESMOID TUMORS: A MULTI-INSTITUTIONAL RETROSPECTIVE STUDY

Michael J. Nathenson¹, Neeta Somaiah², Robert Hsu³, Peter DeMaria³, Heath Catoe³, Karan Malik¹, Christy Harris¹, Ty K. Subhawong⁴, Behrang Amini⁵, Jyothi P. Jagannathan⁶, Marta Braschi-Amirfarzan⁶, Kevin Sweet⁴, Katharina Feister⁴, Junxiao Hu⁷, Jamie Sheren⁸, Andrew Rosenberg⁹, Alexander Lazar¹⁰, Ravin Ratan², Vinod Ravi², Shreyaskumar Patel², Robert Maki¹², Pasquale Benedetto⁸, Jonathan Cohen³, Jonathan Trent¹⁻¹, Breelyn A. Wilky¹¹

¹Medicine, Dana Farber Cancer Institute, Boston, Massachusetts, UNITED STATES; ²Medicine, MD Anderson Cancer Center, Houston, Texas, UNITED STATES; ³Medicine, Sylvester Comprehensive Cancer Center University of Miami, Miami, Florida, UNITED STATES; ⁴Radiology, University of Miami School of Medicine, Miami, Florida, UNITED STATES; ⁵Radiology, MD Anderson Cancer Institute, Houston, Texas, UNITED STATES; ⁶Radiology, Dana Farber Cancer Institute, Boston, Massachusetts, UNITED STATES; ⁷Biostatistics, University of Colorado School of Medicine, Aurora, Colorado, UNITED STATES; ⁸Pathology, University of Colorado School of Medicine, Aurora, Colorado, UNITED STATES; ⁹Pathology, University of Miami School of Medicine, Miami, Florida, UNITED STATES; ¹⁰Pathology, MD Anderson Cancer Center, Houston, Texas, UNITED STATES; ¹¹Medicine, University of Colorado School of Medicine, Aurora, Colorado, UNITED STATES; ¹²Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, UNITED STATES

PHASE 1 DOSE-ESCALATION STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF DCC-3014 IN ADVANCED SOLID TUMORS AND TENOSYNOVIAL GIANT CELL TUMOR (TGCT)

Albiruni Abdul Razak¹, Breelyn A. Wilky², Jacqueline Vuky³, Lara E. Davis³, Todd Bauer³, Hans Gelderblom³, Mary Michenzie³, Maitreyi Sharma⁴, Rodrigo Ruiz-Soto⁴, Matthew L. Sherman⁴, William D. Tap⁷

¹Toronto Sarcoma Program, Princess Margaret Cancer Center, Toronto, Ontario, CANADA; ²Medicine, University of Colorado Cancer Center, Aurora, Colorado, UNITED STATES; ³OHSU Knight Cancer Institute, Portland, Oregon, UNITED STATES; ⁴OHSU Knight Cancer Institute, Portland, Oregon, UNITED STATES; ⁵Medical Oncology, Leiden University Medical Center, Leiden, NETHERLANDS; ⁶Deciphera Pharmaceuticals, LLC, Waltham, Massachusetts, UNITED STATES; ⁷Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, UNITED STATES

1:30 pm - 2:00 pm

CLOSING REMARKS

President: Kirsten Sundby Hall
Program Chairs: Silvia Stacchiotti, Margaret von Mehren, Inga-Marie Schaefer

2:00 pm - 3:00 pm

CTOS Members’ Business Meeting
Poster #001 3412554
DIFFICULTY OF DISTINGUISHING ARTERIAL INTIMAL SARCOMA FROM CHRONIC PULMONARY EMBOLISM THROUGH DIFFERENTIAL DIAGNOSIS
Hirotaka Suto¹, Yumiko Inui², Atsuo Okamura²
¹Kobe University, Kobe, JAPAN; ²Kakogawa Central City Hospital, Kakogawa, JAPAN

Poster #002 3412790
APATINIB FOR TREATMENT OF INOPERABLE METASTATIC OR LOCALLY ADVANCED CHONDROSARCOMA: WHAT CAN WE LEARN ABOUT THE BIOLOGICAL BEHAVIOR OF CHONDROSARCOMA FROM A MULTICENTER STUDY
Lu Xie¹, Jie Xu¹, Jin Gu², Zhe Lv², Xiaodong Tang¹, Wei Guo¹
¹Musculoskeletal Tumor Center, Peking University People’s Hospital, Beijing, BEIJING, CHINA; ²Surgical Oncology, Peking University Shougang Hospital, Beijing, BEIJING, CHINA

Poster #003 3412794
DYNAMIC CHANGES IN QUALITY OF LIFE AND Q-TWIST ANALYSIS FOR EWING SARCOMA PATIENTS FOLLOWING ANLOTINIB AND IRINOTECAN, A COMBINATION OF PHASE 1B AND 2 TRIAL
Lu Xie¹, Jie Xu¹, Wei Guo¹, Xin Sun¹, Xiaodong Tang¹
¹Musculoskeletal Tumor Center, Peking University People’s Hospital, Beijing, BEIJING, CHINA

Poster #004 3412832
THE CLINICAL IMPLICATIONS OF TUMOR MUTATIONAL BURDEN IN OSTEOSARCOMA
Lu Xie¹, Yu-Fei Yang², Wei Guo¹, Dongxue Che², Jie Xu¹, Xin Sun¹, Kuisheng Liu¹, Xiaodong Tang¹
¹Musculoskeletal Tumor Center, Peking University People’s Hospital, Beijing, BEIJING, CHINA; ²Genetronhealth. Co. Ltd., Beijing, CHINA

Poster #005 3413225
EXTRASKELETAL MYXOID CHONDROSARCOMA: A HIGH INCIDENCE OF METASTATIC DISEASE TO LYMPH NODES
Matthew R. Claxton², Peter S. Rose¹, Doris Wenger², Matthew T. Houdek¹
¹Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota, UNITED STATES; ²School of Medicine, Mayo Clinic, Rochester, Minnesota, UNITED STATES

Poster #006 3420516
CLINICAL EXPERIENCE OF 6 CASES OF MYXOID PLEOMORPHIC LIPOSARCOMA
Chiaki Sato¹, Eisuke Kobayashi¹, Akira Kawai¹
¹National Cancer Center Japan, Chu-ou-ku, Tokyo, JAPAN
**VERSICAN AND EXTRACELLULAR MATRIX REMODELING PROMOTE CIRCULATING OSTEOSARCOMA CELL EXTRAVASATION AND METASTATIC SEEDING**


1School of Medicine, Duke University, Durham, North Carolina, UNITED STATES; 2Duke University Cancer Institute, Durham, North Carolina, UNITED STATES; 3Nazareth College, Rochester, New York, UNITED STATES; 4Orthopaedics, Duke University, Durham, North Carolina, UNITED STATES; 5Department of Orthopaedic Surgery, Duke Cancer Institute, Durham, North Carolina, UNITED STATES; 6College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina, UNITED STATES

**THE ANATOMIC DISTRIBUTION OF OSTEOSARCOMA**

*Jeffrey Brown*, David Matichak, John Groundland

1Orthopedics, University of Miami Miller School of Medicine, Miami, Florida, UNITED STATES; 2Orthopedics, Huntsman Cancer Institute, Salt Lake City, Utah, UNITED STATES

**PROGNOSIS OF PATIENTS WITH METASTATIC SOFT TISSUE SARCOMA: ADVANCES IN RECENT YEARS**

*Jakob Lochner*, Franka Menge, Nikolaos Vassos, Peter Hohenberger, Bernd Kasper

1Interdisciplinary Tumor Center, Mannheim University Medical Center, Mannheim, GERMANY

**RECURRENT MULTIFOCAL PLEOMORPHIC SARCOMA OF THE SCALP RESPONDING TO PEMBROLIZUMAB**

*Benjamin Powers*, Elizabeth Friedman

1Medical Oncology, U of Kansas Cancer Center, Overland Park, Kansas, UNITED STATES; 2Pathology and Laboratory Medicine, U of Kansas Health System, Kansas City, Kansas, UNITED STATES

**PROGNOSTIC FACTORS OF HIGH-GRADE OSTEOSARCOMA: ANALYSIS OF 20 YEARS DATA AT A SINGLE CENTER IN JAPAN**

*Akane Ariga*, Yoshiaki Ando, Chigusa Sawamura, Jun Manabe, Tabu Gokita

1Department of Orthopaedic Surgery, Saitama Cancer Center, Saitama, JAPAN

**CHARACTERISTICS AND OUTCOMES OF LOCALLY RECURRENT RETROPERITONEAL SARCOMA AFTER FIRST RELAPSE IN A SINGLE TERTIARY ASIAN CENTRE AND APPLICABILITY OF THE SARCULATOR**

*Hui Jun Lim*, Ru Xin Wong, Yen Sin Koh, Zhirui Shaun Ho, Chin-Ann Johnny Ong, Farid Bin Harunal Rashid Mohamad, Ching Ching Melissa Teo

1Department of Radiation Oncology, National Cancer Centre Singapore, Singapore, SINGAPORE; 2Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology, National Cancer Centre Singapore, Singapore, SINGAPORE; 3Department of Medical Oncology, National Cancer Centre Singapore, Singapore, SINGAPORE

**CURRICULUM-BASED ONLINE CME IMPROVES PHYSICIAN KNOWLEDGE OF EPITHELIOID SARCOMA**

*Micahel A. Worst*, Mindy Tanzola, Emily Van Laar, Mrinal Gounder, Mark Agulnik

1Medscape Oncology, New York, New York, UNITED STATES; 2Memorial Sloan Kettering Cancer Center, New York, New York, UNITED STATES; 3Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, UNITED STATES
ASSOCIATION BETWEEN OCCUPATIONAL EXPOSURES AND SARCOMA INCIDENCE AND MORTALITY: SYSTEMATIC REVIEW AND META-ANALYSIS

Dali Edwards¹, Angelina Voronina², Kristopher Attwood⁰, Anne Grand'Maison⁴
¹Department of Medicine, University at Buffalo, Buffalo, New York, UNITED STATES; ²Department of Medicine, New York–Presbyterian Queens, New York, New York, UNITED STATES; ³Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, UNITED STATES; ⁴Department of Sarcoma Medical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, UNITED STATES

PELVIC SOFT TISSUE SARCOMAS: AN INTERNATIONAL RETROSPECTIVE STUDY FROM THE TRANS-ATLANTIC AUSTRALASIAN RETROPERITONEAL SARCOMA WORKING GROUP (TARPSWG)

Marco Fiore¹, Catherine Sarre-Lazcano¹, Sinziana Dumitra³, Charles Honoré⁴, Paul Sargos⁴, Giovanni Grignani⁵, Shintaro Iwata⁶, Carolyn Nessim⁷, Marko Novak⁸, Dmitri Tzanis⁹, David E. Gyorki¹⁰, Piotr Rutkowski¹¹, Antoine Bouchard-Fortier¹², Kenneth Cardona¹³, Sergio D. Quildrian¹⁴, Dorian Y. Garcia-Ortega¹⁷, Winan J. van Houdt¹⁵, Sergio Valeri¹⁶, Carlo Abatini¹, Mario Terlizzi¹, Francesco Tolomeo⁵, Michelle J. Wilkinson¹⁰, Jecek Skoczylas¹¹, Sandro Pasquali¹, Alessandro Gronchi¹
¹Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY; ²McGill University, Montreal, Ontario, CANADA; ³Gustave Roussy, Villejuif, FRANCE; ⁴Institut Bergonié, Bordeaux, FRANCE; ⁵Candiolo Cancer Institute, FPO IRCCS, Candiolo, ITALY; ⁶National Cancer Center Hospital, Tokyo, JAPAN; ⁷The Ottawa Hospital, Ottawa, Ontario, CANADA; ⁸Institute of Oncology Ljubljana, Ljubljana, SLOVENIA; ⁹Institut Curie, PSL University, Paris, FRANCE; ¹⁰Peter McCallum Cancer Center, Melbourne, Victoria, AUSTRALIA; ¹¹Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, POLAND; ¹²Alberta Health Services - University of Calgary, Calgary, Alberta, CANADA; ¹³Winship Cancer Institute, Emory University, Atlanta, Georgia, UNITED STATES; ¹⁴Angel H. Rofo Institute of Oncology, British Hospital, Buenos Aires, ARGENTINA; ¹⁵Antoni van Leeuwenhoek / The Nederland Cancer Institute, Amsterdam, NETHERLANDS; ¹⁶Campus Biomedico, Rome, ITALY; ¹⁷National Cancer Institute, Mexico City, MEXICO

OSTEOSARCOMA ORGANOIDS DEMONSTRATE FUNCTIONAL AND THERAPEUTIC HETEROGENEITY DEPENDING UPON GEOGRAPHIC SITE OF ORIGIN WITHIN THE TUMOR

Etienne M. Flamant¹, Mark M. Cullen¹, Sarah Hoskinson², Beatrice Thomas², Sehwa Oh³, Gabrielle Rupprecht³, Joanne Tuohy³, David S. Hsu³, William C. Eward³, Jason A. Somarelli¹³
¹Duke University School of Medicine, Durham, North Carolina, UNITED STATES; ²Department of Orthopaedic Surgery, Duke University Medical Center, Durham, North Carolina, UNITED STATES; ³Department of Medicine, Duke University Medical Center, Durham, North Carolina, UNITED STATES; ³Department of Small Animal Clinical Sciences, Virginia-Maryland College of Veterinary Medicine, Blacksburg, Virginia, UNITED STATES

RADIOLOGICAL ANALYSIS OF TUMOR RESPONSE TO AN EFFECTIVE TYROSINE KINASE INHIBITOR (TKI), PEXIDARTINIB, IN TENOSYNOVIAL GIANT CELL TUMORS (TGCT) FROM THE PHASE 3 ENLIVEN STUDY

Charles Peterfy¹, William D. Tap², John H. Healey², Andrew J. Wagner³, Souhil Zaim³, Hans Bloem³, Qiang Wang⁴, Dale Shuster⁵, Yan Chen⁶, Michel van de Sande²
¹Spire Sciences, Boca Raton, Florida, UNITED STATES; ²Department of Orthopaedic Surgery, Duke University Medical Center, New York, New York, UNITED STATES; ³Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York, UNITED STATES; ³Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, UNITED STATES; ⁴Bioclinica, Newark, California, UNITED STATES; ⁵Leiden University Medical Center, Leiden, NETHERLANDS; ⁶Daiichi Sankyo, Inc., Basking Ridge, New Jersey, UNITED STATES
Poster #018  3437421
A NOVEL PRE-OPERATIVE RISK SCORE TO GUIDE PATIENT SELECTION FOR RESECTION OF SOFT TISSUE SARCOMA LUNG METASTASES: AN ANALYSIS FROM THE UNITED STATES SARCOMA COLLABORATIVE
Rachel Lee¹, Cecilia Ethun¹, Adriana Gamboa¹, Michael Turgeon¹, Thuy Tran², George Poultsides², Valerie Grignon³, J H. Howard³, Meena Bedi³, Harveshp Mogal³, Callisia Clarke³, Jennifer Tseng³, Kevin Roggin⁴, Konstantinos Chouliaras⁴, Konstantinos Votanopoulos⁴, Bradley Krasnick⁵, Ryan Fields⁵, Shervin Oskouei⁵, David Monson⁵, Nickolas Reimer⁵, Shishir Maithel⁵, Allan Pickens⁶, Kenneth Cardona¹
¹Division of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, Atlanta, Georgia, UNITED STATES; ²Department of Surgery, Stanford University Medical Center, Palo Alto, California, UNITED STATES; ³Department of Surgical Oncology, Department of Surgery, The Ohio State University, Columbus, Ohio, UNITED STATES; ⁴Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin, UNITED STATES; ⁵Division of Surgical Oncology, Department of Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin, UNITED STATES; ⁶Department of Surgery, University of Chicago Medicine, Chicago, Illinois, UNITED STATES; ⁷Department of Surgery, Wake Forest University, Winston-Salem, North Carolina, UNITED STATES; ⁸Department of Surgery, Washington University School of Medicine, St Louis, Missouri, UNITED STATES; ⁹Division of Cardiothoracic Surgery, Department of Surgery, Emory University, Atlanta, Georgia, UNITED STATES

Poster #019  3437427
THE ACCURACY OF A NOVEL SONOGRAPHIC SCANNING AND REPORTING PROTOCOL TO SURVEY FOR SOFT TISSUE SARCOMA LOCAL RECURRENCE: RESULTS OF A PROSPECTIVE PILOT STUDY
Adam D. Singer¹, Philip K. Wong², Monica B. Umpierrez², Nickolas Reimer¹, Felix M. Gonzalez², David A. Reiter², Shervin Oskouei¹, Kenneth Cardona¹
¹Surgery, Winship Cancer Institute, Emory University, Atlanta, Georgia, UNITED STATES; ²Radiology, Emory University, Atlanta, Georgia, UNITED STATES; ³Orthopedics, Emory University, Atlanta, Georgia, UNITED STATES

Poster #020  3437455
HISTOLOGICAL VARIATION AFTER PRE-OPERATIVE HYPOFRACTIONATED VERSUS STANDARD FRACTION RADIOTHERAPY IN SOFT TISSUE SARCOMAS
Casey Hollawell¹, Yulan Gong², Lori Rink², Elizabeth Handorf³, Michael Shu¹, Margaret von Mehren², Jeffrey Farma², Stephanie Greco², John Abraham³, Josh Meyer³, Krisha J. Howell²
¹Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania, UNITED STATES; ²Fox Chase Cancer Center, Philadelphia, Pennsylvania, UNITED STATES; ³Rothman Institute, Philadelphia, Pennsylvania, UNITED STATES

Poster #021  3437674
STRIVE-01: PHASE I STUDY OF EGFR806 CAR T CELL IMMUNOTHERAPY FOR RECURRENT/REFRACTORY SOLID TUMORS IN CHILDREN AND YOUNG ADULTS
Catherine M. Albert¹, Navin R. Pinto¹, Adam J. Johnson¹, Ashley L. Wilson¹, Stephanie Mgebroff¹, Christopher Brown¹, Catherine Lindgren¹, Erin Rudzinski², Bonnie L. Cole³, Nicholas A. Vitanza¹, Juliane Gust³, Michael C. Jensen¹, Julie Park¹
¹Seattle Children’s Research Institute, Seattle, Washington, UNITED STATES; ²Pathology, Seattle Children’s Hospital and University of Washington, Seattle, Washington, UNITED STATES; ³Neurology, University of Washington, Seattle, Washington, UNITED STATES

Poster #022  3437802
NICLOSAMIDE STEARATE PRODRUG THERAPEUTIC (NSPT) ENHANCES MITOCHONDRIAL PROTON LEAK AND INDUCES POTENT CYTOTOXICITY IN OSTEOSARCOMAS
Mark M. Cullen¹, Etienne M. Flamant¹, Philip H. Khoury¹, Hailey E. Brighton³, David L. Kerr³, Gireesh B. Reddy³, Sarah Hoskinson³, Harrison R. Ferlauto¹, Suzanne B. DeWitt³, Kathryn E. Ware³, Beatrice Thomas³, Julia D. Visgauss³, Brian E. Brigman⁴, Jason A. Somarelli⁵, David Needham⁶, William C. Eward⁶
¹School of Medicine, Duke University, Durham, North Carolina, UNITED STATES; ²Duke University, Durham, North Carolina, NITED STATES; ³Duke Cancer Institute, Durham, North Carolina, UNITED STATES; ⁴Department of Orthopaedic Surgery, Duke Cancer Institute, Durham, North Carolina, UNITED STATES; ⁵Department of Materials Science, Duke University, Durham, North Carolina, UNITED STATES; ⁶Department of Comparative Oncology, Duke Cancer Institute, Durham, North Carolina, UNITED STATES; ⁷Department of Orthopaedic Surgery, Duke University Hospital, Durham, North Carolina, UNITED STATES; ⁸Department of Orthopaedic Surgery, University of Miami Health System, Miami, Florida, UNITED STATES

94
Poster #023 3438818
MAGNETIC RESONANCE GUIDED HIGH INTENSITY FOCUSED ULTRASOUND IN COMBINATION WITH THERMOSENSITIVE LIPOSOMAL DOXORUBICIN AS A NOVEL TREATMENT FOR RHABDOMYOSARCOMA
Claire Wunker¹, Ben Keunen³, Karolina Piorkowska³, Warren Foltz², Maximilian Regenold³, Yael Babichev¹, Michael Dunne³, Maryam Siddiqui³, Samuel Pichardo³, Christine Allen³, Adam Waspe³, Rebecca Gladdy¹, Justin T. Gerstle⁶
¹Lunenfeld Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, CANADA; ²Pediatric Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, UNITED STATES; ³Center for Image Guided Innovation and Therapeutic Intervention, The Hospital for Sick Children, Toronto, Ontario, CANADA; ⁴Radiation Oncology, University of Toronto, Toronto, Ontario, CANADA; ⁵Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, CANADA; ⁶University of Calgary, Calgary, Alberta, CANADA

Poster #024 3439734
SOFT TISSUE SARCOMA: IS THERE A SURVIVAL GAP BETWEEN MIDDLE-AGED AND ELDERLY PATIENTS?
Freek Gillissen¹, Robbert Maatman¹, Frits Aarts¹, Paul Nijhuis¹
¹Surgery, VieCuri Medical Centre, Venlo, NETHERLANDS

Poster #025 3439834
MACHINE LEARNING TOOL SUCESSFULLY CLASSIFIES TREATMENT RESPONSE IN HIGH-GRADE OSTEOSARCOMA
Patrick Leavey¹, Ka Yaw Teo², Karin Claussen¹, Kevin Cederberg³, Rami Hallac⁴, Anita Sengupta⁵, Alexandra Callan⁶, Ovidiu Daescu²
¹Pediatrics, UT Southwestern Medical Center, Dallas, Texas, UNITED STATES; ²UT Dallas, Dallas, Texas, UNITED STATES; ³Radiology, UT Southwestern Medical Center, Dallas, Texas, UNITED STATES; ⁴Children’s Health, Children’s Medical Center Dallas, Dallas, Texas, UNITED STATES; ⁵Pathology, UT Southwestern Medical Center, Dallas, Texas, UNITED STATES; ⁶Orthopedics, UT Southwestern Medical Center, Dallas, Texas, UNITED STATES

Poster #026 3440865
OUTCOME OF COMBINING RESECTION OF SARCOMA WITH INVOLVED BOWELS IN PATIENTS WITH PRIMARY RETROPERITONEAL LIPOSARCOMA
Jun Chen¹, Nannan Yan¹, Lili Feng¹, Wening Liu¹, Mei Huang¹, Chengli Miao¹, Chenghua Luo¹
¹Dept. of Retroperitoneal Tumor Surgery, Peking University International Hospital, Beijing, CHINA

Poster #027 3441221
A PHASE 1, MULTICENTER, OPEN-LABEL, FIRST-IN-HUMAN STUDY OF DS-6157A IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR
Suzanne George¹, Steven E. Cohen², Satoshi Nishioka³, Emarjola Bako², Li Liu², Prasanna Kumar², Yoichi Naito⁴
¹Dana-Farber Cancer Institute, Boston, Massachusetts, UNITED STATES; ²Daiichi Sankyo, Inc, Basking Ridge, New Jersey, UNITED STATES; ³Daiichi Sankyo, Co., Ltd, Tokyo, JAPAN; ⁴National Cancer Center Hospital East, Kashiwa, JAPAN

Poster #028 3441532
DUAL-ENERGY CT AS A QUANTITATIVE RESPONSE PARAMETER IN PATIENTS WITH GIST UNDERGOING TARGETED THERAPY – A PROSPECTIVE MULTI-CENTER TRIAL
Mathias Meyer¹, Hideki Ota¹, Christina Messiou², Charlotte Benson³, Thomas Henzler², Stefan O. Schoenberg², Peter Hohenberger²
¹Tohoku University Hospital, Tohoku, JAPAN; ²University Medical Center Mannheim, Mannheim, GERMANY; ³Royal Marsden Hospital and Institute of Cancer Research, London, UNITED KINGDOM

Poster #029 3441865
PROGNOSES OF SUPERFICIAL SOFT TISSUE SARCOMA: THE IMPORTANCE OF FASCIA-TUMOR RELATIONSHIP ON MRI
Ilkyu Han¹, Jeong Hyun Lee¹, Han-Soo Kim¹
¹Orthopedic Surgery, Seoul National University Hospital, Seoul, KOREA (THE REPUBLIC OF)
OUTCOME OF CLINICAL GENETIC TESTING IN PATIENTS WITH SARCOMA

H. C. Miller, Lili Zhao, Erika Koeppel, Erin Cobain, Scott Schuetze, Laurence Baker, Elena Stoffel, Rashmi Chugh

1Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, UNITED STATES; 2Department of Biostatistics, University of Michigan, Ann Arbor, Michigan, UNITED STATES

VARIANCE BETWEEN EXPERTS AND COMMUNITY PRACTITIONERS IN TREATING SOFT TISSUE SARCOMAS: ANALYSIS OF AN ONLINE DECISION SUPPORT TOOL

Ryan P. Topping, Vicki L. Keedy, Shreyaskumar Patel, Richard F. Riedel, Brian A. Van Tine, Timothy A. Quill, William D. Tap

1Clinical Care Options, Reston, Virginia, UNITED STATES; 2Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, UNITED STATES; 3University of Texas MD Anderson Cancer Center, Houston, Texas, UNITED STATES; 4Duke Cancer Institute, Durham, North Carolina, UNITED STATES; 5Washington University School of Medicine, St Louis, Missouri, UNITED STATES; 6Memorial Sloan Kettering Cancer Center, New York, New York, UNITED STATES

ANTI-TUMOR EFFECT OF LAT1 INHIBITOR ON CLEAR CELL SARCOMA CELL LINE

Masayuki Morishita, Takuya Fujimoto, Teruya Kawamoto, Toshihiro Akisue, Ikuo Fujita, Toshiyuki Takemori, Shuichi Fujiwara, Kazumichi Kitayama, Shunsuke Yahiro, Tomohiro Miyamoto, Yohei Kawakami, Naomasa Fukase, Hitomi Hara, Ryosuke Kuroda

1Graduate School of Medicine, Kobe University, Kobe, JAPAN; 2Orthopaedic Surgery, Hyogo Cancer Center, Akashi, JAPAN

OPPORTUNISTIC MUSCLE MEASUREMENTS ON STAGING CHEST CT FOR EXTREMITY AND TRUNCAL SOFT TISSUE SARCOMA ARE ASSOCIATED WITH SURVIVAL

Eileen Phan, Steven W. Thorpe, Felix S. Wong, Sandra Taylor, Augustine M. Saiz, Robert J. Canter, Leon Lenchik, R L. Randall, Robert Boutin

1Sarcoma Services, Department of Orthopaedic Surgery, University of California, Davis, Sacramento, California, UNITED STATES; 2Department of Radiology, Stanford University, Stanford, California, UNITED STATES; 3School of Medicine, University of California, Davis, Sacramento, California, UNITED STATES; 4Department of Radiology, University of California, Davis, Sacramento, California, UNITED STATES; 5Division of Biostatistics, Department of Public Health Sciences, University of California, Davis, Sacramento, California, UNITED STATES; 6Division of Surgical Oncology, Department of Surgery, University of California, Davis, Sacramento, California, UNITED STATES; 7Department of Radiology, Wake Forest School of Medicine, Winston-Salem, North Carolina, UNITED STATES; 8Department of Orthopaedic Surgery, University of California, Davis, Sacramento, California, UNITED STATES

IS SURGICAL RESECTION OF THE PRIMARY SITE ASSOCIATED WITH AN IMPROVED OVERALL SURVIVAL FOR PRIMARY MALIGNANT BONE TUMORS WITH METASTATIC DISEASE AT PRESENTATION?

Azeem T. Malik, John H. Alexander, Safdar N. Khan, Thomas J. Scharschmidt

1Orthopaedics, The Ohio State University Wexner Medical Center, Columbus, Ohio, UNITED STATES; 2Moffit Cancer Center, Tampa, Florida, UNITED STATES

CRYOABLATION: AN EFFECTIVE AND SAFE OPTION IN THE TREATMENT ALGORITHM OF EXTRA-ABDOMINAL DESMOID TUMORS?

Yet Yen Yan, Paul Mallinson, Peter Munk, John P. Walsh, Paul Clarkson, Prem Jayaram, Manraj Heran, Hugue Ouellette, Christine Simmons

1Vancouver General Hospital, Vancouver, British Columbia, CANADA; 2BC Cancer Agency, Vancouver, British Columbia, CANADA
DEVELOPMENT OF A NOVEL ORGANS-ON-A-CHIP MODEL THAT ENABLES PREDICTIVE AND CLINICALLY RELEVANT DRUG SCREENING TO DETERMINE EWING SARCOMA ANTI-TUMOR EFFICACY AND CARDIAC SAFETY

1Biomedical Engineering, Columbia University, Brooklyn, New York, UNITED STATES; 2Department of Chemistry, Materials and Chemical Engineering, Politecnico de Milano, Milan, ITALY; 3Department of Biomedical Engineering, Stevens Institute of Technology, Hoboken, New Jersey, UNITED STATES

THE NITRASARC TRIAL- A NON-RANDOMIZED, OPEN-LABEL PHASE II TRIAL EVALUATING EFFICACY AND FEASIBILITY OF COMBINED TREATMENT WITH TRABECTEDIN AND NIVOLUMAB IN PATIENTS WITH METASTATIC OR INOPERABLE SOFT TISSUE SARCOMAS AFTER FAILURE OF AN ANTHRACYCLINE-CONTAINING REGIMEN: INTERIM SAFETY ANALYSIS


TOPP: TENOSYNOVIAL GIANT CELL TUMOR OBSERVATIONAL PLATFORM PROJECT—PATIENT-REPORTED SYMPTOMS AND QUALITY OF LIFE (QOL) FROM A EUROPEAN AND US PROSPECTIVE REGISTRY

Emanuela Palmerini, Julio Lopez Bastida, Xin Ye, Silvía Stacchiotti, Eric Staals, Geert Spierenburg, Petra Laeis, Eva-Maria Frank, Hans Gelderblom, Michiel van de Sande
1IRCCS Istituto Ortopedico Rizzoli, Bologna, ITALY; 2University of Castilla-La Mancha, Talaver a de la Reina, Toledo, SPAIN; 3Daiichi Sankyo, Inc., Basking Ridge, New Jersey, UNITED STATES; 4Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY; 5Leiden University Medical Center, Leiden, NETHERLANDS; 6Daiichi Sankyo Europe GmbH, Munich, GERMANY

THE DIFFUSE-TYPE TGCT PATIENT JOURNEY: A PROSPECTIVE MULTICENTER STUDY

Geert Spierenburg, Nicholas M. Bertha, John H. Healey, Petra Laeis, Eva-Maria Frank, Silvia Stacchiotti, Emanuela Palmerini, Eric Staals, Michiel van de Sande
1Leiden University Medical Center, Leiden, NETHERLANDS; 2David Geffen School of Medicine at UCLA, Santa Monica, California, UNITED STATES; 3Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York, UNITED STATES; 4Daiichi Sankyo Europe GmbH, Munich, GERMANY; 5Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY; 6IRCCS Istituto Ortopedico Rizzoli, Bologna, ITALY

TREATMENT OUTCOME OF SUPERFICIAL LEIOMYOSARCOMA

Elizabeth P. Wellings, Meagan E. Tibbo, Peter S. Rose, Matthew T. Houdek
1Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota, UNITED STATES
Poster #041 3449895
MOLECULAR ANALYSIS OF ARCHIVAL CLEAR CELL SARCOMA TISSUE SAMPLES FROM EORTC TRIAL 90101 "CREATE" AND CORRELATION WITH RESPONSE TO CRIZOTINIB
Che-Jui Lee¹, Agnieszka Wozniak¹, Elodie Modave², Bram Boeckx², Silvia Stacchiotti³, Piotr Rutkowski⁴, Jean-Yves Blay⁵, Maria Debiec-Rychter⁶, Raf Sciøt¹, Patrick Schöffski⁷
¹Department of Oncology, KU Leuven, Leuven, BELGIUM; ²Center for Cancer Biology / Department of Human Genetics, VIB / KU Leuven, Leuven, BELGIUM; ³Department of Medical Oncology, IRCCS Fondazione Istituto Nazionale Tumori, Milano, ITALY; ⁴Department of Soft Tissue / Bone Sarcoma and Melanoma, Maria Skłodowska-Curie Institute, Warsaw, POLAND; ⁵Department of Medical Oncology, Centre Léon Bérard / Université Claude Bernard Lyon I, Lyon, FRANCE; ⁶Department of Human Genetics, University Hospitals Leuven / KU Leuven, Leuven, BELGIUM; ⁷Department of Pathology, University Hospitals Leuven / KU Leuven, Leuven, BELGIUM

Poster #042 3450727
OPTICAL SENSOR FOR RAPID BACTERIAL DETECTION AND DIAGNOSIS OF IMPLANT ASSOCIATED INFECTIONS IN CANCER PATIENTS
Robert Hunter¹, Mariam Taha¹, Emilio Alarcon³, Hesham Abdelbary², Hanan Anis³
¹The Ottawa Hospital Research Institute, Ottawa, Ontario, CANADA; ²The Ottawa Hospital, Ottawa, Ontario, CANADA; ³University of Ottawa, Ottawa, Ontario, CANADA

Poster #043 3451306
USE OF FDG POSITRON EMISSION TOMOGRAPHY TO PREDICT CHEMOTHERAPY RESPONSE AND OUTCOMES IN PEDIATRIC BONE SARCOMAS
Natalie L. Wu¹, Antoinette Lindberg², Anna Faino², Sara Flash³, Douglas S. Hawkins¹, Catherine M. Albert¹
¹Pediatric Hematology/Oncology, Seattle Children's Hospital, Seattle, Washington, UNITED STATES; ²Orthopedic Surgery, Seattle Children's Hospital, Seattle, Washington, UNITED STATES; ³Seattle Children's Hospital, Seattle, Washington, UNITED STATES

Poster #044 3452161
THE AGE-RELATED IMPACT OF SURVIVING SARCOMA ON HEALTH-RELATED QUALITY OF LIFE: DATA FROM THE DUTCH SURVSARC STUDY
Cas Drabbe¹, Winette T. van der Graaf³, Vicky Soomers³, Winan J. van Houdt¹, Olga Husson¹
AUTHORS/INSTITUTIONS: C. Drabbe, W.T. van der Graaf, O. Husson, Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, NETHERLANDS; V. Soomers, Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, NETHERLANDS; W.J. van Houdt, Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, NETHERLANDS

Poster #045 3452220
PROMISING ACTIVITY OF AN ENZYME-ACTIVATED DOXORUBICIN PRODRUG IN A PANEL OF PATIENT-DERIVED XENOGRAFT MODELS OF SOFT TISSUE SARCOMA
Britt Van Renterghem¹, Ludovica Tarantola¹, Agnieszka Wozniak¹, Jasmien Wellens¹, Madita Nysen¹, Ulla Vanleeuw¹, Che-Jui Lee¹, Yannick Wang¹, Andrea Casazza², Geert Reynolds², Nele Kindt², Patrick Schöffski²
¹Oncology, KU Leuven, Huldenberg, BELGIUM; ²CoBioRes, Leuven, BELGIUM

Poster #046 3452295
BACTERIOPHAGE COCKTAIL TO IMPROVE TREATMENT OF IMPLANT-ASSOCIATED BACTERIAL INFECTIONS IN CANCER PATIENTS
Mariam Taha¹, Joel Werier², Hesham Abdelbary²
¹The Ottawa Hospital Research Institute, Ottawa, Ontario, CANADA; ²The Ottawa Hospital, Ottawa, Ontario, CANADA

Poster #047 3452402
SYSTEMIC INFLAMMATION RESPONSE INDEX (SIRI) AS A PREDICTIVE FACTOR FOR OVERALL SURVIVAL IN ADVANCED SOFT TISSUE SARCOMA TREATED WITH ERIBULIN
Hiroshi Kobayashi¹, Tomotake Okuma¹, Koichi Okajima¹, Yuki Ishibashi², Toshihide Hirai³, Takahiro Ohki⁴, Masachika Ikegami¹, Ryoko Sawada¹, Yusuke Shinoda¹, Toru Akiyama³, Takahiro Goto², Sakae Tanaka¹
¹Orthopaedic Department, The University of Tokyo Hospital, Tokyo, JAPAN; ²Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, JAPAN; ³Saitama Medical Center, Jichi Medical University, Saitama, JAPAN
Poster #048 3452426
STING ACTIVATION AS AN IMMUNOTHERAPEUTIC STRATEGY FOR SOFT TISSUE SARCOMA
Kayla Marritt1, Karys Hildebrand1, Arvind Singla1, Bryan G. Yipp2, Frank Jirik3, Michael Monument1
1Department of Surgery, Cumming School of Medicine, University of Calgary, Calgary, Alberta, CANADA; 2Department of Critical Care, Cumming School of Medicine, University of Calgary, Calgary, Alberta, CANADA; 3Department of Biochemistry and Molecular Biology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, CANADA

Poster #049 3452445
REGORAFENIB FOR PROGRESSIVE RELAPSED METASTATIC OSTEOSARCOMA IN AN ADOLESCENT
Ariel Gliksberg1, Allison Fraum2, Molly M. Aguina3, Mary Lou Schmidt1, Paul Kent1
1Pediatric Hematology/Oncology, University of Illinois Chicago, Chicago, Illinois, UNITED STATES; 2Radiology, UIC, Chicago, Illinois, UNITED STATES; 3Pediatric Hematology/Oncology, Rush University, Chicago, Illinois, UNITED STATES

Poster #050 3452498
OPTIMIZED PATIENT-DERIVED 3D SARCOMA MODEL – ROBUST SYSTEM FOR SARCOMA RESEARCH
Juergen Loskutov1, Manuela Regenbrecht1, Saskia Scharf3, Philipp Stroebel5, Gerrit Erdmann6,
Christian R. Regenbrecht2, Maya Niethard4
1CELLphenomics GmbH, Berlin, GERMANY; 2ASC Oncology GmbH, Berlin, GERMANY; 3Department of Oncology and Palliative Care, Helios Klinikum Berlin-Buch, Berlin, GERMANY; 4Department for Tumor Orthopedics, Helios Klinikum Berlin-Buch, Berlin, GERMANY; 5Department for Pathology, University Hospital Goettingen, Goettingen, GERMANY; 6NMI-TT, Berlin, GERMANY

Poster #051 3452630
SAFE CLINICAL COMPATIBILITY OF A NON-INVASIVE EXTENDIBLE ELECTROMAGNETIC PROSTHESIS WITH AN IN SITU VENTRICULAR ASSIST DEVICE
Nicholas P. Gannon1, Kristy M. McHugh2, Rebecca K. Ameduri3, Christian M. Ogilvie1
1Department of Orthopaedic Surgery, University of Minnesota, Minneapolis, Minnesota, UNITED STATES; 2Department of Solid Organ Transplant, Fairview, Minneapolis, Minnesota, UNITED STATES; 3Department of Pediatrics, University of Minnesota Masonic Children's Hospital, Minneapolis, Minnesota, UNITED STATES

Poster #052 3452817
SELINEXOR, A FIRST IN CLASS NUCLEAR EXPORT INHIBITOR, FOR THE TREATMENT OF ADVANCED MALIGNANT PERIPHERAL NERVE SHEATH TUMOR
Esmail Al-Ezzi1, Mrinal Gounder2, Albiruni Abdul Razak1, Geoffrey Watson1, Alessandro Mazzocca2, Bruno Vincenzi3
1Toronto Sarcoma Program, Princess Margaret Cancer Centre, Toronto, Ontario, CANADA; 2Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, UNITED STATES; 3Department of Medical Oncology, University Campus Bio-Medico, Via Alvaro del Portillo, Rome, ITALY

Poster #053 3452862
UNRAVELLING THE HETEROGENEITY OF SARCOMA PATIENTS’ HEALTH-RELATED QUALITY OF LIFE: IMPACT OF PRIMARY SARCOMA LOCATION
Dide den Hollander1, Ilse van Eck2, Vicky Soomers2, Winette T. van der Graaf1, Michiel van de Sande3, Jacco de Haan4, Cees Verhoeof5, Ingeborg Vriens6, Winan J. van Houdt7, Han Bonenkamp8, Ingrid Desar2, Olga Husson1
1Medical Oncology, Netherlands Cancer Institute, Amsterdam, NETHERLANDS; 2Medical Oncology, Radboud University Medical Center, Nijmegen, NETHERLANDS; 3Orthopaedics, Leiden University Medical Center, Leiden, NETHERLANDS; 4Medical Oncology, University Medical Center Groningen, Groningen, NETHERLANDS; 5Surgical Oncology, Erasmus Medical Center, Rotterdam, NETHERLANDS; 6Medical Oncology, Maastricht University Medical Center, Maastricht, NETHERLANDS; 7Surgical Oncology, Netherlands Cancer Institute, Amsterdam, NETHERLANDS; 8Surgical Oncology, Radboud University Medical Center, Nijmegen, NETHERLANDS
A RANDOMIZED, OPEN-LABEL PHASE 1/2 STUDY OF RAMUCIRUMAB IN COMBINATION WITH CHEMOTHERAPY IN PEDIATRIC PATIENTS AND YOUNG ADULTS WITH RELAPSED, RECURRENT, OR REFRACTORY DESMOPLASTIC SMALL ROUND CELL TUMOR OR SYNOVIAL SARcoma

Emily K. Slotkin, Michela Casanova, Andrea Ferrari, Douglas J. Harrison, Heather Wasserstrom, Zachary Thomas, Chunxiao Wang, Bwana L. Brooks, Brian A. Van Tine

1Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY; 2MD Anderson Cancer Center, Houston, Texas, UNITED STATES; 3Eli Lilly and Company, Indianapolis, Indiana, UNITED STATES; 4Washington University in St. Louis School of Medicine, St. Louis, Missouri, UNITED STATES; 5Memorial Sloan Kettering Cancer Center, New York, New York, UNITED STATES

A RETROSPECTIVE COHORT STUDY ON THE IMPACT OF REGIONAL ANESTHESIA IN SARCOMA RESECTION SURGERY

Bijan Abar, Amanda Fletcher, Junheng Gao, Andrew Wong, Chinedu Okafor, Sin-Ho Jung, William C. Eward, Brian E. Brigman, Amanda Kumar, Julia D. Visgauss

1Orthopedic Surgery, Duke, Durham, North Carolina, UNITED STATES; 2Duke, Durham, North Carolina, UNITED STATES

CLINICAL AND MOLECULAR CHARACTERISTICS OF A CASE SERIES OF GIST WITH EXTRA-ABDOMINAL METASTASES

Andri Papakonstantinou, Sara Renberg, Felix Haglund, Fredrik Karlsson, Robert Bränström, Jan Åhlen, Li Jalmell, Mikael Eriksson, Christina Linder Stragliotto

1Section for Endocrine Tumors and Sarcoma, Karolinska University Hospital Solna, Stockholm, SWEDEN; 2Department of Clinical Pathology and Cytology, Karolinska University Hospital Solna, Stockholm, SWEDEN; 3Department of Oncology, Skane University Hospital and Lund University, Lund, SWEDEN; 4Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, SWEDEN

CIRCULATING TUMOUR DNA: A POTENTIAL TOOL FOR SARCOMA MANAGEMENT

Paige E. Darville-O’Quinn, Nalan Gokgoz, Ainaz Malekoltojar, Patrick Prochazka, Kim Tsoi, Peter Ferguson, Jay Wunder, Irene Andrulis

1Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, CANADA; 2University of Toronto Musculoskeletal Oncology Unit, Sinai Health System, Toronto, Ontario, CANADA

(GIST) PATIENTS WITH KNOWN MUTATION TRANSITION TO SUBSEQUENT TREATMENTS AT A HIGHER RATE AND HAVE SUPERIOR SURVIVAL COMPARED TO PATIENTS WITHOUT KNOWN MUTATION: RESULTS FROM THE LIFERAFT GROUP (LRG) GIST REGISTRY

Jerry W. Call, Denisse Montoya, Pete Knox, Mary Garland, Sara Rothschild, Norman J. Scherzer, Jonathan Trent

1The Life Raft Group, Wayne, New Jersey, UNITED STATES; 2Medicine, Sylvester Comprehensive Cancer Center, Miami, Florida, UNITED STATES

SUPERFICIAL FIBROMATOSIS LESION SIZE CORRELATES WITH MRI T2 MAPPING AND IMAGE TEXTURE FEATURES

Ty K. Subhawong, Amrutha Ramachandran, Terry Fox, Aaron Wolfson

1Radiology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, UNITED STATES; 2Radiation Oncology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, UNITED STATES

TARGETING THE CMG HELICASE AS A “NEVER” MUTATION TO REDUCE CELLULAR FITNESS IN OSTEOSARCOMA CELLS

Darcy Welch, Elliot Kahan, Mark Alexandrow, Damon Reed

1Moffitt Cancer Center, Tampa, Florida, UNITED STATES
Poster #061 3455574
CHARACTERIZING GROWTH UNDER SELECTION FOR OSTEOSARCOMA HETEROGENEITY MODEL
Damon Reed1, Elliot Kahen1, Darcy Welch1
1Moffitt Cancer Center, Tampa, Florida, UNITED STATES

Poster #062 3455662
EXPLORATION OF IMAGING BIOMARKERS FOR METABOLICALLY-TARGETED OSTEOSARCOMA THERAPY
Shan Huang1, Ling Ren1, Tim Phelps4, Colleen Olkowski4, Anita T. Ton5, Jyoti Roy6, Maggie White6, Aswini Cherukuri7, Stephen Adler1, Karen Wong4, Xiang Zhang3, Falguni Basuli3, Peter Choyke4, Elaine Jagoda4, Amy LeBlanc1
1Comparative Oncology Program, Molecular Imaging Program, NIH/NCI, Bethesda, Maryland, UNITED STATES; 2Laboratory of Genitourinary Cancer Pathogenesis, NIH/NCI, Bethesda, Maryland, UNITED STATES; 3Chemistry and Synthesis Center, NIH/NHLBI, Bethesda, Maryland, UNITED STATES; 4Molecular Imaging Program, NIH/NCI, Bethesda, Maryland, UNITED STATES

Poster #063 3456222
FACTORS AFFECTING GENETIC CONSULTATION IN ADOLESCENT AND YOUNG ADULT PATIENTS WITH SARCOMA
Grace Shea1, Anna L. Zakas2, Fauzia Osman1, Amanda Parkes1
1Department of Medicine, Section of Hematology/Oncology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, UNITED STATES; 2Department of Pediatrics, Section of Oncology Genetics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, UNITED STATES

Poster #064 3457423
RETROSPECTIVE ANALYSIS OF 18 YEARS OF TREATMENT OF MYXOFIBROSARCOMAS IN THE NETHERLANDS
Thomas Schok1, Marlies Keijzers1, Paul Nijhuis1, Frits Aarts1
1Surgery, VieCuri MC, Venlo, NETHERLANDS

Poster #065 3457767
OUTCOMES OF PATIENTS WITH SARCOMA AND COVID-19: A SINGLE INSTITUTION EXPERIENCE
Michael J. Wagner1, Seth Pollack2, Lee D. Cranmer1, Matthew J. Thompson3, Shannon Maxwell1, Stephanie Wright1, Petros Grivas1, Nicole Kuderer3, Gary Lyman4, Elizabeth T. Loggers2
1Oncology, University of Washington, Seattle, Washington, UNITED STATES; 2Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, UNITED STATES; 3University of Washington, Seattle, Washington, UNITED STATES; 4Hutchinson Institute for Cancer Outcomes Research, Seattle, Washington, UNITED STATES

Poster #066 3457998
DECISIONAL CONTROL PREFERENCES IN PATIENTS WITH ADVANCED SOFT TISSUE SARCOMAS STARTING 1ST LINE PALLIATIVE CHEMOTHERAPY: RESULTS FROM THE HOLISTIC STUDY
Eugenie Younger1, Robin L. Jones1, Dide den Hollander2, Vicky Soomers2, Ingrid Desar2, Robin J. Young1, Astrid W. Oosten1, Hans Gelderbloom1, Jacco de Haan1, Neeltje Steeghs1, Olga Husson1, Winette T. van der Graaf7
1Sarcoma Unit, Royal Marsden Hospital, London, UNITED KINGDOM; 2Sarcoma Unit, Radboudumc, Nijmegen, NETHERLANDS; 3Sarcoma Unit, Weston Park Hospital, Sheffield, UNITED KINGDOM; 4Sarcoma Unit, Erasmus MC, Rotterdam, NETHERLANDS; 5Sarcoma Unit, Leiden UMC, Leiden, NETHERLANDS; 6Sarcoma Unit, University Medical Center Groningen, Groningen, NETHERLANDS; 7Sarcoma Unit, Netherlands Cancer Institute, Amsterdam, NETHERLANDS

Poster #067 3458044
IMRIS: A PHASE II STUDY OF INTENSITY MODULATED RADIOTHERAPY (IMRT) IN EXTREMITY SOFT TISSUE SARCOMA (STS)
Beatrice Seddon5, Frael Le Grange5, Rita Simoes5, Chris Stacey5, Shumona Shelly5, Sharon Forsyth1, Laura White1, Charles Candish2, Peter Dickinson5, Aisha B. Miah5, Syed A. Moinuddin5, James Wylie5, Andre Lopes1
1UCL Cancer Trials Centre, London, UNITED KINGDOM; 2Cheltenham General Hospital, London, UNITED KINGDOM; 3Leeds Teaching Hospitals, Leeds, UNITED KINGDOM; 4Royal Marsden Hospital, London, UNITED KINGDOM; 5University College Hospital, London, UNITED KINGDOM; 6Christie Hospital, Manchester, UNITED KINGDOM; 7National Radiotherapy Trials Quality Assurance Group, Mount Vernon Hospital, London, UNITED KINGDOM
GENETIC MODELS REVEAL THAT THE NOVEL VGLL2-NCOA2 FUSION ONCOGENE LEVERAGES EMBRYONIC PROGRAMS FOR SARCOMAGENESIS

**Genevieve Kendall**, Sarah Watson, Lin Xu, Collette LaVigne, Whitney Murchison, Dinesh Rakheja, Franck Tirode, Olivier Delattre, James F. Amatruda

1 Center for Childhood Cancer & Blood Diseases, Nationwide Children’s Hospital, Columbus, Ohio, UNITED STATES; 2 Genetics and Biology of Cancer Unit, Institut Curie, Paris, FRANCE; 3 Department of Population and Data Science, UT Southwestern Medical Center, Dallas, Texas, UNITED STATES; 4 Department of Molecular Biology, UT Southwestern Medical Center, Dallas, Texas, UNITED STATES; 5 Department of Pediatrics, UT Southwestern Medical Center, Dallas, Texas, UNITED STATES; 6 Centre de Recherche en Cancérologie de Lyon, Université Claude Bernard Lyon 1, Lyon, FRANCE; 7 Department of Pathology, UT Southwestern Medical Center, Dallas, Texas, UNITED STATES; 8 Cancer and Blood Disease Institute, Children’s Hospital Los Angeles, Los Angeles, California, UNITED STATES

CONTEMPORARY OUTCOMES AND SECONDARY AMPUTATION AFTER LOCAL RECURRENCE IN PATIENTS AFFECTED BY EXTREMITY SOFT TISSUE SARCOMA TREATED WITH LIMB-SPARING SURGERY AT A REFERENCE INSTITUTION

**Fahmina Buriro**, Sandro Pasquali, Raza Sayyed, Claudia Sangalli, Elena Palassini, Carlo Morosi, Marta Barisella, Chiara Colombo, Stefano Radaelli, Dario Callegaro, Alessandro Gronchi, Marco Fiore

1 Patel Hospital & European School of Soft Tissue Sarcoma Surgery (ESSTSS), Karachi, PAKISTAN; 2 Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY; 3 Radiation Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY; 4 Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY; 5 Radiology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY; 6 Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY

HARNESSING THE ELECTRONIC MEDICAL RECORD TO IMPROVE THE EVALUATION OF SOFT TISSUE MASSES IN THE PRIMARY CARE SETTING: A PILOT STUDY ON THE IMPACT OF A BEST PRACTICE ALERT

**Nicholas J. Reiners**, Brandon Diessner, Robert Gao, Melissa Albersheim, Randolph W. Hurley

1 HealthPartners Cancer Care Center Rein in Sarcoma, University of Minnesota, St Paul, Minnesota, UNITED STATES

TUMOR RESPONSE TO WINDOW THERAPY WITH TEMSIROLIMUS, IRINOTECAN, AND TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED HIGH-RISK EWING SARCOMA; A PHASE II SINGLE INSTITUTION STUDY

**Jessica Gartrell**, Fariba Navid, Michael Dubrovin, Fang Wang, Haitao Pan, Beth McCarville, Barry Shulkin, Alberto Pappo, Sara Federico

1 Columbia University, New York, New York, UNITED STATES; 2 St. Jude Children’s Research Hospital, Memphis, Tennessee, UNITED STATES; 3 Cancer and Blood Disease Institute, Children’s Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California, UNITED STATES

RETROSPECTIVE ANALYSIS OF THE CLINICAL PRESENTATION, TREATMENT AND OUTCOME OF ANGIOSARCOMA IN A SARCOMA REFERRAL CENTER

**Thomas Meyskens**, Iris Timmermans, Che-Jui Lee, Raf Sciot, Herlinde Dumez, Hans Wildiers, Daphne Hompes, Melissa Christiaens, Patrick Schöffski

1 Oncology, UZ Leuven, Leuven, BELGIUM; 2 Pathology, UZ Leuven, Leuven, BELGIUM; 3 Surgical Oncology, UZ Leuven, Leuven, BELGIUM; 4 Radiotherapy, UZ Leuven, Leuven, BELGIUM

POTENTIAL MOLECULAR BIOMARKERS OF RESPONSE TO ERIBULIN IN PATIENTS WITH LEIOMYOSARCOMA

**Agnieszka Wozniak**, Bram Boeckx, Elodie Modave, Amy Weaver, Diether Lambrechts, Bruce A. Littlefield, Patrick Schöffski

1 Laboratory of Exp. Oncology, Department of Oncology, KU Leuven, Leuven, BELGIUM; 2 Laboratory of Translational Genetics, KU Leuven and VIB Center for Cancer Biology, Leuven, Leuven, BELGIUM; 3 Global Oncology, Eisai Inc., Cambridge, Massachusetts, UNITED STATES
GENETIC PROFILE OF GASTROINTESTINAL STROMAL TUMORS (GIST) TREATED IN EORTC 1317 “CABOGIST” PHASE 2 TRIAL

Agnieszka Wozniak¹, Huiwen Che², Isabelle Vanden Bempt³, Tatjana Jatsenko², Laura De Meulemeester³, Ionela Stanciu², Olivier Mir³, Peter Hohenberger⁴, Hans Gelderblom⁵, Raf Sciot⁶, Joris Vermeesch⁷, Patrick Schöffski⁸
¹Lab of Exp.Oncology, Dept. of Oncology, KU Leuven, Leuven, BELGIUM; ²Department of Human Genetics, KU Leuven, Leuven, BELGIUM; ³European Organization for Research and Treatment of Cancer, Brussels, BELGIUM; ⁴Department of Medical Oncology, Gustave Roussy, Villejuif, FRANCE; ⁵Sarcoma Unit, Interdisciplinary Tumor Center Mannheim, Mannheim University Medical Center, Mannheim, GERMANY; ⁶Department of Medical Oncology, Leiden University Medical Center, Leiden, NETHERLANDS; ⁷Department of Pathology, University Hospitals Leuven, Leuven, BELGIUM

LONG-TERM OUTCOME OF PATIENTS WITH NONMETASTATIC BONE OSTEOSARCOMA: A CONDITIONAL SURVIVAL ANALYSIS

Ruoyu Miao¹, Haotong Wang¹, Edwin Choy², Gregory M. Cote³, Kevin A. Raskin¹, Joseph H. Schwab³, Francis J. Hornicek⁴, Thomas F. DeLaney¹, Yen-Lin E. Chen¹
¹Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, UNITED STATES; ²Department of Medical Oncology, Massachusetts General Hospital, Boston, Massachusetts, UNITED STATES; ³Department of Orthopedic Oncology, Massachusetts General Hospital, Boston, Massachusetts, UNITED STATES; ⁴Department of Orthopedic Surgery, University of California Los Angeles, Los Angeles, California, UNITED STATES

EVALUATION OF PROGNOSTIC NOMOGRAMS FOR OUTCOMES AFTER RESECTION OF PRIMARY RETROPERITONEAL SARCOMA

Malcolm H. Squires¹, Erin E. Donahue¹, Megan H. Jagosky², Michael Livingston², William Ahrens³, Jennifer H. Benbow¹, Nicole L. Gower¹, Sally J. Trufan¹, Joshua S. Hill¹, Jonathan Salo¹
¹Division of Surgical Oncology, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, UNITED STATES; ²Division of Medical Oncology, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, UNITED STATES; ³Department of Pathology, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, UNITED STATES

DEVELOPMENT OF RHABDOMYOSARCOMA SPECIFIC SEQUENCING ASSAY

Kelly Klega¹, Samuel Abbou¹, Alanna Church², Alyaa Al-Ibraheemi³, Junko Tsuji², Alma Imamovic-Tuco⁴, Jusin Abreu³, David Hall⁶, Tammy Lo⁷, Don Barkauskas⁸, Carrie Cibulskis⁹, Erin Rudzinski⁹, Jack Shern⁹, Abha A. Gupta⁹, Brian Crompton¹
¹Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, UNITED STATES; ²Boston Children’s Hospital, Boston, Massachusetts, UNITED STATES; ³Broad Institute, Cambridge, Massachusetts, UNITED STATES; ⁴Dana-Farber Cancer Institute, Boston, Massachusetts, UNITED STATES; ⁵Children’s Oncology Group, Monrovia, California, UNITED STATES; ⁶Seattle Children's Hospital, Seattle, Washington, UNITED STATES; ⁷National Institutes of Health, Bethesda, Maryland, UNITED STATES; ⁸The Hospital for Sick Children, Toronto, Ontario, CANADA

THE PROGNOSTIC IMPORTANCE OF PATHOLOGIC FRACTURE IN LIMB SALVAGE SURGERY FOR OSTEOSARCOMA: A SINGLE-INSTITUTION REVIEW OF 304 PATIENTS

Danielle Greig¹, Rishi Trikha¹, Troy Sekimura¹, Jeffrey Eckardt¹, Nicholas Bernthal¹
¹Orthopaedic Surgery, University of California, Los Angeles, Los Angeles, California, UNITED STATES

SARCOMA IN YOUNG AGE – AN OVERVIEW OF CLINICAL, PATHOLOGICAL AND MOLECULAR FINDINGS IN A LARGE SINGLE CENTER COHORT

Samuele Renzi¹, Noelle Cullinan¹, Sarah Cohen-Gogo¹, Karin Langenberg-Ververgaert¹, Orli Michaeli¹, Jalila Alkendi¹, Anne L. Ryan¹, Bailey Gallinger¹, Katrina M. Ingle¹, Sevan Hopyan², Rose Chami³, Abha A. Gupta¹
¹Pediatric Haematology/Oncology, Hospital for Sick Children, Toronto, Ontario, CANADA; ²Clinical and Metabolic Genetics, The Hospital for Sick Children, Toronto, Ontario, CANADA; ³Paediatric Laboratory Medicine, The Hospital for Sick Children, Toronto, Ontario, CANADA
THE UTILITY OF FDG PET-CT SCAN IN OFF-TREATMENT SURVEILLANCE OF PEDIATRIC BONE TUMORS
Lucy E. Cain¹, Kevin London², Theo Kitsos³, Geoff McCowage¹
1Cancer Centre for Children, The Children's Hospital at Westmead, Sydney, New South Wales, AUSTRALIA; 2Department of Nuclear Medicine, The Children’s Hospital at Westmead, Sydney, New South Wales, AUSTRALIA

NEUTROPHIL-LYMPHOCYTE AND PLATELET-LYMPHOCYTE RATIOS AS ROBUST PROGNOSTIC MARKERS IN SARCOMAS - A POPULATION-BASED ANALYSIS OF 3746 SARCOMA PATIENTS FROM HONG KONG
Herbert Loong¹, Sampson K. Kwai², Chu Wa Ho³, Yingjun Zhang⁴, Teresa Tse¹, Yat-ming Lau¹, Gordon C. Tang¹, Teresa Tan⁴, Carlos K. Wong²
1Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, HONG KONG; 2Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, HONG KONG; 3Department of Family Medicine & Primary Care, The University of Hong Kong, Hong Kong, HONG KONG; 4Department of Surgery, The Chinese University of Hong Kong, Hong Kong, HONG KONG

AGE RELATED DIFFERENCES OF ONCOLOGICAL OUTCOMES IN PRIMARY EXTREMITY SOFT TISSUE SARCOMA: A MULTISTATE MODEL INCLUDING 6260 PATIENTS
Ibtissam Acem¹, Cees Verhoef⁵, Anja Ruten-Budde¹, Winan J. van Houdt³, Dirk Grunhagen², Michiel van de Sande¹
1Leiden University Medical Centre, Leiden, NETHERLANDS; 2Erasmus Medical Centre, Rotterdam, NETHERLANDS; 3The Netherlands Cancer Institute, Amsterdam, NETHERLANDS

ANALYSIS OF TUMOR INFILTRATING NK AND T CELLS HIGHLIGHTS IL-15 STIMULATION AND TIGIT BLOCKADE AS A COMBINATION IMMUNOTHERAPY STRATEGY FOR SOFT TISSUE SARCOMAS
Sean Judge¹, Morgan A. Darrow², Steven W. Thorpe³, Alicja A. Ginchrich¹, Edmond F. O’Donnell³, Alyssa R. Bellini¹, Ian R. Sturgill⁴, Logan V. Vick⁵, Cordelia Duna⁶, Kevin M. Stoffel⁷, Yue Lyu⁸, Shuai Chen⁹, May Cho¹⁰, Robert B. Rebhun⁷, Arta M. Monjazeb⁸, William J. Murphy⁷, Robert J. Canter¹
1Surgery, University of California, Davis, Sacramento, California, UNITED STATES; 2Pathology and Laboratory Medicine, University of California, Davis, Sacramento, California, UNITED STATES; 3Orthopedic Surgery, University of California, Davis, Sacramento, California, UNITED STATES; 4Dermatology, University of California, Davis, Sacramento, California, UNITED STATES; 5Public Health Sciences, University of California, Davis, Sacramento, California, UNITED STATES; 6Internal Medicine, University of California, Davis, Sacramento, California, UNITED STATES; 7Center for Companion Animal Health, University of California, Davis, Sacramento, California, UNITED STATES; 8Radiation Oncology, University of California, Davis, Sacramento, California, UNITED STATES

MANAGEMENT AND OUTCOMES OF CIC-REARRANGED SARCOMA; AN AUSTRALIAN MULTI-CENTRE REVIEW
Elizabeth Connolly¹, David Pryor¹, Stephen Thompson², Johnathan Wake³, Vivek Bhadri⁴, Peter Grimison⁴, Annabelle Mahar⁵, Fiona Maclean⁶, Madeleine Strach⁷, Angela Hong³
1Radiation Oncology, Princess Alexandra Hospital, Brisbane, Queensland, AUSTRALIA; 2Radiation Oncology, Prince of Wales Hospital, Sydney, New South Wales, AUSTRALIA; 3Radiation Oncology, Chris O'Brien Lifehouse, Sydney, New South Wales, AUSTRALIA; 4Medical Oncology, Chris O'Brien Lifehouse, Sydney, New South Wales, AUSTRALIA; 5NSW Health Pathology, Pathology, Sydney, New South Wales, AUSTRALIA; 6Anatomical Pathology, Douglas Hanly Moor Pathology, Sydney, New South Wales, AUSTRALIA

IDENTIFICATION OF NOVEL THERAPEUTIC TARGETS FOR METASTATIC OSTEOSARCOMA
Rebekah Belayneh¹, Ivy John¹, Margaret Hankins¹, David Boone², Sarangarajan Ranganathan³, Rita Alaggio⁴, Vaidehi Patel⁴, Benjamin Martin³, Kurt R. Weiss¹, Rebecca Watters³
1UPMC, Pittsburgh, Pennsylvania, UNITED STATES; 2Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, Pennsylvania, UNITED STATES; 3University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, UNITED STATES; 4Cincinnati Children's Hospital, Cincinnati, Ohio, UNITED STATES; 5University-Hospital of Padua, Padua, ITALY
Poster #086 3460952
EVALUATION OF CIRCULATING TUMOR CELLS IN RECURRENT OSTEOSARCOMA PATIENTS TREATED ON A PHASE II TRIAL OF GEMCITABINE AND NAB-PACLITAXEL: A REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION
Masanori Hayashi, Javier Oesterheld, David Loeb, Damon Reed, Leo Mascarenhas, Michael Isakoff, Bhuvana Setty, Joanne Lagmay, Emi Caywood, Eric Sandler, Matteo Trucco, Christine Pratilas, Tiffany Smith, Brooke Fridley, Lars M. Wagner
1Children's Hospital Colorado, Denver, Colorado, UNITED STATES; 2Carolinas Medical Center, Charlotte, North Carolina, UNITED STATES; 3Montefiore Medical Center, Bronx, New York, UNITED STATES; 4Moffitt Cancer Center, Tampa, Florida, UNITED STATES; 5Children’s Hospital Los Angeles, Los Angeles, California, UNITED STATES; 6Connecticut Children’s Medical Center, Hartford, Connecticut, UNITED STATES; 7Nationwide Children’s Hospital, Columbus, Ohio, UNITED STATES; 8University of Florida, Gainesville, Florida, UNITED STATES; 9Alfred DuPont Hospital for Children, Wilmington, Delaware, UNITED STATES; 10Nemours Children’s Clinic, Jacksonville, Florida, UNITED STATES; 11Cleveland Clinic Foundation, Cleveland, Ohio, UNITED STATES; 12Johns Hopkins University, Baltimore, Maryland, UNITED STATES; 13National Pediatric Cancer Foundation, Tampa, Florida, UNITED STATES; 14Duke University Medical Center, Durham, North Carolina, UNITED STATES

Poster #087 3461000
UBIQUITIN-LIGASE ATROGIN MEDIATES ADAPTATION TO KIT TARGETED INHIBITION IN GASTROINTESTINAL Stromal Tumor
Alfonso García-Valverde, Jordi Rosell, Sergi Sayols, David Gómez-Peregrina, Daniel Pilco-Janeta, Enrique de Álava, Joan Maurel, Claudia Valverde, Anna Esteve, Marta Gut, Jordi Barretina, Joan Carles, George Demetri, Jonathan Fletcher, Joaquín Arribas, César Serrano
1Sarcoma Translational Research Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, SPAIN; 2Institut d’Investigació Biomèdica de Girona (IDIBGI), Girona, SPAIN; 3Centro Nacional de Análisis Genómicos (CNAG), Barcelona, SPAIN; 4Medical Oncology, Vall d’Hebron University Hospital, Barcelona, SPAIN; 5Dana-Farber Cancer Institute/Harvard Medical School, Boston, Massachusetts, UNITED STATES; 6Brigham and Women’s Hospital/Harvard Medical School, Boston, Massachusetts, UNITED STATES; 7Growth Factors Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, SPAIN; 8Hospital Virgen del Rocío, Sevilla, SPAIN; 9Hospital Clinic, Barcelona, SPAIN

Poster #088 3461083
BONE METASTASIS OF GASTROINTESTINAL Stromal Tumor: Case Report and Review of the Literature
Caroline Braunstein, François Sirveaux, Elsa Kalbacher, Sébastien Aubry, Delphine Delroeux, Paul Hubert, Béatrice Marie, Guillaume Meynard, Ionela Mihai, Loïc Chaigneau
1Oncology, University Hospital, Besançon, FRANCE; 2Radiology, University Hospital, Besançon, FRANCE; 3Pathology, University Hospital, Nancy, FRANCE; 4Pathology, General Hospital, Belfort-Montbéliard, FRANCE; 5Pathology, University Hospital, Besançon, FRANCE; 6Orthopedic surgery, University Hospital, Nancy, FRANCE; 7Visceral Surgery, University Hospital, Besançon, FRANCE

Poster #089 3461140
FIVE-YEAR SURVIVAL OF A PATIENT WITH DEDIFFERENTIATED CHONDROSARCOMA TREATED WITH CHEMOTHERAPY AND JOINT SPARING SURGERY
Charles D. Gomez, Mark S. Anderson, Scott C. Epperly, Lee M. Zuckerman
1Orthopaedic Surgery, Loma Linda University Medical Center, Loma Linda, California, UNITED STATES; 2Orthopaedic Surgery, City of Hope National Medical Center, Duarte, California, UNITED STATES; 3Georgia Pediatric Orthopaedics, Macon, Georgia, UNITED STATES; 4Orthopaedic Surgery, Lovelace Health System, Albuquerque, New Mexico, UNITED STATES

Poster #090 3461203
IMPACT OF IMMUNOTHERAPY AND TARGETED THERAPY ON TUMOR GROWTH RATE IN SARCOMA
Esmail Al-Ezzi, Geoffrey Watson, Zachary Veitch, Eitan Amir, Alibruni Abdul Razak
1Toronto Sarcoma Program, Princess Margaret Cancer Centre, Toronto, Ontario, CANADA; 2Division of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, CANADA
PRIMARY SITE SURGERY IS ASSOCIATED WITH IMPROVED SURVIVAL IN METASTATIC SOFT TISSUE SARCOMA OF THE EXTREMITY
Alicia A. Gingrich, Sarah Bateni, Steven W. Thorpe, Amanda Kirane, Arta M. Monjazeb, Morgan A. Darrow, Richard Bold, R L. Randall, Robert J. Canter
1Surgery, University of California, Davis, Sacramento, California, UNITED STATES; 2Orthopedic Surgery, UC Davis, Sacramento, California, UNITED STATES; 3Radiology, UC Davis, Sacramento, California, UNITED STATES; 4Pathology, UC Davis, Sacramento, California, UNITED STATES

CHARACTERIZATION OF TUMOR INFILTRATING IMMUNE CELLS FROM ADULT SOFT TISSUE SARCOMAS
Jacky H. Chen, Nalan Gokgoz, Jay Wunder, Irene Andrulis
1Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, CANADA; 2University of Toronto Musculoskeletal Oncology Unit, Sinai Health System, Toronto, Ontario, CANADA; 3Lunenfeld Tanenbaum Research Institute, Toronto, Ontario, CANADA

IMPACT OF NEOADJUVANT CHEMOTHERAPY FOR RETROPERITONEAL SARCOMAS: A PROPENSITY BASED ANALYSIS OF A RETROSPECTIVE INTERNATIONAL, MULTICENTER COHORT
Matthieu Faron, Charles Honoré, Dirk Strauss, Alessandro Gronchi, Carol J. Swallow, Peter Hohenberger, Piotr Rutkowski, Frits van Coevorden, Winan J. van Houdt, Sylvie Bonvalot, Axel Le Cesne
1Surgical Oncology, Gustave Roussy Cancer Campus, Villejuif, FRANCE; 2Royal Marsden Hospital NHS Foundation Trust, London, UNITED KINGDOM; 3Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, ITALY; 4Mount Sinai Hospital and Princess Margaret Cancer Centre, Toronto, Ontario, CANADA; 5Mannheim University Hospital, Manheim, GERMANY; 6Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, POLAND; 7Netherlands Cancer Institute, Amsterdam, NETHERLANDS; 8Institut Curie, Paris, FRANCE; 9Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, FRANCE

SURGICAL MANAGEMENT OF PRIMARY LESION OF SOFT TISSUE SARCOMA MAY IMPROVE OVERALL SURVIVAL OF PATIENTS WITH INITIAL METASTASIS
Liuzhe Zhang, Toru Akiyama, Hiroshi Kobayashi
1Orthopedics, Jichi Medical University Saitama Medical Center, Saitama, Saitama, JAPAN; 2The University of Tokyo Hospital, Tokyo, JAPAN

PATIENT-SPECIFIC CUTTING GUIDES AND 3D-PRINTED TECHNOLOGY FOR PELVIC AND SACRAL TUMOR RESECTION AND COMPLEX ALLOGRAFT RECONSTRUCTION: OUR EXPERIENCE IN THE RESECTION OF PELVIC AND SPINAL SARCOMA OF BONE
Matthew Gasparro, Obianuju Obioha, Charles Gusho, Steven Gitelis, Alan Blank, Matthew Colman
1Department of Orthopedics, Division of Orthopedic Oncology, Rush University Medical Center, Chicago, Illinois, UNITED STATES

NON-RANDOM ASSOCIATION OF BREAST IMPLANT SURGERY AND DESMOID TUMOR FORMATION
Philippos A. Costa, Staci Marbin, Andrea Espejo-Freire, Bruna Costa, Eduardo Saul, Priscila Barreto-Coelho, Akheel Allen, Neha Goel, Ty K. Subhawong, Gina D’amato, Jonathan Trent
1University of Miami, Miami, Florida, UNITED STATES; 2Univasf, Petrolina, Pe, BRAZIL

A PHASE 1B/3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TAZEMETOSTAT PLUS DOXORUBICIN AS FRONTLINE THERAPY FOR PATIENTS WITH ADVANCED EPITHELIOID SARCOMA
Shiraj Sen, Meredith McKean, Laura Sierra, Jessica Ainscough, Jay Yang, Anthony Hamlett
1Sarah Cannon Research Institute, Denver, Colorado, UNITED STATES; 2Tennessee Oncology, Nashville, Tennessee, UNITED STATES; 3Epizyme, Inc., Cambridge, Massachusetts, UNITED STATES; 4Sarcoma Oncology Center, Santa Monica, California, UNITED STATES
OUTCOMES OF EWING SARCOMA/ EWING'S-LIKE SARCOMA (ES) IN PATIENTS AGED OVER 25
Sudha Karanam, Jenny Sherriff, David Peake, Hassan Douis, Mariam Jafri
1Oncology, University Hospitals Birmingham, Birmingham, UNITED KINGDOM

GRADE OF PRIMARY CUTANEOUS LEIOMYOSARCOMA DICTATES CLINICAL OUTCOME RISK
Michael J. Carr, William A. Adams, James Sun, Ricardo J. Gonzalez, John Mullinax, Jonathan S. Zager
1Morsani College of Medicine, University of South Florida, Tampa, Florida, UNITED STATES; 2Department of Surgery, Case Western Reserve University, Cleveland, Ohio, UNITED STATES; 3Department of Sarcoma, Moffitt Cancer Center, Tampa, Florida, UNITED STATES

OXYGEN TENSION AND MACROPHAGES MEDIATE PROLIFERATION OF OSTEOSARCOMA CELLS IN 3-DIMENSIONAL CULTURE
Victoria Thai, Katherine H. Griffin, Steven W. Thorpe, R L. Randall, J. K. Leach
1Orthopaedic Surgery, University of California, Davis, Sacramento, California, UNITED STATES; 2Biomedical Engineering, University of California, Davis, California, UNITED STATES

PATIENT-SPECIFIC CUTTING GUIDES AND 3D-PRINTED TECHNOLOGY FOR INTERCALARY LONG BONE RESECTION AND ALLOGRAFT RECONSTRUCTION: OUR EXPERIENCE IN THE RESECTION OF EXTREMITY SARCOMA OF BONE
Matthew Gasparro, Charles Gusho, Obianuju Obioha, Marta Batus, Matthew Colman, Steven Gitelis, Alan Blank
1Department of Orthopedics, Division of Orthopedic Oncology, Rush University Medical Center, Chicago, Illinois, UNITED STATES; 2Internal Medicine, Division of Hematology, Oncology and Cell Therapy, Rush University Medical Center, Chicago, Illinois, UNITED STATES

SHORTCOMINGS OF FUNCTIONAL IMAGING: FAILURE OF MIBG SCAN TO DETECT A BENIGN TRANSFORMATION OF SOFT-TISSUE MALIGNANCY IN THREE CHILDREN
Lauren Riggs, Janay McKnight, Paul Kent
1Rush University Medical Center, River Forest, Illinois, UNITED STATES

SE LINEXOR IS MORE ACTIVE THAN DOXORUBICIN IN PATIENT-DERIVED XENOGRAFTS OF DEDIFFERENTIATED LIPOSARCOMA
Valentina Zuco, Sandro Pasquali, Monica Tortoreto, Chiara Colombo, Roberta Sanfilippo, Silvia Brich, Marta Barisella, Paolo Giovanni Casali, Alessandro Gronchi, Silvia Stacchiotti, Nadia Zaffaroni
1Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale Tumori, Milano, ITALY; 2Department of Surgery, Fondazione IRCCS Istituto Nazionale Tumori, Milano, ITALY; 3Department of Cancer Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milano, ITALY; 4Department of Pathology, Fondazione IRCCS Istituto Nazionale Tumori, Milano, ITALY
AN UPDATED ANALYSIS OF THE CLINICAL EFFICACY AND SAFETY OF ENTRECTINIB IN NTRK FUSION-POSITIVE (NTRK-FP) SARCOMA


1Sarcoma Oncology Center, Santa Monica, California, UNITED STATES; 2Hospital Universitario 12 de Octubre, Madrid, SPAIN; 3Department of Medicine, University of Minnesota, Minneapolis, Minnesota, UNITED STATES; 4Southern California Permanente Medical Group, Los Angeles, California, UNITED STATES; 5Department of Clinical Oncology, Princess Margaret Hospital, Kwai Chung, Hong Kong Special Administrative Region, CHINA; 6Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, Washington, UNITED STATES; 7Mayo Clinic Arizona, Phoenix, Arizona, UNITED STATES; 8Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, UNITED STATES; 9Earle A Chiles Research Institute, Providence Cancer Institute, Portland, Oregon, UNITED STATES; 10Hospital Universitario Virgen de la Victoria de Málaga, Málaga, SPAIN; 11Center for Integrated Oncology, University Hospital of Cologne, Cologne, GERMANY; 12Department of Oncology, Medical Oncology 1, Veneto Institute of Oncology, IOV-IRCCS, Padua, ITALY; 13F. Hoffmann-La Roche Ltd, Basel, SWITZERLAND; 14Genentech Inc., South San Francisco, California, UNITED STATES; 15Georgetown University Medical Center, Washington, District of Columbia, UNITED STATES

LAROTRECTINIB EFFICACY AND SAFETY IN ADULT PATIENTS WITH TRK FUSION SARCOMAS


1Stanford Cancer Institute, Stanford University, Palo Alto, California, UNITED STATES; 2The University of Texas MD Anderson Cancer Center, Houston, Texas, UNITED STATES; 3St. Vincent's University Hospital & University College Dublin, Dublin, IRELAND; 4Vanderbilt University Medical Center, Nashville, Tennessee, UNITED STATES; 5Dana-Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, Massachusetts, UNITED STATES; 6University of Colorado Cancer Center, Denver, Colorado, UNITED STATES; 7University Hospitals Ahuja Medical Center, Beachwood, Ohio, UNITED STATES; 8START MADRID-FJD, Hospital Fundación Jiménez Díaz, Madrid, SPAIN; 9Rigshospitalet, Copenhagen, DENMARK; 10UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, UNITED STATES; 11Charité – Universitätsmedizin Berlin, Berlin, GERMANY; 12Vall d’Hebron Children’s Hospital, Barcelona, SPAIN; 13Northwestern University, Chicago, Illinois, UNITED STATES; 14Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, UNITED STATES; 15Bayer HealthCare Pharmaceuticals, Whippany, New Jersey, UNITED STATES; 16Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York, UNITED STATES; 17National Cancer Center, Singapore, SINGAPORE

IMPACT OF NEXT GENERATION SEQUENCING (NGS) ON THE TREATMENT OF PATIENTS WITH SARCOMA

Brian Schulte1, Neelima Katam2, Amir Behdad2, Massimo Cristofanilli3, Jeffrey Wayne4, Karl Bilimoria3, Terrance Peabody1, Samer Attar3, John Hayes3, Jean-Paul Wolinsky3, Borislav Alexiev5, Firas Wehbe2, Mark Agulnik1

1Oncology, Northwestern University, Chicago, Illinois, UNITED STATES; 2Pathology, Northwestern University, Chicago, Illinois, UNITED STATES; 3Surgical Oncology, Northwestern University, Chicago, Illinois, UNITED STATES; 4Radiation Oncology, Northwestern University, Chicago, Illinois, UNITED STATES; 5Neurological Surgery, Northwestern University, Chicago, Illinois, UNITED STATES
Poster #107 3461682
HISTOLOGY AND TUMOUR BIOLOGY ARE MORE IMPORTANT IN PREDICTING OVERALL SURVIVAL THAN MARGINS OF RESECTION
Boaz Wong1, Sameer Apte1, Fabio Tirotta2, Alessandro Parente2, Johanne Mathieu1, Sam Ford3, Anant Desai2, Max Almond2, Carolyn Nessim1
1Surgical Oncology, The Ottawa Hospital, Ottawa, Ontario, CANADA; 2University Hospital Birmingham NHS Foundation Trust, Birmingham, UNITED KINGDOM

Poster #108 3461698
HISTOLOGIC MARKERS PREDICTIVE OF WOUND HEALING COMPLICATIONS IN SOFT TISSUE SARCOMA TREATED WITH PREOPERATIVE RADIATION
Jacob Gylten1, Stephanie Chen1, Jane Persons1, Qiang An1, Munir Tanas1, Benjamin J. Miller1
1University of Iowa, Iowa City, Iowa, UNITED STATES

Poster #109 3461710
INTEGRATED SAFETY ANALYSIS OF TAZEMETOSTAT 800 MG TWICE DAILY IN ADULT PATIENTS WITH HEMATOLOGIC AND SOLID TUMORS
Franck Morschhauser1, Pamela McKay2, Gilles Salles3, Silvia Stacchiotti4, Gary Schwartz5, Hervé Tilly6, Marjorie Zauderer7, Dean Fennell8, Robin L. Jones4, Patrick Schöffski9, Tycel Phillips10, Aristeidis Chaidos11, Victor Villalobos12, George Demetri13, Gregory M. Cote14, Laura Sierra15, Jay Yang16, Pam Slatcher16, Shefali Agarwal16, Mrinal Gounder7
1Université Lille, CHU Lille, ULR 7365 – GRITA – Groupe de Recherche sur les Formes Injectables et les Technologies Associées, Lille, FRANCE; 2Beatson West of Scotland Cancer Centre, Glasgow, Scotland, UNITED KINGDOM; 3Lyon-Sud Hospital, University of Lyon, Pierre-Bénite, FRANCE; 4Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY; 5Herbert Irving Comprehensive Care Center, Columbia University Irving Medical Center, New York, New York, UNITED STATES; 6Centre Henri Becquerel and Rouen University, Rouen, FRANCE; 7Memorial Sloan Kettering Cancer Center, New York, New York, UNITED STATES; 8University of Leicester and University Hospitals of Leicester NHS Trust, Leicester, UNITED KINGDOM; 9The Royal Marsden Hospital and Institute for Cancer Research, London, UNITED KINGDOM; 10Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, Leuven, BELGIUM; 11University of Michigan, Ann Arbor, Michigan, UNITED STATES; 12Imperial College London & Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UNITED KINGDOM; 13University of Colorado School of Medicine, Boulder, Colorado, UNITED STATES; 14Dana Farber Cancer Institute and Ludwig Center at Harvard Medical School, Boston, Massachusetts, UNITED STATES; 15Massachusetts General Hospital, Boston, Massachusetts, UNITED STATES; 16Epizyme, Inc., Cambridge, Massachusetts, UNITED STATES

Poster #110 3461748
RECRUITMENT PATTERNS IN A LARGE INTERNATIONAL RANDOMIZED CONTROLLED TRIAL OF PERIOPERATIVE CARE IN CANCER PATIENTS
Aaron M. Gazendam1, Anthony Bozzo1, Tricia Schneider1, Victoria Giglio1, David Wilson1, Michelle Ghert1
1Orthopaedic Surgery, McMaster University, Hamilton, Ontario, CANADA

Poster #111 3461782
FACTORS INFLUENCING UNPLANNED READMISSION AFTER SURGERY IN SOFT TISSUE SARCOMAS
David L. Kerr1, Alexander L. Lazarides1, Mark M. Cullen2, Preet Patel3, Sneha Rao3, Marcello Cerullo3, Dan G (Trey) Blazer3, Brian E. Brigman1, Julia D. Visgauss1, William C. Eward1
1Orthopedic Surgery, Duke University Hospital, Durham, North Carolina, UNITED STATES; 2Duke University School of Medicine, Durham, North Carolina, UNITED STATES; 3General Surgery, Duke University Hospital, Durham, North Carolina, UNITED STATES

Poster #112 3461852
18F-FDG PET/CT CAN HELP SOLVE THE GRADING DILEMMAS IN CARTILAGE BONE NEOPLASMS? SURGEON’S INTERPRETATION FOR TREATMENT PLANNING
Manit K. Gundavda1, Manish Agarwal1, Rajeev Reddy1, Rajat Gupta1, Ashik Bary1
1Orthopaedic Oncology, P.D. Hinduja Hospital and Medical Research Centre, Mumbai, INDIA
Poster #113
3461875
CLINICOPATHOLOGICAL FEATURES AND TREATMENT OUTCOME OF OESOPHAGEAL GASTROINTESTINAL STROMAL TUMOUR (GIST): A LARGE, RETROSPECTIVE MULTICENTER EUROPEAN STUDY
1Medical Oncology, Leiden University Medical Center, Leiden, NETHERLANDS; 2Medical Oncology, Netherlands Cancer Institute, Amsterdam, NETHERLANDS; 3Surgical Oncology & Thoracic Surgery, Mannheim University Medical Center, Mannheim, GERMANY; 4Soft Tissue/Bone Sarcoma and Melanoma, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, POLAND; 5Medical Oncology, Virgen del Rocío University Hospital, Seville, SPAIN; 6The Royal Marsden NHS Foundation Trust / Institute of Cancer Research, London, UNITED KINGDOM; 7Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY; 8General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Leuven, BELGIUM; 9Surgical Oncology & Thoracic Surgery, Mannheim University Medical Center, Mannheim, GERMANY; 10Sarcoma Unit, The Royal Marsden NHS Foundation Trust, London, UNITED KINGDOM; 11Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY; 12Erasmus MC Cancer Institute, Rotterdam, NETHERLANDS; 13Radboud University Medical Center, Nijmegen, NETHERLANDS; 14University Medical Center Groningen, Groningen, NETHERLANDS; 15Surgical Oncology, Antoni van Leeuwenhoek – Netherlands Cancer Institute, Amsterdam, NETHERLANDS; 16Surgery/ Medical Oncology, Leiden University Medical Center, Leiden, NETHERLANDS

Poster #114
3461883
AVAPRITINIB VS REGORAFENIB IN PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST): EFFICACY AND SAFETY DATA FROM PHASE 3 VOYAGER STUDY
Yoon-Koo Kang, Suzanne George, Robin L. Jones, Piotr Rutkowski, Lin Shen, Olivier Mir, Shreyaskumar Patel, Yongjian Zhou, Margaret von Mehren, Peter Hohenberger, Victor Villalobos, Mehdi Brahmi, William D. Tap, Jonathan Trent, Maria Pantaleo, Patrick Schöffski, Kevin He, Paggy Hew, Kate Newberry, Maria Roche, Michael Heinrich, Sebastian Bauer
1Asan Medical Center, University of Ulsan College of Medicine, Seoul, KOREA (THE REPUBLIC OF); 2Sarcoma Center, Dana Farber Cancer Institute, Boston, Massachusetts, UNITED STATES; 3Royal Marsden Hospital and Institute of Cancer Research, London, UNITED KINGDOM; 4Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, POLAND; 5Peking University Cancer Hospital and Institute, Beijing, CHINA; 6Institut Gustave Roussy, Villejuif, FRANCE; 7MD Anderson Cancer Center, Houston, Texas, UNITED STATES; 8Fujian Medical University Union Hospital, Fuzhou, CHINA; 9Fox Chase Cancer Center, Philadelphia, Pennsylvania, UNITED STATES; 10University of Heidelberg (UMM), Mannheim, GERMANY; 11University of Colorado Denver – Anschutz Medical Campus, Aurora, Colorado, UNITED STATES; 12Centre Léon Bérard, Lyon, FRANCE; 13Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York, UNITED STATES; 14University of Miami–Sylvester Comprehensive Cancer Center, Miami, Florida, UNITED STATES; 15University of Bologna, Bologna, ITALY; 16University Hospitals Leuven, Leuven, BELGIUM; 17Blueprint Medicines Corporation, Cambridge, Massachusetts, UNITED STATES; 18Portland VA Health Care System and OHSU Knight Cancer Institute, Portland, Oregon, UNITED STATES; 19Sarcoma Center, West German Cancer Center, DKTK-Partner-Site, University of Duisburg, Essen, GERMANY

Poster #115
3462029
LAROTRECTINIB EFFICACY AND SAFETY IN PEDIATRIC PATIENTS WITH TRK FUSION SARCOMAS
Theodore W. Laetsch, Stefan Bielack, Daniel Orbach, Steven DuBois, Noah Federman, Birgit Gooeberger, Leo Mascarenhas, Ramamoorthy Nagasubramanian, Daniel Morgenstern, Alberto Pappo, Johannes Schulte, Neerav Shukla, John A. Reeves, Laura Dima, Esther De La Cuesta, Catherine M. Albert, Cornelis M. van Tilburg
1University of Texas Southwestern Medical Center/Children’s Health, Dallas, Texas, UNITED STATES; 2Klinikum Stuttgart-Olgahospital, Stuttgart, GERMANY; 3Institut Curie and Paris University, Paris, FRANCE; 4Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Boston, Massachusetts, UNITED STATES; 5David Geffen School of Medicine, University of California, Los Angeles, California, UNITED STATES; 6Gustave Roussy Cancer Center, Université Paris-Saclay, INSERM U1015, Villejuif, FRANCE; 7Children’s Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, California, UNITED STATES; 8Nemours Children’s Hospital, Orlando, Florida, UNITED STATES; 9Hospital for Sick Children and University of Toronto, Toronto, Ontario, CANADA; 10St. Jude Children’s Research Hospital, Memphis, Tennessee, UNITED STATES; 11Charité-Universitätsmedizin Berlin, Berlin, GERMANY; 12Memorial Sloan Kettering Cancer Center, New York, New York, UNITED STATES; 13Bayer HealthCare Pharmaceuticals, Inc., Whippany, New Jersey, UNITED STATES; 14Bayer Pharmaceuticals, Basel, SWITZERLAND; 15Seattle Children’s Hospital, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, Washington, UNITED STATES; 16Hopp Children’s Cancer Center Heidelberg (KITZ), Heidelberg University Hospital and German Cancer Research Center (DKFZ), Heidelberg, GERMANY
Poster #116 3462147
MANAGEMENT OF HEMANGIOENDOTHELIOMA AT A DEDICATED SARCOMA CLINIC IN INDIA: TIME TO LOOK TOWARDS ANTI-ANGIOGENIC THERAPY
Ghazal Tansir1, Sameer Rastogi2, Adarsh Barwad3, Ekta Dhamija3, Shamim A. Shamim4
1Medical Oncology, All India Institute of Medical Sciences, New Delhi, Delhi, INDIA; 2Pathology, All India Institute of Medical Sciences, New Delhi, INDIA; 3Radiodiagnosis, All India Institute of Medical Sciences, New Delhi, Delhi, INDIA; 4Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, Delhi, INDIA

Poster #117 3462149
MODELING THE EFFICACY OF NY-ESO-1 TCR T CELLS (LETETRESGENE AUTOLEUCEL; GSK3377794) IN PATIENTS WITH SYNOVIAL SARCOMA: CORRELATIONS OF RESPONSE WITH TRANSDUCED CELL KINETICS AND BIOMARKERS
Alexandra Gyurdieva1, Stefan Zajic1, Ya-Fang Chang1, E. Andres Houseman1, Shan Zhong1, Jaegil Kim1, David C. Turner1, Laura A. Johnson1, Ioanna Eleftheriadou1, Jenna Tress1, Aisha Hasan1, Victoria L. Chiou1, Naimish Pandya1, John Glod2, Dejka Araujo3, Warren Chow1, Mihaela Druta4, George Demetri5, Brian A. Van Tine1, Sandra D’Angelo6
1GlaxoSmithKline, Collegeville, Pennsylvania, UNITED STATES; 2National Cancer Institute, Bethesda, Maryland, UNITED STATES; 3University of Texas/MD Anderson Cancer Center, Houston, Texas, UNITED STATES; 4City of Hope Comprehensive Cancer Center, Duarte, California, UNITED STATES; 5H. Lee Moffitt Cancer Center, Tampa, Florida, UNITED STATES; 6Dana Farber Cancer Institute and Ludwig Center at Harvard, Boston, Massachusetts, UNITED STATES; 7Washington University in St. Louis, St. Louis, Missouri, UNITED STATES; 8Memorial Sloan Kettering Cancer Center, New York, New York, UNITED STATES

Poster #118 3462192
CAN PATIENTS AT HIGH RISK FOR R2 RESECTION OF RETROPERITONEAL SARCOMA (RPS) BE IDENTIFIED PREOPERATIVELY?
Deanna Ng1, Dario Callegaro2, Chandrajit Raut3, Dirk Strauss4, Charles Honoré5, Eberhard Stoelckle6, Sylvie Bonvalot7, Winan J. van Houdt8, Piotr Rutkowski9, Marco Fiore2, Carol J. Swallow1
1University of Toronto, Toronto, Ontario, CANADA; 2Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY; 3Brigham and Women’s Hospital Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, UNITED STATES; 4Royal Marsden NHS Foundation Trust, London, UNITED KINGDOM; 5Gustave Roussey, Paris, FRANCE; 6Institut Bergonie, Bordeaux, FRANCE; 7Institut Curie, Paris, FRANCE; 8The Netherlands Cancer Institute, Amsterdam, NETHERLANDS; 9Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, POLAND

Poster #119 3462260
ADDED VALUE OF SURGICAL NAVIGATION FOR CHALLENGING INTRA-ABDOMINAL OR PELVIC SARCOMA
Sophie Reijers1, Wouter J. Heerink1, Ruben van Veen1, Jasper Nijkamp1, Nikie J. Hoetjes1, Yvonne Schrage1, Alexander van Akkooi1, Geerard L. Beets1, Frits van Coevorden1, Theo J. Ruers1, Harald C. Groen1, Winan J. van Houdt1
1Surgical Oncology, Antoni van Leeuwenhoek ziekenhuis, Amsterdam, Noord Holland, NETHERLANDS

Poster #120 3462325
MANAGEMENT OF HIGH-GRADE EXTREMITY SOFT TISSUE SARCOMAS: AN EXPERT SURVEY
Ibtissam Acem1, Merel Smit2, Cees Verhoef3, Winan J. van Houdt4, Dirk Grunhagen5, Michel van de Sande1
1Leiden University Medical Centre, Leiden, NETHERLANDS; 2The Netherlands Cancer Institute, Amsterdam, NETHERLANDS; 3Erasmus Medical Center, Rotterdam, NETHERLANDS
Poster #121  3462376
COMPLETE PATHOLOGICAL RESPONSE TO NEOADJUVANT TREATMENT IS ASSOCIATED WITH BETTER SURVIVAL OUTCOMES IN PATIENTS WITH SOFT TISSUE SARCOMA
Sylvie Bonvalot1, Jay Wunder2, Alessandro Gronchi3, Javier Martin-Broto4, Robert Turcotte5, Marco Rastrelli6, Zsuzsanna Papai7, Stefano Radaelli8, Lars Lindner9, Felix Shumelinsky9, Antonio Cubillo10, Piotr Rutkowski11, Danielle Strens12, Clémentine Demaire12, Georgi Nalbantov12
1Surgery, Institut Curie, Paris, FRANCE; 2Surgery, Sinai Health System, Toronto, Ontario, CANADA; 3Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY; 4Medical Oncology, Hospital Virgen del Rocío, Sevilla, SPAIN; 5Surgery, McGill University Health Centre, Montreal, Quebec, CANADA; 6Surgical Oncology, Istituto Oncologico Veneto, Padova, ITALY; 7Oncology, Honved Hospital - Hungarian Defence Forces Military Hospital, Budapest, HUNGARY; 8Internal Medicine, University Hospital of Munich, Munich, GERMANY; 9Surgery--Bone and Connective Tissue Tumour Surgery, Jules Bordet Institute, Brussels, BELGIUM; 10Medical Oncology, Hospital Universitario Sanchinarro. Centro Integral Oncológico Clara Campal HM CIOCC, Madrid, SPAIN; 11Soft Tissue/Bone Sarcoma and Melanoma, Maria Skłodowska-Curie Institute-Oncology Center, Warsaw, POLAND; 12Health Economics & Outcome Research Team, Monitor Deloitte, Zaventem, BELGIUM

Poster #122  3462419
OVERALL SURVIVAL AFTER PERIOPERATIVE CHEMOTHERAPY IN THE MANAGEMENT OF PULMONARY METASTASIS IN OSTEOSARCOMA
Zeba Siddiqui1, Megan Delisle2, Amirrtha Srikanthan3, Ying Wang4
1Internal Medicine Residency Training Program, University of Ottawa, Ottawa, Ontario, CANADA; 2General Surgery Residency Program Department, University of Manitoba, Winnipeg, Manitoba, CANADA; 3The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, Ontario, CANADA; 4BC Cancer Vancouver, University of British Columbia, Vancouver, British Columbia, CANADA

Poster #123  3462424
PRECLINICAL ASSESSMENT AND ANALYSIS OF ANTI-SEMA4D TREATMENT FOR OSTEOSARCOMA
Gabrielle Robbins1, Branden Smeester1, Branden Moriarity1
1Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, UNITED STATES

Poster #124  3462442
NCI PROTOCOL 10330: A PHASE 2 STUDY OF BELINOSTAT AND SGI-110 (GUADECITABINE) FOR THE TREATMENT OF UNRESECTABLE AND METASTATIC CONVENTIONAL CHONDROSARCOMA
Jay H. Oza1, Matthew Ingham1, Shing Lee1, Tahir Sheikh1, Richard Piekarski2, Gary Schwartz3
1Department of Medicine (Division of Hematology and Oncology), Columbia University, New York, New York, UNITED STATES; 2National Cancer Institute, Bethesda, Maryland, UNITED STATES; 3Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, New York, UNITED STATES

Poster #125  3462457
D-3-PHOSPHOGLYCERATE DEHYDROGENASE (PHGDH) INHIBITION DRIVES PRO-SURVIVAL MTOR DEPENDENCY IN OSTEOSARCOMA
Richa Rathore1, Katharine E. Caldwell1, Caitlyn B. Brashears1, Brian A. Van Tine1
1Medical Oncology, Washington University in St. Louis, University City, Missouri, UNITED STATES

Poster #126  3462463
TARGETING PARACRINE FIBROBLASTIC NETWORKS IN GASTROINTESTINAL STROMAL TUMOR INHIBITS CANCER GROWTH AND METASTASIS
Hyunho Yoon1, Chih-Min Tang1, Sudeep Banerjee2, Mayra Yebra3, Sangkyu Noh4, Adam M. Burgoyne5, Jorge De la Torre5, Martina De Siena6, Mengyuan Liu6, Lilli Klug6, Yoon Young Choi6, Antonio Delgado6, Zhiyong Wang5, Randall P. French7, Andrew M. Lowy8, Ronald deMatteo9, Michael Heinrich9, Alfredo A. Molinolo9, J. Silvio Gutkind9, Olivier Harismendy10, Jason K. Sicklick11
1Department of Surgery, Division of Surgical Oncology, University of California, San Diego, La Jolla, California, UNITED STATES; 2UCLA, Los Angeles, California, UNITED STATES; 3University of Pennsylvania, Philadelphia, Pennsylvania, UNITED STATES; 4Oregon Health and Science University, Portland, Oregon, UNITED STATES; 5Moores Cancer Center, San Diego, California, UNITED STATES
Poster #127 3462528
DIRECT INTERACTION OF THE ATP-SENSITIVE K⁺ CHANNEL BY THE TYROSINE KINASE INHIBITOR IMATINIB, SUNITINIB AND NILOTINIB
Robin Fröbom¹, Erik Berglund¹, Robert Bränström¹
¹Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Stockholm, SWEDEN

Poster #128 3462552
TP53 AS PROGNOSTIC MARKER IN PATIENTS WITH ADVANCED SARCOMA: A POOLED ANALYSIS OF MOSCATO AND PROFILER STUDIES
Elise Nassif¹, Rastilav Bahleda¹, Edouard Auclin³, Charles Honoré², Sarah Dumont², Mehdi Brahmi⁴, Olivier Tredan⁴, Olivier Mir², Isabelle Ray-Coquard⁴, Axel Le Cesne³, Jean-Yves Blay¹, Christophe Massard⁴, Armelle Dufresne⁴
¹DITEP, Institut Gustave Roussy, Paris, FRANCE; ²Gustave Roussy, Villejuif, FRANCE; ³APHP, Paris, FRANCE; ⁴Centre Léon Bérard, Lyon, FRANCE

Poster #129 3462565
DIAGNOSTIC CHALLENGES OF INFANTILE SARCOMAS DRIVEN BY EGFR INTERNAL TANDEM DUPLICATIONS: A CASE SERIES
Ajay Gupta¹, Ryan D. Roberts², Catherine Cottrell³, Kathleen Schieffer³, Selene Koo⁴, Elaine Mardis¹, Mark Ranalli², Bhuvana Setty²
¹Pediatric Oncology, Roswell Park Cancer Institute, Buffalo, New York, UNITED STATES; ²Hematology, Oncology, Blood and Marrow Transplant, Nationwide Children’s Hospital, Columbus, Ohio, UNITED STATES; ³The Steve and Cindy Rasmussen Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, Ohio, UNITED STATES; ⁴Pathology, Nationwide Children's Hospital, Columbus, Ohio, UNITED STATES

Poster #130 3462585
GENOMIC CHARACTERISTICS RELATED TO THE EFFICACY OF ANLOTINIB IN LEIOMYOSARCOMA
Wenshui Liu¹, Qingping Zou³, Hanxing Tong¹, Rongyuan Zhuang², Chenlu Zhang², Xi Guo², Chentao Lv¹, Hua Yang¹, Qiaowei Lin³, Zhiming Wang², Feng Shen², Lijie Ma¹, Chun Dai¹, Jun Liu¹, Guan Wang⁴, Yong Zhang⁴, Weiqi Lu³, Yuhong Zhou²
¹Department of General Surgery, Shanghai Public Health Clinical Center, Fudan University, Shanghai, CHINA; ²Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, CHINA; ³Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, CHINA; ⁴GenomiCare Biotechnology, Shanghai, CHINA

Poster #131 3462616
DESPITE ADVANCES IN TUMOR MANAGEMENT MODALITIES, SURGERY SEEMS TO BE THE BEST PREDICTOR OF SURVIVAL FOR OSTEOSARCOMA: AN ANALYSIS OF PRIMARY OSSEOUS TUMOR CHARACTERISTICS, MANAGEMENT, AND OUTCOMES FROM THE NATIONAL CANCER DATABASE (NCDB)
Taylor D. Ottesen¹, Blake S. Shultz¹, Alana M. Munger¹, Cosmas Sibindi¹, Alp Yurter¹, Arya R. Varthi¹, Jonathan N. Grauer¹
¹Orthopaedics and Rehabilitation, Yale School of Medicine, Orem, Utah, UNITED STATES

Poster #132 3462658
THE EFFECT OF EXTENSOR MECHANISM REPAIR ON FUNCTIONAL OUTCOME FOLLOWING PROXIMAL TIBIA REPLACEMENT
Rishi Trikha¹, Danielle Greig¹, Troy Sekimura¹, Michael Arnold¹, Alexander Stavrakis¹, Jeffrey Eckardt¹, Nicholas Bernthal¹
¹Orthopaedics, University of California, Los Angeles, Santa Monica, California, UNITED STATES

Poster #133 3462660
SURVIVAL FOLLOWING EPITHELIOD SARCOMA DIAGNOSIS: A SEER DATABASE ANALYSIS
Elizabeth T. Loggers¹, Michael J. Wagner³, Bonny Chau¹, Seth Pollack¹, Matthew J. Thompson¹, Edward Kim³, Gabrielle Kane³, Jared Harwood³, Teresa Kim³, Lee D. Cranmer¹
¹Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, UNITED STATES; ²University of Washington, Seattle, Washington, UNITED STATES; ³University of Washington, Seattle, Washington, UNITED STATES
Poster #134  3462671
THE INCIDENCE, RISK FACTORS AND MICROBIAL PROFILE OF INFECTED ENDOPROSTHETIC RECONSTRUCTIONS
Rishi Trikha1, Danielle Greig1, Troy Sekimura1, Jeffrey Eckardt1, Nicholas Bernthal1
1Orthopaedics, University of California, Los Angeles, Santa Monica, California, UNITED STATES

Poster #135  3462922
SURGICAL TREATMENT PATTERNS AND HEALTHCARE RESOURCE UTILIZATION IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMORS WHO UNDERWENT JOINT SURGERY IN THE UNITED STATES
Feng Lin1, Winghan J Kwong1, Willy Wynant2, Raluca Ionescu-Ittu2, Sherry Shi2, Irina Pivneva2, Eric Q. Wu2, John A. Abraham4
1Daiichi Sankyo, Inc., Basking Ridge, New Jersey, UNITED STATES; 2Analysis Group, Inc., Montreal, Quebec, CANADA; 3Analysis Group, Inc., Boston, Massachusetts, UNITED STATES; 4Rothman Institute and Fox Chase Cancer Center, Philadelphia, Pennsylvania, UNITED STATES

Poster #136  3462983
GEMCITABINE-CONTAINING REGIMENS FOR THE TREATMENT OF METASTATIC MYXOFIBROSARCOMA REFRACTORY TO DOXORUBICIN
Arielle Elkrief1, Suzanne Kazandjian1, Thierry Alcindor4
1Oncology, McGill University Health Centre, Montreal, Quebec, CANADA

Poster #137  3463019
TNT: A PHASE 2 STUDY USING TALIMOGENE LAHERPAREPVEC, NIVOLUMAB AND TRABECTEDIN AS FIRST, SECOND/THIRD LINE THERAPY FOR ADVANCED SOFT TISSUE SARCOMA, INCLUDING DESMOID TUMOR AND CHORDOMA [NCT03886311]
Sant P. Chawla1, Victoria Chua-Alcala1, Ted T. Kim1, Kelly Wang1, Paul S. Dy1, Nicole L. Angel1, Micaela K. Paz1, Ania M. Moradkhani1, Doris M. Quon1, Steven M. Wong1, Omid Jafari1, Erlinda M. Gordon1
1Sarcoma Oncology Center, Santa Monica, California, UNITED STATES

Poster #138  3463040
THE PROGNOSTIC IMPORTANCE OF PATHOLOGIC FRACTURE IN LIMB SALVAGE SURGERY FOR CHONDROSARCOMA
Danielle Greig1, Rishi Trikha1, Troy Sekimura1, Jeffrey Eckardt1, Nicholas Bernthal1
1Orthopaedic Surgery, University of California, Los Angeles, Los Angeles, California, UNITED STATES

Poster #139  3463046
ASEPTIC LOOSENING FOLLOWING LIMB SALVAGE SURGERY FOR TUMOR: A REVIEW OF 245 PRIMARY CEMENTED STEM DISTAL FEMORAL REPLACEMENTS IMPLANTED OVER A 40-YEAR PERIOD
Danielle Greig1, Rishi Trikha1, Samuel Clarkson1, Troy Sekimura1, Adam A. Sassoon1, Jeffrey Eckardt1, Nicholas Bernthal1
1Orthopaedic Surgery, University of California, Los Angeles, Los Angeles, California, UNITED STATES

Poster #140  3463093
THE OUTCOMES AND PROGNOSTIC FACTORS IN PATIENTS WITH OSTEOASRCOMA ACCORDING TO AGE* A JAPANESE NATIONWIDE STUDY WITH FOCUSING ON THE AGE DIFFERENCES
Yusuke Tsuda1, Hiroshi Kobayashi1, Yusuke Shinoda1, Sakae Tanaka1
1Tokyo University, Tokyo, JAPAN

Poster #141  3463134
COMBINING SHELF OSTEOTOMY WITH PROXIMAL FEMORAL RECONSTRUCTION AFTER ONCOLOGIC RESSECTION
Joanne Zhou1, Cara Lai1, Stephanie Pun1, Raffi Avedian1, Robert Steffner1
1Orthopaedic Surgery, Stanford University, Redwood City, California, UNITED STATES
COMPREHENSIVE MASSIVELY PARALLEL SEQUENCING OF SARCOMAS: EXPERIENCE FROM AN AUSTRALIAN TERTIARY HOSPITAL LABORATORY AND STATE SARCOMA SERVICE

Daniel Wong1, Tindaro Giardina1, Cleo Robinson1, Marc Thomas1, Timothy Humphries2, Peter Robbins1, Anne Long2, Michael Millward2, Richard Carey-Smith1, Benhur Amanuel1

1Anatomical Pathology, PathWest, Perth, Western Australia, AUSTRALIA; 2Medical Oncology, Sir Charles Gairdner Hospital, Perth, Western Australia, AUSTRALIA; 3Orthopaedic Surgery, Sir Charles Gairdner Hospital, Perth, Western Australia, AUSTRALIA

TARGETING CYCLIN DEPENDENT KINASE 8 IN FUSION POSITIVE RHABDOMYSARCOMA

Marissa Just1, Seth Zimmerman3, Christian Cerda Smith4, Kris Wood3, Chris Counter3, Corinne Linardic2

1Pediatrics, Duke University, Durham, North Carolina, UNITED STATES; 2Pediatrics and Pharmacology and Cancer Biology, Duke University, Durham, North Carolina, UNITED STATES; 3Pharmacology and Cancer Biology, Duke University, Durham, North Carolina, UNITED STATES; 4School of Medicine, Duke University, Durham, North Carolina, UNITED STATES

CLINICAL BENEFIT WITH RIPRETINIB AS ≥4TH LINE TREATMENT IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR: UPDATE FROM THE PHASE 3 INVICTUS STUDY

Hans Gelderblom1, Michael Heinrich2, Suzanne George3, John Zalcberg4, Sebastian Bauer5, Patrick Schöffski6, César Serrano7, Robin L. Jones8, Steven Attia9, Gina D’amato10, Ping Chi11, Peter Reichardt12, Julie Meade13, Vienna L. Reichert13, Kelvin Shi13, Rodrigo Ruiz-Soto13, Margaret von Mehren14, Jean-Yves Blay15

1Medical Oncology, Leiden University Medical Center, Leiden, NETHERLANDS; 2OHSU Knight Cancer Institute, Portland, Oregon, UNITED STATES; 3Dana-Farber Cancer Institute, Boston, Massachusetts, UNITED STATES; 4Monash University, Melbourne, Victoria, AUSTRALIA; 5Sarcoma Center, West German Cancer Center, Essen, GERMANY; 6General Medical Oncology, University Hospitals Leuven, Leuven, GERMANY; 7Medical Oncology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, SPAIN; 8Sarcoma Unit, Royal Marsden and Institute of Cancer Research, London, UNITED KINGDOM; 9Oncology, Mayo Clinic, Jacksonville, Florida, UNITED STATES; 10Sylvester Comprehensive Cancer Center/University of Miami, Miami, Florida, UNITED STATES; 11Human Oncology and Pathogenesis Program & Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, UNITED STATES; 12Oncology and Palliative Care, Sarcoma Center, Helios Klinikum Berlin-Buch, Berlin, GERMANY; 13Deciphera Pharmaceuticals, LLC, Waltham, Massachusetts, UNITED STATES; 14Hematology Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, UNITED STATES; 15Medecine, Centre Léon Bérard, Lyon, FRANCE

INCIDENCE OF SARS-COV-2 IN PEDIATRIC ONCOLOGY CLINIC AT THE EPICENTER OF THE PANDEMIC

Molly M. Aguina1, Ariel Gliksberg1, Samantha Bents1, Janay McKnight1, Paul Kent1

1Pediatric Hematology/Oncology, Rush University Hospital, Chicago, Illinois, UNITED STATES

DEDIFFERENTIATION WITHIN A WELL DIFFERENTIATED LIPOSARCOMA OF THE EXTREMITY OR TRUNK – IMPLICATIONS FOR CLINICAL MANAGEMENT

William W. Tseng1, Francesco Barretta2, Marco Baia2, Marco Fiore2, Alessandro Gronchi2

1Surgery, Division of Breast, Endocrine and Soft Tissue Surgery, University of Southern California, Keck School of Medicine, Los Angeles, California, UNITED STATES; 2Surgery, Sarcoma Service, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY; 3Clinical Epidemiology and Trials Organization Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY

LOCAL RECURRENCE OF SOFT TISSUE SARCOMA REVISITED: IS THERE A ROLE FOR “SELECTIVE” RADIATION?

Nathan Saxby1, Qiang An1, Benjamin J. Miller1

1University of Iowa, Iowa City, Iowa, UNITED STATES
A NOVEL METHOD FOR THREE-DIMENSIONAL GROWTH AND ASSAY OF PAX3-FOXO1 FUSION-POSITIVE RHABDOMYOSARCOMA CELLS ENRICHES IN CANCER STEM CELL CHARACTERISTICS

Kristianne M. Oristian, Katherine Slemmons, Michael Deel, Yi-Tzu Lin, Napasorn Kuprasertkul, Lisa Crose, Katia Genadry, Po-Han Chen, Jen-Tsan Ashley Chi, Corinne Linardic

Pediatrics-Hematology/Oncology Pharmacology & Cancer Biology, Duke University School of Medicine, Durham, North Carolina, UNITED STATES; Pediatrics-Hematology/Oncology Oncology, Duke University School of Medicine, Durham, North Carolina, UNITED STATES; Biology, Duke University, Durham, North Carolina, UNITED STATES; Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, North Carolina, UNITED STATES

ARID1A DELETION ENHANCES OSTEOSARCOMAGENESIS IN HUMAN CELL LINES AND MURINE MODEL

Jared J. Barrott, Yanliang Wang, Kaniz Fatema, Shawn Plyler, Christopher Nartker, Kevin B. Jones

Biomedical and Pharmaceutical Sciences, Idaho State University, Pocatello, Idaho, UNITED STATES; Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, UNITED STATES

BIOMARKERS FOR DELTAREX-G, THE SAFER CHECKPOINT INHIBITOR FOR SARCOMA: A SINGLE CENTER EXPERIENCE

Paul S. Dy, Kelly Wang, Ted T. Kim, Sant P. Chawla, Sheng Xiao, Frederick L. Hall, Erlinda M. Gordon

Sarcoma Oncology Center, Santa Monica, California, UNITED STATES; Cytogenetics Laboratory, Brigham and Womens Hospital, Boston, Massachusetts, UNITED STATES; Oncology, Delta Next-Gen, LLC, Santa Monica, California, UNITED STATES

TARGETING SPHINGOLIPID METABOLISM IN SYNOVIAL SARCOMA

Jared J. Barrott, Sarah Luelling, Farjana Afrin, Adriene Pavek, Austen Kalivas, Srinath Pashikanti

Biomedical and Pharmaceutical Sciences, Idaho State University, Pocatello, Idaho, UNITED STATES

30-YEAR FOLLOW-UP RESULTS OF 170 CEMENTED ENDOPROSTHETIC RECONSTRUCTIONS FOR TUMORS OF THE UPPER EXTREMITY

Danielle Greig, Rishi Trikha, Troy Sekimura, Michael Arnold, Jeffrey Eckardt, Nicholas Bernthal

Orthopaedic Surgery, University of California, Los Angeles, Los Angeles, California, UNITED STATES
Poster #154  3463673
ACIDIC MICRONENVIRONMENTS IN SOFT TISSUE SARCOMA PROMOTES FOXM1 EXPRESSION AND TUMORIGENESIS
Toshihiko Nishisho1, Shunichi Toki1, Ryo Miyagi1, Koichi Sairyo1
1Orthopedics, Tokushima University, Tokushima, JAPAN

Poster #155  3463677
KAPOSI SARCOMA AFTER SOLID ORGAN TRANSPLANTATION, A SINGLE CENTRE EXPERIENCE
Sara Damaso1, Raquel L. Brás1, Cecilia M. Alvim1, Pedro M. Garrido2, Luis Costa1, João Borges-Costa2, Isabel Fernandes1
1Medical Oncology Department, Centro Hospitalar Universitário Lisboa Norte – Hospital Santa Maria, Lisboa, PORTUGAL; 2Dermatology Department, Centro Hospitalar Universitário Lisboa Norte – Hospital Santa Maria, Lisboa, PORTUGAL

Poster #156  3463723
NEOADJUVANT CHEMORADIOTHERAPY IN ADVANCED SOFT TISSUE SARCOMA: NASAR STUDY
Jeronimo Martinez-Garcia1, Pablo Puertas-Sandoval2, Antonio Valcarcel3, Juan Angel Fernandez1, Pilar Sanchez-Henarejos1, Ana Puertes1, M Dolores Jimenez1, Ana Sanchez-Saura1, Jose Emilio Hernandez1, David Lopez1, M Dolores Abellan1, Andres Lopez-Sanchez2, Begoña Torregrosa2, Isabel de la Fuente3, Enrique Cardenas3, Jose Luis Navarro1, Clemente Fernandez-Pascual3, M Jose Roca3, Thelmo Quiros3, Antia Lopez1, Domingo Sanchez1, Irene Martinez1, Blanca Sanchez1, Jose Luis Alonso1
1Medical Oncology, Clinical University Hospita Virgen de la Arrixaca, El Palmar, Murcia, SPAIN; 2Traumatologia, Clinical University Hospital Virgen de la Arrixaca, Murcia, SPAIN; 3Surgery, Clinical University Hospital Virgen de la Arrixaca, Murcia, SPAIN; 4Pathology, Clinical University Hospital Virgen de la Arrixaca, Murcia, SPAIN; 5Radiology, Clinical University Hospital Virgen de la Arrixaca, Murcia, SPAIN; 6Raditherapy, Clinical University Hospital Virgen de la Arrixaca, Murcia, SPAIN; 7Nuclear Medicine, Clinical University Hospital Virgen de la Arrixaca, Murcia, SPAIN; 8Thoracic Surgery, Clinical University Hospital Virgen de la Arrixaca, Murcia, SPAIN

Poster #157  3463757
GENOMIC LANDSCAPE OF METASTATIC SOFT TISSUE SARCOMA
Erik Wiemer1, Melissa Vos1, Harmen J. van de Werken2, Job van Riet2, Neeltje Steeghs1, Martijn P. Lolkema1, Carla M. van Herpen1, Derk J. de Groot1, Hans Gelderblom2, Vivianne C. Tjan-Heijnen1, Edwin Cuppen8, Stefan Sleijfer1
1Medical Oncology, Erasmus Medical Center, Rotterdam, NETHERLANDS; 2Cancer Computational Biology Center, Erasmus Medical Center, Rotterdam, NETHERLANDS; 3Medical Oncology, Antoni van Leeuwenhoek - Netherlands Cancer Institute, Amsterdam, NETHERLANDS; 4Medical Oncology, Radboud University Medical Center, Nijmegen, NETHERLANDS; 5Medical Oncology, University Medical Center Groningen, Groningen, NETHERLANDS; 6Medical Oncology, Leiden University Medical Center, Leiden, NETHERLANDS; 7Medical Oncology, Maastricht University Medical Center, Maastricht, NETHERLANDS; 8Center for Molecular Medicine and Oncode Institute, University Medical Center Utrecht, Utrecht, NETHERLANDS

Poster #158  3463788
IDENTIFICATION AND AUTHENTICATION OF A NOVEL "FET/ETS" FUSION ONCOPROTEIN IN EWING SARCOMA
Mark Winstanley2, Megann Boone1, Cenny Taslim1, Mike Watson1, James Hamil1, Peter Heppner1, Andrew Wood1, Jesse Crow1, Julia Selich-Anderson1, Stephen L. Lessnick1
1Center for Childhood Cancer, Nationwide Children’s Hospital, Columbus, Ohio, UNITED STATES; 2Starship Paediatric Blood & Cancer Centre, Auckland, NEW ZEALAND; 3LabPlus, Auckland District Health Board, Auckland, NEW ZEALAND

Poster #159  3463800
CUTANEOUS ANGIOSARCOMA: CLINICAL AND MOLECULAR PROFILE AND IMMUNOTHERAPY IN A CASE SERIES
Jacob N. Stein1, Francie Jenkins2, Stergios Moschos1, Paul Googe3, Bradley Merritt2, Juneko E. Grilley-Olson1
1Medicine/Oncology, UNC Chapel Hill, Durham, North Carolina, UNITED STATES; 2School of Medicine, University of North Carolina, CHAPEL HILL, North Carolina, UNITED STATES; 3Dermatology, Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, North Carolina, UNITED STATES
FEWER THAN TWO PULMONARY MICRONODULES IDENTIFIED ON PRESENTATION IN PATIENTS WITH OSTEOSARCOMA HAVE NO EFFECT ON 5 YEAR OVERALL SURVIVAL

Reid Davison1, Fadi Hamati1, Paul Kent1
1College of Medicine, Rush Medical College, Chicago, Illinois, UNITED STATES

MALIC ENZYME 1 ABSENCE IN SYNOVIAL SARCOMA ALTERS GLUCOSE METABOLISM AND THE GLUTATHIONE-TIREDOXIN AXIS

Caitlyn B. Brashears1, Bethany Prudner1, Richa Rathore1, Anthony Robinson1, Brian A. Van Tine1
1Oncology, Washington University in St. Louis School of Medicine, St. Louis, Missouri, UNITED STATES

PROXIMAL FEMORAL REPLACEMENT IN THE TREATMENT OF ONCOLOGIC DISORDERS OF THE PROXIMAL FEMUR: THE EXPERIENCE OF A SINGLE INSTITUTION

Charles Gusho1, Bishir Clayton1, Mick P. Kelly1, Pedro Escobedo1, Matthew Colman1, Steven Gitelis1, Alan Blank1
1Department of Orthopedics, Division of Orthopedic Oncology, Rush University Medical Center, Chicago, Illinois, UNITED STATES

DISTAL FEMORAL REPLACEMENT FOR TREATMENT OF ONCOLOGIC DISORDERS OF THE LOWER EXTREMITY: THE EXPERIENCE OF A SINGLE INSTITUTION

Charles Gusho1, Bishir Clayton1, Joshua Greenspoon1, Jonathan Bauer1, Matthew Colman1, Steven Gitelis1, Alan Blank1
1Department of Orthopedics, Division of Orthopedic Oncology, Rush University Medical Center, Chicago, Illinois, UNITED STATES

LURBINETEDIN IN COMBINATION WITH IRINOTECAN IN PATIENTS (PTS) WITH SOFT TISSUE SARCOMAS (STS)

1PharmaMar, Madrid, Colmenar Viejo, SPAIN; 2Massachussets General Hospital, Boston, Massachusetts, UNITED STATES; 3Hospital Universitario 12 de Octubre, Madrid, SPAIN; 4Hospital Universitario Virgen del Rocio, Sevilla, SPAIN

SPATIAL DETECTION OF CELLULAR CROSS-PRESENTATION AS A PROGNOSTIC TOOL IN SOFT TISSUE SARCOMA

Monika Ehnman1, Panagiotis Tsagkozis2, Yanhong Su3, Nicholas P. Tobin4, Okan Gultekin5, Anna Malmerfelt1, Katrine Ingelshed2, Johanna Lundquist1, Wiem Chaabane6, Maya H. Nisancioglu2, Lina W. Leiss1, Arne Östman1,4, Jonas Bergh1,2,3, Kaisa Lehtih5,6, Saikiran Sedimbi3, Felix Haglund1
1Department of Oncology-Pathology, Karolinska Institutet, Stockholm, SWEDEN; 2Department of Molecular Medicine and Surgery, Karolinska Institutet and Muskuloskeletal Tumor Service, Karolinska University Hospital, Stockholm, SWEDEN; 3Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, SWEDEN; 4Centre for Cancer Biomarkers CCBIO, University of Bergen, Bergen, NORWAY; 5Department of Oncology-Pathology, Karolinska Institutet, Radiumhemmet, Karolinska University Hospital, Stockholm, SWEDEN; 6Department of Biomedical Laboratory Science, Norwegian University of Science and Technology, Trondheim, NORWAY

DEMOGRAPHICS AND OUTCOME OF PATIENTS WITH ADULT HEAD AND NECK SARCOMA: THE OTTAWA EXPERIENCE

Taylor Barrett1, Samy El-Sayed2, Prudence Buchanan1, Ionut Busca1
1The Ottawa Hospital Research Assistant, Ottawa, Ontario, CANADA; 2University of Ottawa, Ottawa, Ontario, CANADA
RIPRETINIB DEMONSTRATED ACTIVITY ACROSS ALL KIT/PDGFRα MUTATIONS IN PATIENTS WITH FOURTH-LINE ADVANCED GASTROINTESTINAL STROMAL TUMOR: ANALYSIS FROM THE PHASE 3 INVICTUS STUDY

Patrick Schöffski1, Sebastian Bauer2, Michael Heinrich3, Suzanne George4, John Zalcberg5, Hans Gelderblom6, César Serrano7, Robin L. Jones8, Steven Attia9, Gina D’amato10, Ping Chi11, Peter Reichardt12, Julie Meade13, Kelvin Shi13, Ying Su13, Rodrigo Ruiz-Soto13, Margaret von Mehren14, Jean-Yves Blay15

1General Medical Oncology, University Hospitals Leuven, Leuven, BELGIUM; 2Sarcoma Center, West German Cancer Center, Essen, GERMANY; 3Hematology/Medical Oncology, OHSU Knight Cancer Institute, Portland, Oregon, UNITED STATES; 4Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, UNITED STATES; 5School of Public Health, Faculty of Medicine, Monash University, Melbourne, Victoria, AUSTRALIA; 6Medical Oncology, Leiden University Medical Center, Leiden, NETHERLANDS; 7Medical Oncology, Vall d’Hebron Institute of Oncology, Barcelona, SPAIN; 8Sarcoma Unit, Royal Marsden and Institute of Cancer Research, London, UNITED KINGDOM; 9Oncology, Mayo Clinic, Jacksonville, Florida, UNITED STATES; 10Medical Oncology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida, UNITED STATES; 11Human Oncology and Pathogenesis Program & Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, UNITED STATES; 12Oncology and Palliative Care, Sarcoma Center, Helios Klinikum Berlin-Buch, Berlin, GERMANY; 13Deciphera Pharmaceuticals, LLC, Waltham, Massachusetts, UNITED STATES; 14Hematology Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, UNITED STATES; 15Centre Leon Berard, Lyon, FRANCE

REFINING THE APPROACH TO PATIENTS WITH PRIMARY SOFT TISSUE SARCOMA OF THE EXTREMITIES AND TRUNK WALL (ESTSs): OUTCOME IMPROVEMENT OVER 30 YEARS AT A SINGLE INSTITUTION

Maria Danieli2, Francesco Barretta1, Marco Fiore2, Stefano Radaelli2, Claudia Sangalli2, Marta Barisella1, Silvia Stacchiotti3, Elena Palassini3, Rosalba Miceli1, Dario Callegaro2, Paolo Giovanni Casali3, Alessandro Gronchi2

1Department of Clinical Epidemiology and Trial Organisation, Istituto Nazionale dei Tumori, Milan, ITALY; 2Surgery, Istituto Nazionale dei Tumori, Milan, ITALY; 3Department of Cancer Medicine, Istituto Nazionale dei Tumori, Milan, ITALY; 4Radiotherapy, Istituto Nazionale dei Tumori, Milan, ITALY; 5Pathology, Istituto Nazionale dei Tumori, Milan, ITALY

Cardiototoxicity among patients with sarcoma treated with doxorubicin: a real-world database study

Lee D. Cranmer2, Lisa M. Hess1, Tomoko Sugihara3, Yajun E. Zhu1, Howard G. Muntz1

1Eli Lilly and Company, Indianapolis, Indiana, UNITED STATES; 2University of Washington, Seattle, Washington, UNITED STATES; 3Syneos Health, Austin, Texas, UNITED STATES

Novel gene fusions in pediatric rhabdomyosarcomas

Kelsi Willis1, Naseem Uddin1, Jason Park1, Dinesh Rakheja1

1Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, UNITED STATES

A novel patient-derived, aggressive, extraosseous Ewing sarcoma cell line

Kelsi Willis1, Lindsay Mendyka2, Lane Beeman3, Patricia Tiburcio2, Deyssy Carrillo3, Jennifer Wagenfuehr3, Jason Park1, Kenneth Chen2, Dinesh Rakheja1

1Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, UNITED STATES; 2Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas, UNITED STATES; 3Pathology, Children’s Health, Dallas, Texas, UNITED STATES

Soft-tissue sarcoma in elderly patients: patterns of care and survival

Toshihiko Nishisho1, Shunichi Toki1, Ryō Miyagi1, Koichi Sairyo1

1Orthopedics, Tokushima Prefectural Central Hospital, Tokushima, JAPAN
THE FREQUENCY OF TP53 GERMLINE PATHOGENIC VARIANTS IN RHABDOMYOSARCOMA EXHIBITING ANAPLASIA: A REPORT FROM THE CHILDREN’S ONCOLOGY GROUP
Douglas Fair1, Luke Maese1, Yueh-Yun Chi2, Minjie Li3, Douglas S. Hawkins4, Rajkumar Venkatraman5, Erin Rudzinski6, David Parham7, Lisa Teot8, David Malkin9, Sharon Plon10, Hurley Li11, Aniko Sabo12, Philip Lupo12, Joshua Schiffman1
1Pediatrics, University of Utah, Primary Children’s Hospital | Huntsman Cancer Institute, Salt Lake City, Utah, UNITED STATES; 2Pediatric and Preventative Medicine, University of Southern California, Los Angeles, California, UNITED STATES; 3Statistics and Data Center, Children’s Oncology Group, Gainesville, Florida, UNITED STATES; 4Fred Hutchinson Cancer Research Center, Seattle Children’s Hospital, Seattle, Washington, UNITED STATES; 5Department of Pediatrics, Baylor College of Medicine, Texas Children’s Hospital, Houston, Texas, UNITED STATES; 6Department of Laboratories, Seattle Children’s Hospital, Seattle, Washington, UNITED STATES; 7Pathology and Laboratory Medicine, Children’s Hospital Los Angeles and Keck School of Medicine, Los Angeles, California, UNITED STATES; 8Pathology, Boston Children’s Hospital, Boston, Massachusetts, UNITED STATES; 9Pediatrics, The Hospital for Sick Children, Toronto, Ontario, CANADA; 10Pediatrics, Baylor College of Medicine, Houston, Texas, UNITED STATES; 11Human Genome Sequencing Center, Baylor College of Medicine, Houston, Texas, UNITED STATES; 12Division of Hematology/Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, UNITED STATES; 13Human Genome Sequencing Center, Baylor College of Medicine, Houston, Texas, UNITED STATES

OSTEOSARCOMA HEALTH LITERACY: A QUANTITATIVE ASSESSMENT OF ONLINE PATIENT EDUCATION MATERIAL
Trevor R. Gulbrandsen1, Mary K. Skalitzky1, Alan Shamrock1, Burke Gao1, Obada Hasan1, Benjamin J. Miller1
1Orthopedic Surgery, University of Iowa Hospitals and Clinics, Iowa City, Iowa, UNITED STATES

DEMographics and outcome of patients with gymnAe sarcoma ( gS ), the ottawa experience
Samy El-Sayed1, Prudence Buchanan1
1Radiation Oncology, University of Ottawa, Ottawa, Ontario, CANADA

MIFAMuRTIDE CUMULATIVE DOSE AND PROGNOSIS IN THE ADJUVANT TREATMENT OF PATIENTS WITH NON METASTATIC EXTREMITY HIGH GRADE OSTEOSARCOMA: RESULTS OF THE ITALIAN SARCOMA GROUP (ISG), MULTICENTRIC, PROSPECTIVE, ISG/OS-2 TRIAL
Emanuela Palmerini1, Cristina Meazza1, Angela Tamburini1, Gianni Bisogno1, Virginia Ferraresi1, Sebastian Asaftei2, Giuseppe Maria Milano2, Luca Coccoli3, Carla Manzitti3, Roberto Luksch3, Davide M. Donati4, Massimo Serra4, Rossella Bertulli4, Marco Gambarotti4, Claudio Favre5, Alessandra Longhi5, Massimo Eraldo Abate6, Silverio Perrotta7, Maurizio Mascarin8, Paolo D’angelo9, Marilena Cesarì10, Paolo Giovanni Casali10, Piero Picci10, Franca Fagioli10, Stefano Ferrari1

PAZOPANIB IN METASTATIC BONE SARCOMAS - A UNICENTRIC RETROSPECTIVE ANALYSIS AT A TERTIARY UNIVERSITY HOSPITAL
Raquel L. Brás1, Sara Damaso1, Rita Paiva1, Daniela Macedo1, Luis Costa1, Isabel Fernandes1
1Oncology, Hospital Santa Maria, CHULN, Lisboa, PORTUGAL
PROGNOSIS OF PATIENTS WITH GENITO-URINARY SOFT TISSUE SARCOMAS (GUSTS), 10 YEARS EXPERIENCES IN A TERTIARY CARE CANCER CENTRE.

Samy El-Sayed¹, Prudence Buchanan¹
¹Radiation Oncology, University of Ottawa, Ottawa, Ontario, CANADA

RADIATION-INDUCED SARCOMA: A RETROSPECTIV POPULATION-BASED STUDY OVER 34 YEARS IN A SINGLE INSTITUTION

Louise Bach Callesen¹, Akmal Safwat¹, Thomas Baad Hansen², Flemming Brandt Sørensen³, Hanne Krog Rose¹, Ninna Aggerholm-Pedersen¹
¹Department of Oncology, Aarhus University Hospital, Aarhus, DENMARK; ²Department of Orthopaedic Surgery, Aarhus University Hospital, Aarhus, DENMARK; ³Department of Pathology, Aarhus University Hospital, Aarhus, DENMARK

FAVORABLE INITIAL TUMOR RESPONSE WITH COMBINATION CABOZANTINIB AND NIVOLUMAB IN STAGE 4 ALVEOLAR SOFT PART SARCOMA

Kristen Obiakor¹, Alicia Obiakor², Paul Kent¹
¹Pediatric Hematology/Oncology, Rush University Medical Center, Chicago, Illinois, UNITED STATES; ²Shorewood High School, Shorewood, Wisconsin, UNITED STATES

UNDERSTANDING A RARE SUBTYPE: A REVIEW OF 46 PATIENTS WITH GASTROINTESTINAL LEIOMYOSARCOMA TREATED AT A TERTIARY CARE CENTRE

Alannah Smrke¹, Myles Smith¹, Dirk Strauss¹, Andrew Hayes¹, Khin Thway¹, Cyril Fisher², Christina Messiou¹, Charlotte Benson¹, Robin L. Jones¹
¹The Royal Marsden Hospital, London, UNITED KINGDOM; ²University Hospitals Birmingham, Birmingham, UNITED KINGDOM

POSTERIOR KNEE ARTHROSCOPY FOR PIGMENTED VILLONODULAR SYNOVITIS UTILIZING ULTRASOUND GUIDANCE

Lee M. Zuckerman¹, Hasan M. Syed², Nadine L. Williams³, Christopher M. Jobe²
¹Orthopaedic Surgery, City of Hope National Medical Center, Duarte, California, UNITED STATES; ²Orthopaedic Surgery, Oroville Hospital, Oroville, California, UNITED STATES; ³Orthopaedic Surgery, Loma Linda University Medical Center, Loma Linda, California, UNITED STATES

USE OF MAGNETIC GROWING INTRAMEDULLARY NAILS WITH INTERCALARY ALLOGRAFT RECONSTRUCTION AFTER TUMOR RESECTION

Lee M. Zuckerman¹, Nadine L. Williams²
¹Orthopaedic Surgery, City of Hope National Medical Center, Duarte, California, UNITED STATES; ²Orthopaedic Surgery, Loma Linda University Medical Center, Loma Linda, California, UNITED STATES

ONCOLOGIC INDICATIONS FOR ELECTROMAGNETIC INTRAMEDULLARY NAILS

Lee M. Zuckerman¹
¹Orthopaedic Surgery, City of Hope National Medical Center, Duarte, California, UNITED STATES

SUPPORTING CLINICAL DECISION-MAKING FOR PI3K/AKT/MTOR INHIBITORS FOR HIGH-RISK PAEDIATRIC AND AYA SARCOMA

Emmy D. Fleuren¹, Emmy Dolman¹, Loretta Lau¹, Jinhua Xie¹, Daniel Batey¹, Chelsea Mayoh¹, Paulette Barahona¹, Alexandra Sherstyk¹, Dong Anh Khuong Quang², Marie Wong³, ZERO Preclinical Drug Testing Team¹, ZERO Omics Team¹, David Thomas¹, Emily Mould¹, Murray Norris¹, Michelle Haber¹, Toby Trahair¹, Glenn Marshall¹, David Ziegler¹, Vanessa Tyrrell¹, Mark Cowley¹, Richard Lock¹, Paul G. Ekert¹
¹Personalised Medicine, Children’s Cancer Institute, Sydney, New South Wales, AUSTRALIA; ²Royal Children’s Hospital, Melbourne, Victoria, AUSTRALIA; ³Garvan Institute of Medical Research, Sydney, New South Wales, AUSTRALIA
Poster #186 3464494
ADJUVANT PALBOCICLIB FOR THE PREVENTION OF LOCAL RECURRENCE IN RESECTED LIPOSARCOMA
Luke V. Selby1, David A. Liebner1, James Chen1, Gabriel Tinoco1, Joal Beane1, Raph Pollock1, Valerie Grignol1
1Medical Oncology, The Ohio State University, Columbus, Ohio, UNITED STATES

Poster #187 3464514
EARLY DIAGNOSIS OF UTERINE SARCOMA IS ASSOCIATED WITH GRAVIDITY, PARITY, AND HISPANIC ETHNICITY
Caroline Hana1, Gina D’amato2, Jonathan Trent2
1Internal Medicine, University of Miami, Boynton Beach, Florida, UNITED STATES; 2Oncology, University of Miami, Miami, Florida, UNITED STATES

Poster #188 3464550
TRANSFORMED CANINE AND MURINE MESENCHYMAL STEM CELLS AS A MODEL FOR HIGH GRADE SARCOMA WITH COMPLEX GENOMICS
Natasja Franceschini1, Bas Verbruggen1, Marianna Tryfonidou2, Alwine B. Kruisselbrink1, Hans Baelde1, Karin de Visser3, Karoly Szuhai1, Anne-Marie Cleton-Jansen1, Judith V. Bovee1
1Leiden University Medical Center, Leiden, NETHERLANDS; 2Utrecht University, Utrecht, NETHERLANDS; 3Netherlands Cancer Institute, Amsterdam, NETHERLANDS

Poster #189 3464563
PATIENT ADVOCATES TRANSFORMING SARCOMA CARE IN INDIA
Priyanka Banga1, Pankaj Banga1
1Sarcoma Cancer Care Foundation, Faridabad, INDIA

Poster #190 3464611
CHARACTERIZING THE EFFICACY OF IMMUNE CHECKPOINT INHIBITOR-BASED TREATMENT IN SELECTIVE SUBTYPES OF ADVANCED SARCOMA PATIENTS
Yang You1, Xi Guo1, Rongyuan Zhuang1, Chenlu Zhang1, Zhiming Wang1, Yan Wang1, Yong Zhang1, Weiqi Li1, Yingyong Hou1, Yuhong Zhou1
1Oncology Department, Zhongshan Hospital, Shanghai, Shanghai, CHINA

Poster #191 3464643
IMMUNE-MATRIX GENE EXPRESSION SIGNATURES OF CYTOKINES, CHEMOKINES, IMMUNE CHECKPOINTS, MATRIX METALLOPROTEINASES AND TISSUE INHIBITORS OF METALLOPROTEINASES IN FORMALIN-EMBEDDED HUMAN CHONDROSARCOMA SAMPLES
Paulo Rodrigues-Santos1, Patricia Couceiro2, Jani Sofia Almeida1, Paulo Freitas-Tavares3, José Manuel Casanova3
1Instituto de Imunologia, Faculdade de Medicina da Universidade de Coimbra, Coimbra, PORTUGAL; 2Laboratório de Imunologia e Oncologia, Centro de Neurociencias e Biologia Celular, Universidade de Coimbra, Coimbra, PORTUGAL; 3Unidade de Tumores do Aparelho Locomotor, Serviço de Ortopedia, Centro Hospitalar e Universitário de Coimbra, Coimbra, PORTUGAL

Poster #192 3464670
THE MUSCULOSKELETAL TUMOR REGISTRY: LESSONS, BARRIERS, AND FUTURE GOALS
Benjamin J. Miller1, Eric Henderson2, Adam Levin3, George Calvert4, Joel Mayerson5, Nathan Mesko6, Lukas Nystrom6, Robert Steffner1
1University of Iowa, Iowa City, Iowa, UNITED STATES; 2Dartmouth, Lebanon, New Hampshire, UNITED STATES; 3Johns Hopkins, Baltimore, Maryland, UNITED STATES; 4Norton, Louisville, Kentucky, UNITED STATES; 5Ohio State, Columbus, Ohio, UNITED STATES; 6Cleveland Clinic, Cleveland, Ohio, UNITED STATES; 7Stanford, Redwood City, California, UNITED STATES

Poster #193 3464730
PATTERN OF PRESENTATIONS, OUTCOME OF TREATMENT, AND PATTERN OF FAILURE OF PATIENTS WITH GASTROINTESTINAL ADULT SOFT TISSUE SARCOMAS: A 10 YEARS’ EXPERIENCE IN A TERTIARY CANCER CENTRE
Dalia Ibrahim1, Prudence Buchanan1, Samy El-Sayed2
1Ottawa Hospital Research Institute, Ottawa, Ontario, CANADA; 2University of Ottawa, Ottawa, Ontario, CANADA
Poster #194 3464830
ASSOCIATIONS OF KNOWN SUSCEPTIBILITY LOCI AND GENETIC ANCESTRY ON EWING SARCOMA RISK IN LATINOS
Brandon Diessner1, Patrick Monnahan1, Brenda Weigel1, Stephen Lessnick2, Joshua Schiffman3, Logan Spector1
1University of Minnesota, Minneapolis, Minnesota, UNITED STATES; 2Nationwide Children’s Hospital, Columbus, Ohio, UNITED STATES; 3 Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, UNITED STATES

Poster #195 3464895
DETERMINING THE CONTRIBUTIONS OF GENES CO-EXPRESSED WITH PD-L1 IN UNDIFFERENTIATED PLEOMORPHIC SARCOMA (UPS) CASES IN THE TUMOUR-IMMUNE MICROENVIRONMENT
Victoria Coward1, Alice Ko2, Maisha Syed5, Nalan Gokgoz3, Jay Wunder4, Irene Andrulis1
1Molecular Genetics, University of Toronto, Toronto, Ontario, CANADA; 2Laboratory Medicine and Pathology, University of Toronto, Toronto, Ontario, CANADA; 3Lunenfeld-Tanenbaum Research Institute, Toronto, Ontario, CANADA; 4Mount Sinai Hospital, Toronto, Ontario, CANADA; 5Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, CANADA

Poster #196 3464925
SARCOMA OF BONE ABOUT THE KNEE AND LIMB LENGTH IN PRE-ADOLESCENT PATIENTS: ALL OPTIONS STILL ON THE TABLE
Sean P. Kelly2, Dipak B. Ramkumar2, Brooke Crawford3, Santiago A. Lozano-Calderon1, Megan E. Anderson2, Mark C. Gebhardt2
1Massachusetts General Hospital, Powhatan, Virginia, UNITED STATES; 2Boston Childrens Hospital, Boston, Massachusetts, UNITED STATES; 3UCLA Medical Center, Santa Monica, California, UNITED STATES

Poster #197 3464936
REPEAT SURGICAL RESECTION FOR PATIENTS WITH RE-RECURRENT RETROPERITONEAL LIPOSARCOMA
Wenqing Liu1, Jun Chen1, Chengli Miao1, Mei Huang1, Yue Hu2, Chenghua Luo1
1Dept. of Retroperitoneal Tumor Surgery, Peking University International Hospital, Beijing, CHINA; 2Beijing Spanal Medical Scientific Co. Ltd., Beijing, CHINA

Poster #198 3464946
PATTERNS OF FAILURE IN PATIENTS WITH MYXOFIBROSARCOMA TREATED WITH PERIOPERATIVE RADIATION
Yu M. Zhou1, Alan Blank2, Yixiang Liao1, Steven Gitelis2, Matthew Colman2, Marta Batus2, Dian Wang1
1Radiation Oncology, Rush University Medical Center, Chicago, Illinois, UNITED STATES; 2Rush University Medical Center, Chicago, Illinois, UNITED STATES

Poster #199 3464982
ATRX PROMOTES AGGRESSIVE FEATURES OF OSTEOSARCOMA ACROSS SPECIES
Suzanne Bartholf DeWitt1, Sarah Hoskinson1, Dharsan Sivaraj1, Elaina J. Martz1, Maya Sheth1, Hailey E. Brighton1, Robert W. Floyd1, Brian E. Brigan1, Ben Alman2, Jason A. Somarelli2, William C. Eward1
1Orthopaedic Surgery, Duke University, Durham, North Carolina, UNITED STATES; 2Medicine, Duke University, Durham, North Carolina, UNITED STATES

Poster #200 3465022
TREATMENT STRATEGIES IN PATIENTS WITH DESMOPLASTIC SMALL ROUND CELL TUMORS (DSRCT) IN THE FIRST LINE SETTING: A SYSTEMATIC REVIEW
Tomás J. Soulé1, Federico Waisberg1, Martin Angel1, Andres Rodriguez1, Yanina Pfluger1, Matias Chacon1
1Oncology, Instituto Alexander Fleming, Ciudad Autonoma de Buenos Aires, ARGENTINA

Poster #201 3465049
THE PROGNOSTIC VALUE OF A NEW 4 GENE MOLECULAR PROFILE OF SEVERE HYPOXIA IN LOCALIZED HIGH GRADE SOFT TISSUE SARCOMA PATIENTS
Ninna Aggerholm-Pedersen1, Anna Jensen2, Steffen Nielsen2, Akmal Safwat1, Brita Singer Sørensen2
1Department of Oncology, Aarhus University Hospital, Aarhus N, DENMARK; 2Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus N, DENMARK
THE DIAGNOSIS AND MANAGEMENT OF GASTROINTESTINAL STROMAL TUMORS IN INDIA: A SCOPING REVIEW
Azgar A. Rasheed, Sameer Rastogi
1Medical Oncology, All India Institute of Medical Sciences, New Delhi, New Delhi, INDIA

THE DIAGNOSIS AND MANAGEMENT OF GASTROINTESTINAL STROMAL TUMORS IN INDIA: A PHASE 1/2 STUDY OF ABI-009 (NAB-SIROLIMUS) WITH PAZOPANIB IN PATIENTS WITH ADVANCED NONADIPOCYTIC SOFT TISSUE SARCOMAS
Lee D. Cranmer, Elizabeth T. Loggers, Seth Pollack, Roxanne O. Moore, Sarah Duffy, Michael J. Wagner
1Division of Oncology, University of Washington, Seattle, Washington, UNITED STATES; 2Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, UNITED STATES

SAINT: AN EXPANDED PHASE 2 STUDY USING SAFE AMOUNTS OF IPILIMUMAB (I), NIVOLUMAB (N), AND TRABECTEDIN (T) AS FIRST-LINE TREATMENT OF ADVANCED SOFT TISSUE SARCOMA [NCT03138161]
1Sarcoma Oncology Center, Santa Monica, California, UNITED STATES; 2Surgery, USC Keck School of Medicine, Los Angeles, California, UNITED STATES

LANDSCAPE OF ALK FUSIONS IN SOFT-TISSUE SARCOMAS (STS)
Roman Groisberg, James Chen, Zhijie Jiang, Michelle Churchman, Ming Poi, Santosh Mishra, Oliver Hampton, Ashley B. Anderson, Michael Cawner, Rebecca Dodd, Stephen Edge, Kevin B. Jones, Vipul G. Pareek, Damon Reed, Breelyn A. Wilky, Andrew Brohl, David A. Liebner
1Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, UNITED STATES; 2The Ohio State University, Columbus, Ohio, UNITED STATES; 3Sarcoma Department, Moffitt, Tampa, Florida, UNITED STATES; 4M2Gen, Tampa, Florida, UNITED STATES; 5Uniformed Services University of the Health Sciences and Walter Reed, Bethesda, Maryland, UNITED STATES; 6University of Kentucky, Lexington, Kentucky, UNITED STATES; 7University of Iowa, Iowa City, Iowa, UNITED STATES; 8Roswell Park, Buffalo, New York, UNITED STATES; 9Huntsman Cancer Institute, Salt Lake City, Utah, UNITED STATES; 10Stephenson Cancer Center, Oklahoma City, Oklahoma, UNITED STATES; 11University of Colorado, Aurora, Colorado, UNITED STATES

ANGIOSARCOMA TREATMENT USING PROPRANOLOL: A SINGLE INSTITUTION EXPERIENCE IN ARGENTINA
Andres Rodriguez, Tomás J. Soulé, Martin Angel, Federico Waisberg, Enrico Diego, Yanina Pfluger, Reinaldo Chacón, Matias Chacon
1Clinical Oncology, Instituto Alexander Fleming, Buenos Aires, ARGENTINA

SQ3370, A NOVEL APPROACH TO LOCALLY CAPTURE AND ACTIVATE CYTOTOXIC DRUGS, PRODUCES SUSTAINED RESPONSES IN INJECTED AND NON-INJECTED LESIONS VIA IMMUNE ACTIVATION IN PRECLINICAL MODELS
Sangeetha Srinivasan, Nathan Yee, Kui Wu, Amir Mahmoodi, Michael Zakarian, Maksim Royzen, Jose Mejia Oneto
1Shasqi, Inc., San Francisco, California, UNITED STATES; 2University of Albany (SUNY), Albany, New York, UNITED STATES

EWS/FLI DRIVES DYNAMIC REORGANIZATION OF LSD1 AND REST IN EWING SARCOMA CELLS
Julia Selich-Anderson, Stephen L. Lessnick, Emily R. Theisen
1Center for Childhood Cancer, Nationwide Children’s Hospital, Columbus, Ohio, UNITED STATES
Poster #209 3465136
HEAD AND NECK ALVEOLAR RHABDOMYOSARCOMA – A RARE ENTITY
Raquel L. Brás¹, Gonçalo Fernandes², Daniela Macedo³, Dolores López¹, Ana Rita Santos¹, Luis Costa¹, Isabel Fernandes¹
¹Oncology, Hospital Santa Maria, CHULN, Lisboa, PORTUGAL; ²Oncology, Hospital da Luz, Lisbon, PORTUGAL;
³Pathology, Hospital Santa Maria, CHULN, Lisbon, PORTUGAL; ⁴Otorhinolaryngology, Hospital Santa Maria, CHULN,
Lisbon, PORTUGAL

Poster #210 3465158
PROMIS-10 SURVEY T-SCORES AND UNPLANNED HOSPITAL ADMISSION/EMERGENCY ROOM VISITS
Marium Husain¹, Audra Phillips¹, David A. Liebner¹
¹Medical Oncology, The Ohio State University James Comprehensive Cancer Center, Columbus, Ohio, UNITED STATES

Poster #211 3465174
SORAFENIB IN DESMOID TUMOR: A BRAZILIAN CANCER CENTER EXPERIENCE
Maria F. Simões¹, Celso Mello¹, Ulisses R. Nicolau¹, Maria Nirvana Formiga¹, Cassia Silva¹, Fernando Campos¹
¹Medical Oncology, A.C. Camargo Cancer Center, São Paulo, Sao Paulo, BRAZIL

Poster #212 3465223
SILVER-COATED MEGAPROTHESES IN THE MITIGATION OF PROSTHETIC JOINT INFECTIONS – A COST-EFFECTIVENESS ANALYSIS
Dipak B. Ramkumar¹, Sean P. Kelly¹, Marcel Brown³, Niveditta Ramkumar², Kevin A. Raskin¹,
Santiago A. Lozano-Calderon¹
¹Massachusetts General Hospital, Boston, Massachusetts, UNITED STATES; ²The Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, New Hampshire, UNITED STATES; ³Dartmouth Geisel School of Medicine, Lebanon, New Hampshire, UNITED STATES

Poster #213 3465226
LEVERAGING EVOLUTIONARY FITNESS BOTTLENECKS AS THERAPEUTIC VULNERABILITIES IN DOXORUBICIN-RESISTANT OSTEOSARCOMA
Etienne M. Flamant¹, Anika Agarwal², Anna Slingerland², Ella Gunnady², Abby Milwicz², Cameron Bozdog²,
Maya Sheth², Kathryn E. Ware², Mark M. Cullen¹, David Corcoran³, Joseph Prinz¹, Nicolas Devos³, William C. Eward⁴,
So Young Kim⁵, Jason A. Somarelli²
¹Duke University School of Medicine, Durham, North Carolina, UNITED STATES; ²Department of Medicine, Duke University, Durham, North Carolina, UNITED STATES; ³Center for Genomic and Computational Biology, Duke University, Durham, North Carolina, UNITED STATES; ⁴Department of Orthopaedic Surgery, Duke University Medical Center, Durham, North Carolina, UNITED STATES; ⁵Department of Molecular Genetics and Microbiology, Duke University, Durham, North Carolina, UNITED STATES

Poster #214 3465233
ADJUNCT DIAGNOSTIC STRATEGIES IN IMPROVING DIAGNOSTIC YIELDS IN IMAGE-GUIDED BIOPSIES – A COST-EFFECTIVENESS ANALYSIS
Dipak B. Ramkumar¹, Sean P. Kelly¹, Soterios Gyftopoulos², Kevin A. Raskin¹, Santiago A. Lozano-Calderon¹,
Connie Y. Chang¹
¹Massachusetts General Hospital, Boston, Massachusetts, UNITED STATES; ²NYU Langone Health, New York, New York, UNITED STATES

Poster #215 3465243
CIRCULATING TUMOR DNA IN CYTOGENETICALLY COMPLEX SOFT TISSUE SARCOMAS
Gabriel Tinoco¹, Katharine Collier¹, David A. Liebner¹, Daniel Stover¹, James Chen¹, Raph Pollock¹, Claire Verschraegen²
¹Surgery, The Ohio State University, Columbus, Ohio, UNITED STATES; ²Oncology, The Ohio State University, Columbus, Ohio, UNITED STATES
**Poster #216 3465258**

**EVALUATION OF PATIENT AND HEALTHCARE PROVIDER KNOWLEDGE, ATTITUDES, AND BEHAVIOR (KAB) FOR SAFETY AND USE OF PEXIDARTINIB**

*Maribel Salas*, Michele Julian*, Youngsook Cho*, Zahid Islam*, Mackenzie Henderson*, Annette Stemhagen*, Natalie O’Donnell†, Nora Tu†

1Epidemiology, Clinical Safety and Pharmacovigilance, Daiichi Sankyo, Inc, Basking Ridge, New Jersey, UNITED STATES; 2CCCB. CPerT, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, UNITED STATES; 3Epidemiology, Clinical Safety and Pharmacovigilance, Daiichi Sankyo Inc, Basking Ridge, New Jersey, UNITED STATES; 4Safety, Epidemiology, Registries & Risk Management, United BioSource LLC, McLean, Virginia, UNITED STATES; 5Rutgers Institute for Pharmaceutical Industry Fellowships, Piscataway, New Jersey, UNITED STATES

**Poster #217 3465259**

**PATIENT-DERIVED SARCOMA MODELS TOWARDS NOVEL BIOLOGY AND TREATMENT**


1Division of Rare Cancer Research, National Cancer Center, Tokyo, JAPAN; 2Central Animal Division, National Cancer Center, Tokyo, JAPAN; 3Department of Musculoskeletal Oncology, National Cancer Center Hospital, Tokyo, JAPAN; 4Department of Diagnosis Pathology, National Cancer Center Hospital, Tokyo, JAPAN; 5Division of Diagnostic Pathology, Tochigi Cancer Center, Tochigi, JAPAN; 6Division of Hepato-Biliary-Pancreatic Surgery, Tochigi Cancer Center, Tochigi, JAPAN; 7Division of Musculoskeletal Oncology and Orthopaedics Surgery, Tochigi Cancer Center, Tochigi, JAPAN; 8Fuji Memorial Institute of Medical Science, Tokushima University, Tokushima, JAPAN; 9Fundamental Innovative Oncology Core, National Cancer Center, Tokyo, JAPAN

**Poster #218 3465280**

**OUTCOMES OF WOUND HEALING WITH A TOPICAL SKIN ADHESIVE AFTER TUMOR RESECTION**

*Lee M. Zuckerman*, Nadine L. Williams*

1Orthopaedic Surgery, City of Hope National Medical Center, Duarte, California, UNITED STATES; 2Orthopaedic Surgery, Loma Linda University Medical Center, Loma Linda, California, UNITED STATES

**Poster #219 3465283**

**A NEW INDUCIBLE ZEBRAFISH MODEL OF EWING SARCOMA REVEALS THE IMPORTANCE OF ECM IN DEVELOPMENT OF THE DISEASE**

*Elena Vasileva*, Timothy J. Triche*, James F. Amatruda*

1HemOncBMT, Children’s Hospital of Los Angeles, Los Angeles, California, UNITED STATES; 2Children’s Hospital Los Angeles, Los Angeles, California, UNITED STATES

**Poster #220 3465290**

**SQ3370-001: A MULTI-CENTER, OPEN-LABEL PHASE I DOSE-ESCALATION STUDY OF SQ3370, A NOVEL INTRATUMORAL AND SYSTEMIC APPROACH TO ADMINISTER ANTHRACYCLINES FOR TREATING SOFT TISSUE SARCOMAS AND OTHER ADVANCED SOLID TUMORS**


1Shasqi, Inc., San Francisco, California, UNITED STATES; 2Stanford Cancer Institute, Palo Alto, California, UNITED STATES; 3Chris O’Brien Lifehouse, Camperdown, New South Wales, AUSTRALIA; 4Royal North Shore Hospital, St. Leonards, New South Wales, AUSTRALIA; 5MD Anderson Cancer Center., Houston, Texas, UNITED STATES; 6Cedar Sinai Angeles Clinic, Los Angeles, California, UNITED STATES; 7Stanford Medicine, Redwood City, California, UNITED STATES; 8Henry Ford Hospital., Detroit, Michigan, UNITED STATES

**Poster #221 3465303**

**PEDIATRIC ONCOLOGY PROVIDERS’ MENTAL HEALTH IN THE EPICENTER OF THE PANDEMIC, PRELIMINARY REPORT**

*Alexandra Arca*, Paige Reilly*, Janay McKnight*, Paul Kent†

1Pediatric Oncology/Hematology, Rush, Chicago, Illinois, UNITED STATES; 2University of Illinois at Chicago, Chicago, Illinois, UNITED STATES
Poster #222 3465305
A META-ANALYTIC EVALUATION OF THE CORRELATION BETWEEN SURROGATE ENDPOINTS AND OVERALL SURVIVAL IN RANDOMIZED CONTROLLED TRIALS OF NEWLY DIAGNOSED OSTEOSARCOMA
Kazuhiro Tanaka1, Masanori Kawano1, Tatsuya Iwasaki1, Yuta Kubota1, Ichiro Itonaga1, Hiroshi Tsumura1
1Department of Orthopaedic Surgery, Oita University, Yufu, Oita, JAPAN

Poster #223 3465320
IMMUNE-CHECKPOINT GENES AS PREDICTIVE BIOMARKERS OF TRABECTEDIN IN ADVANCED SOFT-TISSUE SARCOMA (STS): A SPANISH GROUP FOR RESEARCH ON SARCOMAS (GEIS) TRANSLATIONAL STUDY
David S. Moura1, Nadia Hindi1, Maria Lopez-Alvarez1, Paloma Sanchez-Bustos1, Irene Carrasco-Garcia2, Paloma Santos-Fernandez2, Paula Martinez-Delgado1, Serena Lacerenza1, Elena Blanco-Alcaina1, José L. Mondaza-Hernandez1, Antonio Gutierrez2, Rosa Alvarez-Alvarez4, Magda Conceicao1, Luis M. De Sande-Gonzalez2, Gloria Marquina2, Juana M. Cano2, Josefina Cruz6, Claudia Valverde6, Javier Martinez-Trufero10, Javier Martin-Broto1
1Oncohematology and genetics, Institute of Biomedicine of Seville, Seville, Seville, SPAIN; 2P. Santos-Fernandez, University Hospital Virgen del Rocio, Seville, SPAIN; 3University Hospital Son Espases, Mallorca, SPAIN; 4University Hospital Gregorio Marañon, Madrid, SPAIN; 5University Hospital of Leon, Leon, SPAIN; 6Hospital Clinico San Carlos, Madrid, SPAIN; 7Hospital Ciudad Real, Ciudad Real, SPAIN; 8Canarias University Hospital, Santa Cruz de Tenerife, SPAIN; 9Val d’Hebron University Hospital, Barcelona, SPAIN; 10University Hospital Miguel Servet, Zaragoza, SPAIN

Poster #224 3465381
HETEROGENEITY OF CHEMOTHERAPY EFFECT IN HIGH-RISK PATIENTS WITH EXTREMITY SOFT TISSUE SARCOMA
Ibtissam Acem1, Cees Verhoeef5, Winan J. van Houdt1, Dirk Grunhagen2, Michiel van de Sande1
1Leiden University Medical Centre, Leiden, NETHERLANDS; 2Erasmus Medical Center, Rotterdam, NETHERLANDS; 3The Netherlands Cancer Institute, Amsterdam, NETHERLANDS

Poster #225 3465410
DEFINING A TEXTBOOK SURGICAL OUTCOME FOR PATIENTS FOR UNDERGOING SURGICAL RESECTION OF INTERMEDIATE AND HIGH-GRADE SOFT TISSUE SARCOMAS OF THE EXTREMITIES
Alexander L. Lazarides1, Marcelo Cerullo2, Dimitrios Moris2, Brian E. Brigman1, Dan G (Trey) Blazer2, William C. Eward1
1Department of Orthopaedic Surgery, Duke University Medical Center, Durham, North Carolina, UNITED STATES; 2Department of Surgery, Duke University Medical Center, Durham, North Carolina, UNITED STATES

Poster #226 3465411
FUNCTIONAL CONSEQUENCES OF OVEREXPRESSION OF MIR-26A AND MIR-3913 IN WDLPS AND DDLPS
Erik Wiemer1, Melissa Vos1, Anne Vriends1, Patricia F. van Kuijk1, Dirk Grunhagen2, Cees Verhoeef5, Stefan Sleijfer1
1Medical Oncology, Erasmus Medical Center, Rotterdam, NETHERLANDS; 2Surgical Oncology, Erasmus Medical Center, Rotterdam, NETHERLANDS

Poster #227 3465438
MISMATCH REPAIR DEFICIENCY IN BONE AND SOFT TISSUE TUMORS: IS THERE A RATIONAL FOR ROUTINE TESTING IN ADVANCED SARCOMA?
Suk Wai Lam1, Marie Kostine3, Noel de Miranda1, Hans Moreau1, Judith V. Bovee1
1Pathology, LUMC, Leiden, NETHERLANDS; 2Centre Hospitalier Universitaire de Bordeaux Groupe hospitalier Pellegrin, Bordeaux, FRANCE
Poster #228 3465449
PROGNOSTIC VALUE OF PGP AS STRATIFICATION FACTOR FOR THE TREATMENT OF PATIENTS WITH NON-METASTATIC EXTREMITY HIGH-GRADe OSTEOSARCOMA: A SPANISH SOCIETY OF PEDIATRIC HEMATOLOGY AND ONCOLOGY (SEHOP) AND SPANISH GROUP FOR RESEARCH IN SARCOMAS (GEIS) STUDY
Catalina Marquez1, Francisco J. Bautista2, Robert D. Beveridge3, Adela Cañete3, Maria A. Vaz16, Aizpea Echebarria4, Maria E. Liñares5, Cristina Mata6, Alexandra Regueiro7, Jose A. Villegas8, Mercedes Guibelalde10, Guionar Gutierrez11, Ascension Muñoz12, Jeronimo Martinez-Garcia5, Rosa Alvarez-Alvarez9, Montserrat Torrent6, Claudia Valverde13, Elisa Carretta14, Stefano Ferrari14, Piero Picci15, Emanuela Palmerini14, Javier Martin-Broto1, Luis Gros Subias13, Oscar Gallego8
1Hospital Universitario Virgen del Rocío, Seville, SPAIN; 2Hospital Infantil Universitario Niño Jesus, Madrid, SPAIN; 3Hospital Universitario i Politecnic La Fe, Valencia, SPAIN; 4Hospital Universitario Cruces, Baracaldo, SPAIN; 5Hospital Clinico Universitario Virgen de la Arrixaca, Murcia, SPAIN; 6Hospital General Universitario Gregorio Marañón, Madrid, SPAIN; 7Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, SPAIN; 8Hospital de la Santa Creu i Sant Pau, Barcelona, SPAIN; 9Hospital Universitario Central de Asturias, Oviedo, SPAIN; 10Hospital Universitari Son Espases, Palma de Mallorca, SPAIN; 11Hospital Regional Universitario de Malaga, Malaga, SPAIN; 12Hospital Universitario Miguel Servet, Zaragoza, SPAIN; 13Hospital Universitari Vall d'Hebron, Barcelona, SPAIN; 14IRCCS Istituto Ortopedico Rizzoli, Bologna, ITALY; 15Italian Sarcoma Group, Bologna, ITALY; 16Hospital Universitario Ramon y Cajal, Madrid, SPAIN

Poster #229 3465504
LATE CENTRAL NERVOUS SYSTEM AND LUNG RECURRENCE OF EWING’S SARCOMA: A CASE REPORT
Roberto Carmagnani Pestana1, Francinne Luiza Teixeira Tostes1, Andre Felix Gentil1, Eduardo Santamaria Carvalhal Ribas1, Fabiana Hirata1, Vitor Ribeiro Paes2, Carla Macedo2, Antonio Sergio Petrilli2, Suzana Malheiro1, Guilherme Carvalhal Ribas1, Ludmila Koch1
1Hospital Israelita Albert Einstein, Sao Paulo, BRAZIL; 2Institute of Pediatric Oncology (GRAAC), Federal University of Sao Paulo, Sao Paulo, BRAZIL

Poster #230 3465518
LYMPHOVASCULAR INVASION AND HISTOPATHOLOGIC PROFILE PORTENDS WORSE PROGNOSIS IN CHONDROSARCOMA
Alexander L. Lazarides1, Bijan Abar1, Bruce Leckey2, Alexis Musick1, William C. Eward1, Brian E. Brigman1, Diana Cardona2, Julia D. Visgauss1
1Department of Orthopaedic Surgery, Duke University Medical Center, Durham, North Carolina, UNITED STATES; 2Department of Pathology, Duke University Medical Center, Durham, North Carolina, UNITED STATES

Poster #231 3465549
IMPACT OF PATHOLOGICAL STRATIFICATION OF ADVANCED WELL DIFFERENTIATED/DEDIFFERENTIATED (WD/DD) LIPOSARCOMA (LPS) ON THE RESPONSE TO TRABECTEDIN (T)
Roberta Sanfilippo1, Chiara Fabbroni1, Francesca Ligorio1, Elena Fumagalli1, Paola Collini1, Giovanni Fucà1, Marta Barisella1, Rossella Bertulli1, Salvatore Provenzano1, Carlo Morosi1, Silvia Stacchiotti1, Alessandro Gronchi1, Angelo Paolo Dei Tos2, Paolo Giovanni Calsai1
1Istituto Nazionale dei Tumori di Milano, Milan, Milan, ITALY; 2Università degli Studi di Padova, Padua, ITALY

Poster #232 3465550
COMPREHENSIVE IMMUNOPHENOTYPING OF SOFT TISSUE SARCOMA PATIENTS DEFINES ASSOCIATION WITH FUNCTIONALLY DISTINCT LYMPHOCYTE SUBSETS AND MAJOR SUPPRESSOR CELLS
Paulo Rodrigues-Santos1, Jani Sofia Almeida1, Patricia Costa-Martins1, Patricia Couceiro2, Vera Alves1, Manuel Santos-Rosa1, Paulo Freitas-Tavares1, José Manuel Casanova3
1Instituto de Imunologia, Faculdade de Medicina da Universidade de Coimbra, Coimbra, PORTUGAL; 2Laboratório de Imunologia e Oncologia, Centro de Neurociencias e Biologia Celular, Universidade de Coimbra, Coimbra, PORTUGAL; 3P. Freitas-Tavares, J. Casanova, Unidade de Tumores do Aparelho Locomotor, Serviço de Ortopedia, Centro Hospitalar e Universitário de Coimbra, Coimbra, PORTUGAL

Poster #233 3465551
ADVANCED DERMATOFOBROSARCOMA PROTUBERANS: EXPERIENCE FROM A SARCOMA CLINIC IN INDIA
Azgar A. Rasheed1, Saurav Verma1, Anshul Gupta1, Ankur Varshney1, Adarsh Barwadi, Ekta Dhamija1, Sameer Rastogi1
1All India Institute of Medical Sciences, New Delhi, New Delhi, INDIA
NKT-LIKE CELLS DISPLAY ALTERED PATTERNS OF MATURATION, MIGRATION, ACTIVATION AND EXPRESSION OF IMMUNE CHECKPOINTS IN SOFT TISSUE SARCOMA

Jani Sofia Almeida1, Paulo Rodrigues-Santos1, Patricia Couceiro2, Vera Alves1, Manuel Santos-Rosa1, Paulo Freitas-Tavares1, José Manuel Casanova3
1Instituto de Imunologia, Faculdade de Medicina da Universidade de Coimbra, Coimbra, PORTUGAL; 2Laboratório de Imunologia e Oncologia, Centro de Neurociencias e Biologia Celular, Universidade de Coimbra, Coimbra, PORTUGAL; 3Unidade de Tumores do Aparelho Locomotor, Serviço de Ortopedia, Centro Hospitalar e Universitário de Coimbra, Coimbra, PORTUGAL

SOCIOECONOMIC STATUS AND CANCER-RELATED MORTALITY IN SOFT TISSUE SARCOMA: AN ANALYSIS OF THE SEER DATABASE

Dipak B. Ramkumar1, Sean P. Kelly1, Niveditta Ramkumar2, Kevin A. Raskin1, Santiago A. Lozano-Calderon1
1Massachusetts General Hospital, Boston, Massachusetts, UNITED STATES; 2Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, New Hampshire, UNITED STATES

USE OF A HUMANIZED XENOGRAFT MURINE MODEL TO CHARACTERIZE THE TREATMENT EFFECT OF CYTOTOXIC CHEMOTHERAPY AND IMMUNOTHERAPY ON OSTEOSARCOMA

Simon Yaguare1, Valentina Viscarret1, Osama Aldahamsheh1, Jichuan Wang1, Hasibagan Borjihan1, Janet Tingling1, Dana Kamens1, Robert Schneider1, Daniel Weiser2, Rui Yang1, Bang Hoang1, David S. Geller1
1Orthopaedic Surgery, Montefiore Medical Center, Bronx, New York, UNITED STATES; 2Pediatrics, Children’s Hospital at Montefiore, Bronx, New York, UNITED STATES

DEVELOPMENT OF AN UPDATED INTERNATIONAL CONSENSUS ON THE MANAGEMENT OF PRIMARY RETROPERITONEAL SARCOMA (RPS) BY TARPSWG

Carol J. Swallow1, Dirk Strauss2, Sylvie Bonvalot3, Piotr Rutkowski4, Anant Desai5, Rebecca Gladdy1, Ricardo J. Gonzalez6, David E. Gyorki7, Kenneth Cardona18, Carolyn Nessim19, Kenneth Cardona18, Marco Fiore20, Andrew Hayes21, Dmitri Tzanis1, Jacek Skoczylas1, Samuel Ford2, Deanna Ng1, John Mullinax14, Hayden Snow2, Rick L. Haas2, Dario Callegaro15, Myles Smith2, Toufik Bouhadiba3, Silvia Stacchiotti15, Robin L. Jones2, Thomas F. DeLaney16, Christina Roland17, Chandrajit Raut18, Alessandro Gronchi19
1University of Toronto, Toronto, Ontario, CANADA; 2Royal Marsden NHS Foundation Trust, London, UNITED KINGDOM; 3Institut Curie, Paris, FRANCE; 4Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, POLAND; 5University of Birmingham, Birmingham, UNITED KINGDOM; 6H. Lee Moffitt Cancer Center, Tampa, Florida, UNITED STATES; 7Peter MacCallum Cancer Centre, Melbourne, Victoria, AUSTRALIA; 8Brigham and Women's Hospital Center for Sarcoma and Bone Oncology, Boston, Massachusetts, UNITED STATES; 9The Netherlands Cancer Institute, Amsterdam, NETHERLANDS; 10Institut Bergonie, Bordeaux, FRANCE; 11Samsung Medical Center, Seoul, KOREA (THE REPUBLIC OF); 12Ludwig-Maximilians-Universität, University Hospital, Munich, GERMANY; 13University of Ottawa, Ottawa, Ontario, CANADA; 14Winship Cancer Institute, Emory University, Atlanta, Georgia, UNITED STATES; 15Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY; 16Massachusetts General Hospital, Boston, Massachusetts, UNITED STATES; 17The University of Texas MD Anderson Cancer Center, Houston, Texas, UNITED STATES

THE INTERACTION OF SKP2 WITH P27 ENHANCES IN THE PROGRESSION AND TUMOR-INITIATING PROPERTIES OF OSTEOSARCOMA

Jichuan Wang1, Osama Aldahamsheh1, Simon Yaguare1, Hasibagan Borjihan1, Janet Tingling1, Hongling Zhao2, Rui Yang1, David S. Geller1, Bang Hoang1
1Orthopedic Surgery, Montefiore Medical Center, Bronx, New York, UNITED STATES; 2Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, New York, UNITED STATES
LONG-TERM RESULTS OF ADJUVANT MIFAMURTIDE ALONGSIDE CHEMOTHERAPY IN THE TREATMENT OF PEDIATRIC AND ADULT PATIENTS WITH OSTEOSARCOMA

Robert D. Beveridge¹, Carlos Puchades Olmos¹, Alba Torres Martinez¹, Benjamin Domingo Arrue¹, Guillermo Suay Montagud¹, Diego Soriano Polo¹, Antonio Juan², Ana Ferrero¹, Javier Perea Rojo¹, Julio Linares Diaz¹, Nuria Gómez Sepúlveda¹, Adela Cañete²
¹Medical Oncology Department, University Hospital La Fe, Valencia, Valencia, SPAIN; ²Pediatric Oncology Department, University Hospital La Fe, Valencia, SPAIN, SPAIN

ACCURACY OF X-RAY AND MAGNETIC RESONANCE IMAGING IN DEFINING THE TUMOR MARGIN IN PRIMARY BONE SARCOMA

Theodore H. Katz¹, Obada Hasan¹, Benjamin J. Miller¹
¹Orthopedics and Rehabilitation, University of Iowa, Johnston, Iowa, UNITED STATES

IDENTIFICATION AND EVALUATION OF NOVEL RHABDOMYOSARCOMA ANTIGENS FOR USE IN ONCOLYTIC VACCINES

Birdi Harsimrat Kaur¹, Daniel Serrano², Andrew Chen², Mohsen Hooshyar², Youra Kim³, Nicole Forbes², Zaid Taha², Shashi Gujjar¹, Joel Werier¹, Jean Simon S. Diallo²
¹Department of Surgery, The Ottawa Hospital, Ottawa, Ontario, CANADA; ²Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, Ontario, CANADA; ³Virica Biotech Inc, Ottawa, Ontario, CANADA; ⁴Dalhousie University, Halifax, Nova Scotia, CANADA

PILOT STUDY OF THE EFFECT OF HIGH DOSES OF RADIATION ON BONE METABOLISM AND STRUCTURE IN PATIENTS TREATED WITH ADJUVANT RADIOTHERAPY AND SURGERY FOR SACRAL TUMORS.

Quirina Thio¹, Olivier van Wulfoten Palthe¹, Kevin A. Raskin¹, Santiago A. Lozano-Calderon¹, Thomas F. DeLaney², Francis J. Hornicek¹, David Dempster³, Hua Zhou⁴, Joseph H. Schwab¹
¹Orthopaedic Surgery, Massachusetts General Hospital, Boston, Massachusetts, UNITED STATES; ²Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, UNITED STATES; ³Orthopaedic Surgery, UCLA, Los Angeles, California, UNITED STATES; ⁴Helen Hayes Hospital, New York, New York, UNITED STATES; ⁵Clinical Pathology and Cell Biology, Colombia University, New York, New York, UNITED STATES

NEURONAL INFLUENCES IN AN UNDIFFERENTIATED TUMOR: THE NERVOUS MICROENVIRONMENT OF UNDIFFERENTIATED PLEOMORPHIC SARCOMA

Candace L. Haddox¹, Ben Alman²
¹Internal Medicine, Duke University, Durham, North Carolina, UNITED STATES; ²Orthopedic Surgery, Duke University, Durham, North Carolina, UNITED STATES

EVALUATION OF CANCER-TESTIS ANTIGENS IN OSTEOSARCOMA AND DEDIFFRETIATIED LIPOSARCOMA AS TARGETS FOR IMMUNOTHERAPY

Anna Jirovec¹, Ashley Flaman², Bibianna Purgina³, Fanny Tzelepis³, Jean-Simon Diallo³, Joel Werier³
¹Department of Surgery, The Ottawa Hospital, Ottawa, Ontario, CANADA; ²Department of Pathology and Laboratory Medicine, University of Ottawa, Ottawa, Ontario, CANADA; ³Centre for Innovative Cancer Research, Ottawa Hospital Research Institute, Ottawa, Ontario, CANADA

EVALUATION OF BASELINE NEUTROPHIL TO LYMPHOCYTE (NLR), PLATELET TO LYMPHOCYTE (PLR) AND LYMPHOCYTE TO MONOCYTE RATIOS (LMR) AS PROGNOSTIC FACTORS IN OSTEOSARCOMA – THE TORONTO SARCOMA PROGRAM EXPERIENCE

Olubukola Ayodele¹, Anthony Griffin², Peter Ferguson², Abha A. Gupta¹, Jay Wunder², Albiruni Abdul Razak¹
¹Medical Oncology, Princess Margaret Cancer Center, Toronto, Ontario, CANADA; ²Orthopedics, Mount Sinai Hospital, Toronto, Ontario, CANADA
ANCHOR CELLS: A MINOR SUBPOPULATION OF OSTEOSARCOMA CELLS WITH A SENESCENCE-LIKE PHENOTYPE THAT FACILITATES LUNG COLONIZATION

James B. Reinecke1, John M. Hinckley1, Sanjana Rajan1, Amy C. Gross1, Maren Cam1, Ryan D. Roberts1
1Center for Childhood Cancer and Blood Disease, Nationwide Children's Hospital, Columbus, Ohio, UNITED STATES

IMMUNE SIGNATURE AND MOLECULAR PROFILING OF EPITHELIOID HEMANGIOENDOTHELIOMA (EHE): A TORONTO SARCOMA PROGRAM STUDY

Olubukola Ayodele1, Rima Al-Bati2, Brendan Dickson2, Albiruni Abdul Razak1
1Medical Oncology, Princess Margaret Cancer Center, Toronto, Ontario, CANADA; 2Pathology, Mount Sinai Hospital, Toronto, Ontario, CANADA

CAN INTRAOPERATIVE USE OF INDOCYANINE GREEN DYE ANGIOGRAPHY PREDICT RATES OF WOUND COMPLICATIONS IN PATIENTS UNDERGOING SOFT TISSUE RESECTION?

Joanne Zhou1, Ann Richey1, Cara Lai1, Subhro Sen1, David Mohler1, Robert Steffner1
1Orthopaedic Surgery, Stanford University, Redwood City, California, UNITED STATES; 2Plastic and Reconstructive Surgery, Stanford University, Palo Alto, California, UNITED STATES

20-YEAR EXPERIENCE IN THE MANAGEMENT OF PATIENTS WITH EXTRASKELETAL MYXOID CHONDROSARCOMA IN A SARCOMA REFERENCE CENTRE

Robert D. Beveridge1, Benjamin Domingo Arrue1, Javier Perea Rojo1, Ana Ferrero1, Nuria Gómez Sepúlveda1, Alba Torres Martinez1, Carlos Puchades Olmos1, Diego Soriano Polo1, Guillermo Suay Montagud1, Julio Linares Diaz1
1Medical Oncology Department, University Hospital La Fe, Valencia, Valencia, SPAIN

SAFETY OF DISCHARGE AT HIGHER SERUM METHOTREXATE LEVELS IN PEDIATRIC OSTEOSARCOMA PATIENTS

Nathaniel P. Rice1, Janay McKnight1, Paul Kent1
1Rush University Medical Center, Hampton, Connecticut, UNITED STATES

IDENTIFYING MODIFIABLE AND NON-MODIFIABLE RISK FACTORS FOR READMISSION AND SHORT TERM MORTALITY IN OSTEOSARCOMA

Alexander L. Lazarides1, Daniel Evans1, Mark M. Cullen1, Marcelo Cerullo2, Dan G (Trey) Blazer2, Brian E. Brigman1, William C. Eward1
1Department of Orthopaedic Surgery, Duke University Medical Center, Durham, North Carolina, UNITED STATES; 2Department of Surgery, Duke University Medical Center, Durham, North Carolina, UNITED STATES

SURVIVAL OUTCOMES IN PATIENTS WITH RETROPERITONEAL SARCOMA (RPS): AN ANALYSIS OF THE SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS (SEER) DATABASE

Nicholas Damico1, Andrew Gross1, David Mansur1, Aashish Bhatt1
1Radiation Oncology, University Hospitals Cleveland Medical Center, Cleveland, Ohio, UNITED STATES

CLINICAL OUTCOMES OF PATIENTS WITH SARCOMA HARBORING TP53 GERMINATIVE MUTATION – A SINGLE CENTER RETROSPECTIVE ANALYSIS

Fernando Campos1, Maria Nirvana Formiga1, Elizabeth Santana dos Santos1, Joyce Lisboa1, José Cláudio Casali da Rocha2, Ulisses R. Nicolau1, Celso Mello1
1Medical Oncology, A.C. Camargo Cancer Center, São Paulo, Sao Paulo, BRAZIL; 2Oncogenetics, A.C. Camargo Cancer Center, São Paulo, Sao Paulo, BRAZIL
WHY DO ORTHOPAEDIC ONCOLOGY PATIENTS UNDERGOING PROSTHETIC RECONSTRUCTION GET READMITTED?

Alexander L. Lazarides, Etienne M. Flamant, Mark M. Cullen, Harrison R. Ferlauto, Julia D. Visgauss, Brian E. Brigman, William C. Eward

1Department of Orthopaedic Surgery, Duke University Medical Center, Durham, North Carolina, UNITED STATES

DENOSUMAB IN THE MULTIDISCIPLINARY MANAGEMENT OF GIANT-CELL BONE TUMOURS. LONG-TERM EFFICACY AND TOXICITY DATA

Robert D. Beveridge, Alba Torres Martinez, Carlos Puchades Olmos, Benjamin Domingo Arrue, Diego Soriano Polo, Guillermo Suay Montagud, Ana Ferrero, Javier Perea Rojo, Núria Gómez Sepúlveda, Julio Linares Diaz

1Medical Oncology Department, University Hospital La Fe, Valencia, Valencia, SPAIN

SYNCHRONOUS CO-LOCALIZATION OF GIST AND PERITONEAL MESOTHELIOMA: A SINGLE INSTITUTION CASE SERIES

Asimina S. Courelli, Yoon Young Choi, Shirley Sarno, Kaitlyn Kelly, Santiago Horgan, Olivier Harismendy, Joel Baumgartner, Jason K. Sicklick

1Department of Surgery, Division of Surgical Oncology, University of California, San Diego, La Jolla, California, UNITED STATES; 2Department of Surgery, Division of Minimally Invasive Surgery, University of California, San Diego, La Jolla, California, UNITED STATES; 3School of Medicine, University of California, San Diego, La Jolla, California, UNITED STATES; 4S Moores Cancer Center, San Diego, California, UNITED STATES

PEDIATRIC NON-MYOFIBROBLASTIC MESENCHYMAL NEOPLASMS WITH ALK AND ROS1 GENE REARRANGEMENTS

Rebecca Collins, Ameet Thaker, Naseem Uddin, Jason Park, Dinesh Rakheja

1Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, UNITED STATES

UPDATED ANALYSIS OF GENETIC ALTERATIONS IN SARCOMA PATIENTS OF HISPANIC AND NON-HISPANIC ETHNICITY: ANALYSIS OF 174 PATIENTS, A SINGLE INSTITUTION EXPERIENCE

Emily E. Jonczak, Caroline Hana, Andrea Espejo, Junaid Arshad, Philippos Costa, Priscila Barreto-Coelho, Konstantinos Schimas, Brianna Valdes, Gina D’amato, Jonathan Trent

1Medical Oncology, University of Miami, Sylvester Comprehensive Cancer Center, North Bay Village, Florida, UNITED STATES; 2Medic Cal Oncology, University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida, UNITED STATES

PREOPERATIVE RADIOTHERAPY IN LOWER EXTREMITY SOFT TISSUE SARCOMA TO REDUCE MAJOR WOUND HEALING COMPLICATIONS – THE ROLE OF NORMAL TISSUE DOSE REDUCTION

Lulwah Abduljabbar, Anthony Griffin, Zhihui Amy Liu, Peter Chung, Charles Catton, David Shultz, Philip Wong, Kim Tsoi, Peter Ferguson, Jay Wunder, Brian O’Sullivan

1Radiation Oncology, Princess Margaret cancer center, Toronto, Ontario, CANADA; 2Surgery, Princess Margaret Cancer Center, Toronto, Ontario, CANADA

DESPITE EXTENSIVE CLONAL SELECTION, METASTASIS ENRICHES FOR OSTEOSARCOMA CELLS WITH HIGHLY DIVERSE PHENOTYPES

Sanjana Rajan, Maren Cam, Amy C. Gross, Meng Wang, Cenny Taslim, Ryan D. Roberts

1Center for Childhood Cancer and Blood Disease, Nationwide Children’s Hospital, Columbus, Ohio, UNITED STATES

SUPERIOR MESENTERIC ARTERY BRANCHES AS A READOUT FOR PREDICTING FUTURE SMALL BOWEL LENGTH DURING ABDOMINAL AND RETROPERITONEAL LIPOSARCOMA RESECTIONS

Jeremiah Adie, Robert Mallory, Jason K. Sicklick

1Department of Surgery, Division of Surgical Oncology, University of California, San Diego, La Jolla, California, UNITED STATES
THE IMPACT OF RADIATION THERAPY ON SURVIVAL IN MYXOID LIPOSARCOMA

David L. Kerr, Alexander L. Lazarides, Preet Patel, Mark M. Cullen, Sneha Rao, Marcelo Cerullo, Dan G (Trey) Blazer, Brian E. Brigan, Julia D. Visgauss, William C. Eward

Orthopedic Surgery, Duke University Hospital, Durham, North Carolina, UNITED STATES; General Surgery, Duke University Hospital, Durham, North Carolina, UNITED STATES; Duke University School of Medicine, Durham, North Carolina, UNITED STATES

DOES ATTACHMENT STYLE (RELATIONSHIP STATUS) IMPACT OUTCOME IN ADULTS WITH SARCOMA?

Abha A. Gupta, Madeline Li, Nicole Byers, Caroline Rodrigues, Kupere Pathmanathan, Osvaldo Espin-Garcia, Jay Wunder, Peter Ferguson, Kim Tsii, Rebecca Gladdy, Carol J. Swallow, Svataj Brar, Peter Chung, Charles Catton, David Shultz, Philip Wong, Albiruni Razak, Hagit Peretz, Bob Maunder, Anthony Griffin, Jon Hunter

Princess Margaret, Toronto, Ontario, CANADA

WHAT IS THE LIKELIHOOD OF NON-PULMONARY METASTASIS OCCURRING IN THE ABSENCE OF LUNG METASTASIS IN BONE AND SOFT TISSUE SARCOMA? A NESTED CASE CONTROL STUDY FROM A REFERRAL SARCOMA CENTER

Obada Hasan, Momin Nasir, Mustafa Hashimi, Qiang An, Benjamin J. Miller

Orthopaedics and Rehabilitation, University of Iowa Hospitals & Clinics, Iowa City, Iowa, UNITED STATES; University of Iowa, Iowa, Iowa, UNITED STATES

SURGICAL MANAGEMENT REMAINS THE BEST PREDICTOR OF SURVIVAL: LESSONS FROM THE NATIONAL CANCER DATABASE (NCDB) IN DESCRIBING CHARACTERISTICS, MANAGEMENT, AND OUTCOMES FOR PATIENTS WITH CHONDROSARCOMA

Taylor D. Ottesen, Blake S. Shultz, Alana M. Munger, Michael Amick, Jonathan N. Grauer

Orthopaedics and Rehabilitation, Yale School of Medicine, Orem, Utah, UNITED STATES

WHAT ARE THE PREDICTORS OF READMISSION AND SHORT TERM MORTALITY IN CHONDROSARCOMA?

Daniel Evans, Alexander L. Lazarides, Mark M. Cullen, Julia D. Visgauss, Brian E. Brigan, William C. Eward

Department of Orthopaedic Surgery, Duke University Medical Center, Durham, North Carolina, UNITED STATES

PROBING THE THERAPEUTIC LANDSCAPE OF CHONDROSARCOMA WITH INTEGRATED CHEMICAL SCREENING

Trudy Zou, John Martin, Zeyu Huang, Puvindran Nadesan, Miriam Barrios-Rediles, Lauren Caldwell, Adrian Pasculescu, Alessandro Datti, Jason A. Somarelli, Julia D. Visgauss

Orthopedic Surgery, Duke University Medical Center, Durham, North Carolina, UNITED STATES; Duke University, Durham, North Carolina, UNITED STATES; University of Toronto, Toronto, Ontario, CANADA

RACIAL DISPARITIES BY HISTOLOGY FOR SARCOMAS OF SOFT-TISSUE AND BONE

David L. Kerr, Alexander L. Lazarides, Preet Patel, Mark M. Cullen, Sneha Rao, Marcelo Cerullo, Dan G (Trey) Blazer, Brian E. Brigan, Julia D. Visgauss, William C. Eward

Orthopedic Surgery, Duke University Hospital, Durham, North Carolina, UNITED STATES; Duke University School of Medicine, Durham, North Carolina, UNITED STATES; General Surgery, Duke University Hospital, Durham, North Carolina, UNITED STATES

CHARACTERISTICS AND LONG-TERM OUTCOMES OF SURGICALLY MANAGED HIGH-GRADE EXTREMITY CHONDROSARCOMA

Mary K. Skalitzky, Ryan Wendt, Qiang An, Trevor R. Gulbrandsen, Obada Hasan, Benjamin J. Miller

Orthopedic Surgery, University of Iowa Hospitals and Clinics, Iowa City, Iowa, UNITED STATES
IMPACT OF CHEMOTHERAPY TREATMENT ON OVERALL SURVIVAL IN DEDIFFERENTIATED CHONDROSARCOMA: AN ANALYSIS OF THE SEER DATABASE

Lee D. Cranmer, Bonny Chau, Michael J. Wagner, Elizabeth T. Loggers, Seth Pollack, Teresa Kim, Edward Kim, Gabrielle Kane, Matthew J. Thompson, Jared Harwood, Jose Mantilla

1Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, UNITED STATES; 2Division of Oncology, University of Washington, Seattle, Washington, UNITED STATES; 3Department of Surgery, University of Washington, Seattle, Washington, UNITED STATES; 4Department of Radiation Oncology, University of Washington, Seattle, Washington, UNITED STATES; 5Department of Orthopedic Surgery, University of Washington, Seattle, Washington, UNITED STATES; 6Department of Pathology, University of Washington, Seattle, Washington, UNITED STATES

A RARE CASE SERIES OF COMPOSITE HEMANGIOENDOTHELIOMA PRESENTING AS BONE TUMOR

Hariharasudan Mani, Varun Monga, Mohammed Milhem

1University of Iowa, Iowa City, Iowa, UNITED STATES

COMPREHENSIVE COMPLICATION INDEX BETTER ESTIMATES THE IMPACT OF COMPLICATIONS IN RETROPERITONEAL SARCOMA SURGERY COMPARED TO CLAVIEN-DINDO CLASSIFICATION

Fulvia Aymerito, Ferdinando Carlo Maria Cananzi, Laura Samà, Laura Ruspi, Federico Sicolì, Edoardo A. Baccalini, Federica Barzaghi, Vittorio L. Quagliuolo

1Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, ITALY; 2Humanitas Clinical and Research Center – IRCCS, Rozzano, Milan, ITALY; 3Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, ITALY

FOCUSED ULTRASOUND FOR APPENDICULAR SOFT-TISSUE SARCOMAS: TARGETABILITY ASSESSMENT FOR TISSUE-SELECTIVE TREATMENTS

Lauren Mancia, Neffisah D’odoo, Jess Gannon, Nathaniel Meyer, Eli Vlaisavljevich, Geoffrey W. Siegel

1University of Michigan, Ann Arbor, Michigan, UNITED STATES; 2Virginia Polytechnic Institute and State University, Blacksburg, Virginia, UNITED STATES

FOSB-ACTB FUSION IN PSEUDOMYOGENIC HEMANGIOENDOTHELIOMA: CASE STUDY OF THE YOUNGEST PEDIATRIC PATIENT.

Francis Osei, Janay McKnight, Paul Kent

1Pediatric Oncology, Rush University Medical Center, Chicago, Illinois, UNITED STATES

THE AMERICAN COLLEGE OF SURGEONS (ACS) SURGICAL RISK CALCULATOR UNDERESTIMATES THE ACTUAL RISKS OF SURGERY FOR RETROPERITONEAL SARCOMA: RESULTS FROM A REFERRAL CENTER

Laura Samà, Laura Ruspi, Ferdinando Carlo Maria Cananzi, Federico Sicolì, Fulvia Aymerito, Edoardo A. Baccalini, Vittorio L. Quagliuolo

1Department of Biomedical Sciences, Humanitas Clinical and Research Center – IRCCS / Humanitas University, Rozzano, Milan, ITALY; 2Humanitas Clinical and Research Center – IRCCS, Rozzano, Milan, ITALY; 3Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, ITALY

WHAT IS THE UTILITY OF CHEST SURVEILLANCE FOR ATYPICAL LIPOMATOUS TUMORS OF THE EXTREMITIES?

Alexander L. Lazarides, Harrison R. Ferlauto, Zachary D. Burke, Anthony Griffin, Bruce Leckey, Julia D. Visgauss, Nicholas Bernthal, Peter Ferguson, Jay Wunder, Brian E. Brigman, William C. Eward

1Department of Orthopaedic Surgery, Duke University Medical Center, Durham, North Carolina, UNITED STATES; 2Department of Orthopaedic Surgery, UCLA, Los Angeles, California, UNITED STATES; 3Department of Orthopaedic Surgery, Mt Sinai, Toronto, Ontario, CANADA
Poster #277 3467404
PREDICTING THE SURVIVAL PROBABILITY AND ASSESSING PROGNOSTIC FACTORS IN PATIENTS WITH MALIG-NANT EPITHELIOID HEMANGIOENDOTHELIOMA OF BONE: A POPULATION-BASED ANALYSIS
Charles Gusho¹, Alan Blank¹
¹Department of Orthopedics, Division of Orthopedic Oncology, Rush University Medical Center, Chicago, Illinois, UNITED STATES

Poster #278 3467407
RETREATMENT WITH FIRST LINE DRUGS IN MULTIPLY RELAPSED OSTEOSARCOMA
Madeline M. Link¹, Paul Kent¹, Janay McKnight¹, Bethany Gutfrucht¹
¹Pediatric Hem/Oncology, Rush University Medical Center, Chicago, Illinois, UNITED STATES

Poster #279 3467486
IS LOCAL RECURRENCE IN EXTREMITY SARCOMA JUST A LOCAL RECURRENCE, OR DOES IT IMPACT THE OVERALL SURVIVAL; NESTED CASE CONTROL STUDY FROM A SARCOMA REFERRAL CENTER.
Obada Hasan¹, Momin Nasir², Mustafa Hashimi², Qiang An¹, Benjamin J. Miller¹
¹Orthopaedics and Rehabilitation, University of Iowa Hospitals & Clinics, Iowa City, Iowa, UNITED STATES; ²University of Iowa, Iowa, Iowa, UNITED STATES

Poster #280 3467593
NOVEL SCORING CRITERIA FOR PREOPERATIVE PREDICTION OF NEOADJUVANT CHEMOTHERAPY RESPONSE IN OSTEOSARCOMA: A RETROSPECTIVE COHORT STUDY FROM A SARCOMA CENTER
Mustafa Hashimi², Obada Hasan¹, Qiang An¹, Benjamin J. Miller¹
¹Orthopaedics and Rehabilitation, University of Iowa Hospitals & Clinics, Iowa City, Iowa, UNITED STATES; ²University of Iowa, Iowa, Iowa, UNITED STATES